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BONE MARROW STROMAL CELL-DERIVED 
OSTEOPROTEGER IN (OPG)  PROTECTS BREAST 
CANCER CEL LS FROM TRAIL-INDUCED APOPTOSIS  
Helen L Neville-Webbe  , Alyson Evans, Colby Ea ton, Robert
Coleman , an d Ingu nn Hole n 
Cancer Research Centre, Weston Park Hospital, Sheffield 
    OPG binds  to and  inhibits TNF-Related  Apoptosis  Inducing
Ligand (TRAIL), thereby potentially increasing the survival of
tumour cells normally eliminated by this mechanism. We have
investigated whether OPG produced by bone marrow stromal cells
(BMSC) isolated from breast cancer patients has the potential to
inhibit TRAIL-induced apoptosis of breast cancer cells in vitro,
thereby increasing tumour cell survival rates. 
BMSC were isolated from breast cancer patients (following
appropriate ethical approval), and OPG levels determined by
ELISA. Breast cancer cells were exposed to TRAIL in the absence
or presence of 50% BMSC-conditioned medium, and the levels of
apoptotic cell death evaluated. 
BMSC were found to produce substantial levels of OPG in vitro
(45000pg/ml/96hours). In standard medium, TRAIL induced
apoptotic cell death in the breast cancer cell line MDA-MB-436,
(33%vs 0.6% in control). When the breast cancer cells were
exposed to TRAIL in BMSC-conditioned medium containing high
levels of OPG, the levels of TRAIL-induced apoptosis were
reduced by 50% compared to standard medium. 
BMSC isolated from breast cancer patients produce sufficient
levels of OPG in vitro to protect breast cancer cells from TRAIL-
induced apoptosis. Our data suggest that bone-derived OPG may
act as a survival factor for breast cancer cells in vitro. The in vivo
significance of these findings remains to be clarified. 
P2
THE ROLE OF CB1 AND CB2 RECEPTORS IN CANNABIS
INDUCED APOPTOSIS IN VITRO. 
Thomas Powles, Jonathan Shamash, Simon Joel, Tim Oliver and
Wai Liu. New Drug Study Group, St Bartholomew’s Hospital,
London, UK. 
Table: Cannabis receptor levels and cell viability data. 
 R eceptor  level  IC50     9T  %Cell viability 
 CB1 CB2 (∝M) IC 50   9T 
+CB1-ant 
IC50   9T 
+CB2-ant
CEM  9.4 ± 3.0  1.2 ± 0.3  26.5  51 ± 12  41 ± 8.1 
HL60  0.6 ± 0.4 -0.2 ± 0.5  21.1  47 ± 6.8  45 ± 10 
HEL92  5.4 ± 1.0  1.0 ± 0.6  61.4  58 ± 9.9  31 ± 4.0 
Conclusions: Contrary to previous reports, our data suggests CB1
and CB2 receptor levels are unimportant in determining cell
death. It appears that the mechanism of apoptosis is actually
independent of these receptors. 
Background: Delta-9 tetrahydocannabinoid (∆9T) is the activemetabolite 
of cannabis and causes apoptosis in vitro. Both the cannabinoid 1 and 2 
(CB1 and CB2) receptors are thought to beinvolved in this process. We 
have investigated the roleof thesetwo receptors in mediating apoptosis in 3 
leukaemiccell lines.Method: CB1 and CB2 receptor levels in CEM, HEL92 
andHL60 cells weremeasured byusing a novel flow cytometrictechnique 
involving biotinylation of specific ligands to thereceptors. Cells were 
cultured with specific CB1 and CB2agonists or with 9T in the presence or 
absence of the receptorantagonists. Cell parameters including apoptosis 
were assessed onday 3. Results:The levels of CB1 and CB2 receptors are 
shownin the table.  9T, CB1-agonist andCB2-antagonist (ant) resultedin 
decreased cellviability and increased apoptosis in all cell linesirrespective of 
the receptor expression. Increasing concentrationsofCB1- or CB2-
antagonists did not reverse the effects of  9T inany of the cell lines (see 
table). 
P3 
APOMINE INDUCES APOPTOSIS IN BREAST CANCER
CELLS ALTHOUGH THIS IS NOT ACHIEVED THROUGH
INHIBITION OF THE MEVALONATE PATHWAY. 
Lorraine C. Lowe*, Siddhika G. Senaratne, Kay W. Colston. 
St George’s Hospital Medical School, London SW17 0RE, UK.
 Apomine is a new anti-cancer compound that is a member of the1-1, 
bisphosphonate ester familyof cholesterol synthesis inhibitors. Our aim was 
to determine the effect of apomine onbreast cancercellsand to investigate 
further any growth inhibitory effects found. We have found that apomine 
causes a significant level of cell deathin MCF-7 and MDA-MB-231 breast 
cancer cells. This was confirmed as apoptotic cell death using a cell death 
ELISA andbycaspase7 cleavage in MCF-7 cells. The pro-apoptotic 
MAPKinasefamily member p38 is also activated in MCF-7 cells with 
apominetreatment. Amino bisphosphonates, such as zoledronate, 
induceapoptosis in breast cancer cells by inhibiting the mevalonatepathway 
which leads to a decrease in the formation of isoprenoidlipids. These are 
essential for Ras localisation tothe membrane ofthe cell, an action that is 
required for Ras activation. A decrease inthe production of these lipids leads 
to impaired Ras localisation andactivation. To investigate whether apomine 
was acting in a similarmanner we added mevalonate to cell medium while 
also treatingwith apomine. We found that this did not rescue MCF-7 cells 
from a pomine induced death. Western blot analysis showed that apominet 
reatment of MCF-7cells does not impair Ras localisation to the membrane. 
These results indicate that apomine is not inducing apoptosis by inhibiting 
the mevalonate pathway and is acting byanother mechanism.We are 
currentlyinvestigatingwhether thefarnesol X receptor (FXR) may be 
involved in the action ofapomine on breast cancer cells. 
P4 
ZOLEDRONIC ACID INDUCES APOPTOSIS AND INHIBITS
ADHESION OF BREAST AND PROSTATE CANCER CELLS
VIA INHIBITION OF PROTEIN PRENYLATION
Jonathan P Coxon*, Lisa M Pickering, Kay W Colston 
Department of Urology, St George’s Hospital, London, UK 
  Bisphosphonates (BPs) have been shown to have direct effects oncancer 
cell function- for example, inducingapoptosis of breast andprostate cancer 
cells in vitro, previously only after exposure to highdoses (up to 100∝M), 
and for long durations (3-4 days). Potent BPs, such as zoledronic acid (ZA), 
inhibit the mevalonate pathway, which normally allows G-protein 
prenylation, required for membrane localisation. In this study, were-
examinedeffects of ZAon apoptosis and on adhesion of breast and prostate 
cancer cells. We investigated whether effects on adhesion were altered byco-
treatment with analogues of intermediates in the mevalonatepath way: 
farnesol (FOH), or geranylgeraniol (GGOH). We also compared effects with 
C3-exoenzyme (C3X), an inhibitor of Rho.   
  A cell death ELISA was usedto examine apoptosis. To testadhesion, cells 
were exposed to ZA for 24 hours, then seeded on to dentineslices for 24 
hours before being fixed, stained and counted.Cells werealso exposed for 3 
hours toeither FOHor GGOH priorto ZA. Effects of ZA were compared to 
5µg/ml C3X. 
  ZA induced apoptosis and inhibited adhesion in breast andprostate cancer 
cells. Significant induction of apoptosis was seenearlier (1 day), and at lower 
concentrations (1µM), than previously (similar to adhesion). In MCF-7 cells 
(breast), inhibition ofadhesion was rescued byFOH, not GGOH. In DU145 
and PC-3cells (prostate), only GGO Hrescued inhibition. In all cell lines, 
C3X significantly attenuated adhesion. 
  These results show ZA induces apoptosis and inhibits adhesion inthese 
cancer cells, and suggest that the underlying mechanism involves inhibiting 
prenylation of proteins, such as Ras and Rho.
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HUMAN BONE MARROW STROMAL CELLS (hBMSC) 
PROTECT PROSTATE CANCER CELLS FROM TRAIL 
INDUCED APOPTOSIS  
Rachel Nyambo
*, Neil A. Cross, Jenny Lippit, Ingunn Holen,  
A.A. Gordon Bryden and Colby L. Eaton 
Academic Un it Urology, Division of Clinical  Scien ces, 
University of She ffield S1 0 2RX, UK 
P6 
IN VITRO INHIBITORY EFFECTS OF LYCOPENE ON
HUMAN CANCER CELLS IS ASSOCIATED WITH
APOPTOSIS 
Debasish Debnath*, Iain Brown, Mrinalini Bilgi, Steven D Heys,
Frank Thies, Andrew C Schofield 
Department of Surgery, University of Aberdeen, Medical School,
Foresterhill, Aberdeen, AB25 2ZD.
P7 
RADIATION-INDUCED MAPK ACTIVATION PRODUCES
POLYPLOID TUMOUR CELLS THAT UNDERGO DNA
DOUBLE STRAND BREAK REPAIR. 
*Andrey Ivanov1, Mark Cragg2, Jekaterina Erenpreisa3 and Tim
Illidge1.1 Cancer Research UK Wessex Oncology Unit and 
2Tenovus Research Laboratory, Southampton, UK. 3Biomedical
Research and Study Center, Riga, Latvia 
p53 mutant tumor cells respond to genotoxic insults by bypassing the 
G1checkpoint and halting in G2. Following release from G2 arrest they 
undergo complex cellular events termed mitoticcatastrophe, whereby 
mitotic cyclingis suppressed, delayedapoptosis begins and 
endopolyploid cells are produced. Here wepresent evidence that 
DNAdamage induced after irradiation, asshown byan increase inthe 
presence of  -H2AX foci, can berepaired in these endopolyploid cells. 
We studied the kinetics anddistribution of Rad51 protein knownto be 
important inhomologous recombination DNA repair. Expressionof 
Rad51 focireached a maximum5-6 days after irradiation, at the peak of 
endopolyploidy and delayed apoptosis, indicating that selection ofcells 
for survivalor apoptosis was occurring at this time. Further more, the 
proportion of Annexin-V positive cells decreasedas the endopolyploid 
cells continued rounds of DNA replication from day 2-4, indicating that 
endoreduplication is involved inselecting cells resistantto apoptosis. 
Using the MEK1 inhibitor U0126, we wereable to inhibit the abrogation 
of radiation inducedG2 arrest and mitotic catastrophe, with a 
resultingdecrease in bothdelayed apoptosis and the formation of 
endopolyploid cells.Resolution of  -H2AX foci induced after irradiation 
was howeveralso inhibited by U0126. Therefore our findings suggest 
thatendopolyploid cells produced after adaptation of G2 and M-
phasearrest appear to have a greater potential for DNAdouble 
strandbreak repair and are protected from apoptosis suggesting that the 
endopolyploid fraction may be an important repair compartment. 
P8 
INDUCTION OF DIFFERENTIATION AND APOPTOSIS BY
APAG-1 IN ACUTE PROMYELOCYTIC LEUKAEMIA CELLS
Johnson Stanslas*, Shiamala D. Manikam, and Andrea L. Holme, 
Faculty of Medicine and Health Sciences, Universiti Putra 
Malaysia, 43400 UPM, Serdang, Selangor, Malaysia. 
This study was carried out to evaluate the potential of APAG-1, a
naturally occurring diterpenoid lactone as a differentiating agent in
acute promyelocytic leukaemia cells (APL): HL-60 (late FAB-M2),
NB4 (FAB-M3) and NB4-R2 (NB4 cell line made resistant to all-
trans retinoic acid (ATRA)). In an earlier study, APAG-1
showed antitumour activity in breast cancer models (Stanslas et al.
2001, Eur J Cancer, 37 (Suppl. 6): 169). In this study APAG-1 ex- 
hibited 2- and 3-fold increased efficiency in killing HL-60 (IC50 =
2.4 ± 0.5 µM) and NB4-R2 (IC50 = 1.5 ± 0.3 µM) cells, respectively 
compared with NB4 cells (IC50 = 4.5 ± 0.5 µM) (p<0.001).    
   The induction of differentiation in NB4 cells was assessed by the
ability of the cells to produce superoxide, measured by the
reduction of nitroblue tetrazolium (NBT) dye. APAG-1 induced a
linear kinetic differentiation effect throughout the 96 hr exposure
at IC50 concentration. Failure of retinoic acid receptor (RAR) antag-
onist AGN 193109 to reverse the cytotoxic effect of APAG-1 sugg-
ests that this compound exerts its effect through an RAR indepe-
ndent signalling pathway to induce differentiation, unlike ATRA.  
   Morphologically, APAG-1 induced apoptosis and this was later
confirmed by the presence of internucleosomal DNA
fragmentation of 200 bp ladders on agarose gel electrophoresis. In
conclusion, the abilities of APAG-1 to be effective against primary
NB4 cells by inducing differentiation and apoptosis, and its killing
effect on ATRA-resistant APL cells at a concentration range that is
achievable in the plasma i.e. 3 – 30 µM (Stanslas et al. 2001, Eur J
Cancer, 37 (Suppl. 6): 169) suggest that APAG-1 may be useful in
the treatment of primary and ATRA-relapse APL. 
 The bone microenvironment may provide a range of factors that favour 
the growth and survival of prostate cancer cells. Osteoprotegerin (OPG) 
is a molecule involved in bone remodellingand isalso a decoy receptor 
for TRAIL (TNF related apoptosisinducing ligand). The latter activity 
identifies OPG as a potentialsurvivalfactor. Theaim of the study was 
todetermine whetherOPG produced by human tumour associated bone 
marrow stromalcells(hBMSC) could protect prostate cancer cells 
fromTRAILinduced apoptosis.     
 hBMSC cultures were generated frombiopsies of prostate cancerbone 
metastases. Production of OPG by these cells in vitro wasdemonstrated 
by RT-PCR, Western blot and ELISA. When thehuman prostate cancer 
cell line PC3 waschallenged with TRAIL inthe presence of medium 
conditionedby hBMSC, the level ofinduced apoptosis was suppressed 
compared with that observedwith TRAIL in fresh medium. Immuno-
precipitation of OPG, andits removalfrom hBMSC conditioned medium, 
or co-treatment ofcultures with sRANKL, a factor known to bind OPG, 
reversed theinhibitoryeffects of conditioned media on TRAIL 
inducedapoptosis.     
 These data suggest a potential survival mechanism for prostatecancer 
in bone mediatedby the production of OPG by tumourassociated stromal 
cells.
 The mechanismof action of lycopene, an anticancer carotenoid
available in tomatoes, remains unclear. Although lycopene hasshown to
induce apoptosis in Jurkat E6.1 malignant T-lymphoblastcells, no such
effect has been demonstrated on other cancer cells.   
   We aimed to evaluate apoptosis by assessing the presence ofapoptotic
ladder in cells following in vitro exposure to lycopene.  
  Seven human cancer cell lines [A549 (lung), MCF-7 (ER+vebreast),
MDA-MB-231 (ER-ve breast), WiDR (colon), LNCaP(hormone
sensitive prostate), PC-3 (hormone resistant prostate)and AGS
(stomach)] were exposed to lycopene at a concentrationof 1 µM. The
effects were assessed by MTT assays at 24, 48, 72and 96 hours. DNA
was extracted from each cell line (followingexposure to lycopene for 24
hours as well as control) andelectrophoresed on a 2% agarose gel.
  Results showed that lycopene significantly inhibited (18%-55%)
growth of all cell lines (p<0.05), irrespective of the hormonal status.The
levels of inhibition decreased after 48 hours.  Evidence of apoptosis was
demonstrated by the presence of DNA fragmentation  
  Lycopene inhibited the growth of several human cancer celllines,
particularly WiDR and LNCaP.  Furthermore, the inhibitoryeffect of
lycopene appears to be due to apoptosis.  Further workusing more
specific and quantitative measures of apoptosis will becarried out to
validate these results. 
Poster Presentations
S26
British Journal of Cancer (2003) 88(Suppl 1), S25–S54 & 2003 Cancer Research UKP9 
REDOX-ACTIVE COBALT COMPLEXES AS SELECTIVE
ANTICANCER AGENTS: MECHANISMS  OF ACTIVITY
Larissa N. Bubnovskaya*, SergejP. Osinsky,  Ilia Ya. Levitin,Andrej L 
.Sigan, Irina I. Ganusevich, Antonina V. Kovelskaya,Natalia V. 
Valkovskaya, Luigi Campanella, Peter Wardman Institute of Exp. 
Pathol. Oncol. Radiobiol., 03022 Kiev, Ukraine; INEOS, Moscow, 
Russia;  University  “La Sapienza”, Rome,Italy; Gray Cancer Inst., 
Northwood, UK. 
Aim:to study mechanisms of biological activity of  novel 
cobaltcomplexes (CoC)  displaing  anticancer effect.
    Materials&Methods: CoC of the common formula [Co(acac2en)L2] 
X where L nicotinamide (AC-30), or isonicotinamide (AC-40), were 
tested.  Murine tumours [Lewislung carcinoma (3LL), melanoma (B16), 
adenocarcinoma Ca755]were investigated. Pulse radiolysis, 
electrochemical techniques,biochemical methods and NMR 
spectroscopy were applied inmodel and in vivo studies.  All experiments 
have been approvedby the regional animal ethics committee.    
 Results: Growth inhibition of primary tumour and metastasesranged 
from 60 to 80% and from 65 to 99%, respectively. It was shown the 
reduction of CoC caused the formation of reactiveoxygen species 
(ROS). ROS selectively attack cellularbiomolecules in primarytumours 
resulted in the activation of lipidperoxidation, decrease of glutathione 
content, reduction of theenergy status, increase of DNA unwinding (a 
marker of single-strand breaks), and decrease  of matrix 
metalloproteinase 2 and 9activity. AC-30 initiated apoptosis in primary 
tumour by two-phase manner. Theseeffects  were not observed 
innormaltissuesof tumour-bearing animals.    
 Conclusion: ROS formation due to CoC reduction is a keymechanism 
of  CoC effectson cells;   ROS affect DNA andcellular matrix  and  
results in the  inhibition of  tumour growth and metastases.  
The study was supported by INTAS (Grant No 00-665). 
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HOW DO ZINC-PHTHALOCYANINE DERIVATIVES KILL
HUMAN SiHa CELLS DURING PHOTODYNAMIC THERAPY?
S. L. Hankin*
1, D. I. Vernon
1, J. Griffiths
2, J. Schofield
2 & 
S. B. Brown
1. 
Centre for Photobiology and Photodynamic Therapy,
1School of
Biochemistry and Molecular Biology, 
2Department of Colour
Chemistry, University of Leeds, Leeds, LS2 9JT. 
   Photodynamic  therapy (PDT)-mediated  cell  cycle  deregulation
and apoptosis were evaluated using zinc phthalocyanine derivatives
in SiHa cells. Photosensitisers included a zinc phthalocyanine tetra-
sulphonic acid (TSPC) and a series of derivatives with amino-acid
substituents of varying alkyl chain length and degree of branching;
glycine,   -alanine,   -alanine, butyric, valeric and caproic.  
   The  response  was  characterised  using  the  Sulforhodamine B
assay and by flow cytometry for both DNA cell cycle and dual
Annexin V-FITC /PI analysis. All PDT-related experiments
involved a 2-hour drug incubation at specific concentrations and
illumination with 3J/cm
2 using a 665nm laser.  
An overall trend of increased phototoxicity with amino acid chain
length was evident, although phototoxicity was the same order of
magnitude as TSPC. PDT resulted in apoptosis, inhibition of cell
growth and G0/G1 cell cycle arrest in a time and dose dependent
manner. This novel study has provided evidence for the
involvement of cell cycle deregulation during the phthalocyanine
PDT-mediated response.
P11 
BIOAVAILABILITYOF NOVEL ANTICANCER CHALCONES
IN NUDE MICE BEARING XENOGRAFTS 
P. Gibson1*, P.M. Loadman1, S. D.Shnyder1, P.A.Cooper1,
M. C. Bibby1, G. Potter2 and P.C. Butler2 
1Cancer Research Unit, Tom Connors Cancer Research Centre,
University of Bradford, Bradford BD7 1DP
2Cancer Drug Discovery Group, Schoolof Pharmacy, De Montfort
University, Leicester LE1 9BH
Chalcones have shown in vitro cytotoxicity by mechanisms which 
mayinclude interactions with p53 and tubulin. The novelchalcones 
DMU-120, 135, and 175 have been designed as potential tumour 
selective anticancer prodrugs1.  These compounds are effective at 
killing human tumour-derived cell lines in vitro: 50% inhibition of 
growth is achieved between 0.005 and 1 µM insensitive cell lines 
(MCF7 and MDA-468 breast adencocarcinomalines).  With the intention 
of investigating their in vivo efficacyagainst xenograft models of human 
cancer, we undertook a bioavailability study using three lead 
compounds.  Work was doneusingathymic ("nude") mice.  Mice were 
housed and treated according to relevant Home Office guidelines and 
statutes.
 These compounds were found to be very well to lerated, with 
maximum tolerated dose (MTD) being 200mg/kg in each case. Dosing 
at MTD, we found by HPLC analysis that the drugs rapidly reached both 
liver and xenograft (MDA-MB-468) in appreciableconcentrations: 15 
minutes after injection, drugs were present at15-170µM in liver and 20-
75∝M inxenograft.
 Xenograft concentrations remained at up to 10µM for 60 minutes. We 
present here results which show that, given the provenanticancer 
properties of chalconesin vitro, this class of compoundsshould be 
progressed to  preclinical animal studies.
1Potter, G.A., Butler, P.C. & Wanogho, E. Chalcone 
TherapeuticAgents, British Patent PCT: GB 01/01341 (2001). 
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DESIGN OF TUMOUR-ACTIVATED PRODRUGS THAT
HARNESS THE ‘DARK SIDE’ OF MMP-9
Lesley Young
1, Alberto Di Salvo
1, Agnes Turnbull
1, Jason Lyle
2,
Michael C Bibby
2, John A Double
2, Graeme Kay
1, Paul M
Loadman
2, David J Mincher*
1
1School of Life Sciences, Napier University, Edinburgh, EH10
5DT, UK; 
2Cancer Research Unit, University of Bradford, BD7
1DP, Bradford, UK. 
The aimof this study is to design prodrugs that are converted to potent 
compounds within the tumour environment by exploitingthe proteolytic 
action of overexpressed MMP-91. Proptotypes, D-Ala-Ala-Ala-Leu-
Gly-Leu-Pro heptapeptide conjugate(1) and theD-Ala-Ala-Leu-Gly-Nva-
Pro analogue (2) have been designed asefficient substrates for tumour-
associated MMP-9.        Incubation of the non-toxic prodrug (1) with 
human recombinantMMP-9 resulted in cleavage of the heptapeptide 
motif at the Gly-Leu cleavage ‘hot-spot’ to afford the residual 
anthracenyl-Pro-Leu-Glytripeptide conjugate (by LC-MS). Incubation of
(1) withdiluted (1:500) MMP-9-expressing (by 
zymography)HT1080human fibrosarcoma tissue homogenates gave 
rapid (1.8µmolmin-1 g -1)  initialmetabolism to the sametripeptide 
conjugatewhich was further cleaved to the residual,in vivo-active, 
prolinemetabolite NU:UB 31. Introduction of unnatural norvaline 
(Nva),in (2), in which the  -side chain wasmodelled into a 
deephydrophobic S1 pocketon the enzyme surfaceof MMP-9,directed 
the cleavage to the N-terminus of the Nva residue, toafford the cytotoxic 
anthracenyl-Pro-Nva dipeptide metabolite(3). [IC50  3 µM vs. intact 
prodrug (IC50 >100µM) against theMAC15A cellline]. Furthermore, 
differential metabolism of theprodrugs (1) and (2)by tumour tissue and 
non-transformed livertissue is feasible by structural manipulation of the 
peptide motif.1Mincher D J, (2002) British Journal Of Cancer 86(Suppl 
1), S34
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ANTITUMOUR QUINOLS AS NOVEL INHIBITORS OF
THIOREDOXIN SIGNALLING
Jane M. Berry, Andrew D. Westwell, Charles A. Laughton, 
Charles S. Matthews, Malcolm F.G. Stevens and Tracey D.
Bradshaw* 
School of Pharmaceutical Sciences, University of Nottingham,
Nottingham, NG7 2RD
 The antitumour quinols (e.g. AW 464) are a novel seriesofagents found 
to have selective in vitro LC50 activity concentratedin certain colon and 
renal human cancer cell lines (NCI sixty cellline analysis). Recently a 
new generation of antitumour quinolshas been found tobe substantially 
more potent in vitro in anexpanded repertoire of cell lines. For example 
quinol BW 114gives a mean GI50 value of 38.9 nM (sixty cell line 
analysis) with the most potent activity concentrated in colon HCT 116 
(LC5033.1 nM) and renal CAKI-1 (LC50 52.5 nM) cell lines.
 COMPARE analysis within the NCI database has led us to suggest the 
small redox protein thioredoxin as a potential target.Our hypothesis on 
themechanistic role of thioredoxin has nowbeen experimentally verified 
using the insulin reduction assay(dose dependent inhibition of bacterial 
thioredoxin signallingcorrelating within vitro growth inhibition).
 Gene microarray studies (HCT 116 cells treated at1µM) provide 
further verification for thioredoxin as an intracellulartarget (Anne 
Monks, NCI, personnel communication); amongst apanel of some 10K 
cancer related genes, only one (thioredoxinreductase) was upregulated 
more than two-fold. Furthermore, themost highly down regulated gene 
was CDC2 (CDK1), the kinaseresponsible for cycling of the cell into 
G2/M. BW 114 was foundto induce a G2/Mcell cycle block (FACS 
analysis, HCT 116cells). Evidence for an irreversible mode of 
thioredoxin binding has been suggested from modelling and 
biochemical thioredoxininhibitory studies. 
P14 
THALIDOMIDE ANALOGUES CC-5013 AND CC-4047 INDUCE T CELL 
ACTIVATION AND IL-12 PRODUCTION IN PATIENTS WITH BOTH SOLID
TUMOURS AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA. 
Angus Dalgleish*, Steve Schey, Richard Jones, Kavita Raj, Keith Dredge,  
Matthew Streetly and Blake Marriott. Guy's and St Thomas'NHS Trust and  
St George's Hospital Medical School, SW17 ORE  
Two thalidomide analogues are currently in ethically approved  
clinical trials for both solid tumours and multiple myeloma. They were
selected for their enhanced ability to inhibit TNFalpha and negative  
birth defect screens. In vitro studies clearly show stong anti  
angiogenic activity especially for CC-5013 as well as immuneactivation,  
with enhanced co-stimulation reported for CC-4047. We therefore sought
evidence of immune activation in clinical studies and to correlate such  
with clinical responses. 
In all solid tumour patients and in 17/18 myeloma patients  
peripheral blood CD4 and CD8 cells greatly increased their expression  
of the activation and memory marker CD45RO, whilst expression of the
mutually exclusive isoform CD45RA decreased. Serum soluble IL-2  
receptor levels were increased indicating  Il-2 mediated co-stimulation  
and increased IL-12 levels which is probably monocytic and dendrtic  
cell derived. This is consistent with enhanced Th1 responses. Enhanced
NK activity was also seen in keeping with IL12 production. Importantly,  
there were NO effects on pro angiogenic factors incuding IL-8, VEGF or  
FGF, and neither were there any effects seen on serum IL-6 levels. 
Clinical responses were seen some solid tumours including 6/13  
melanomas and  1 prostate cancer whereas the M -protein response was  
<25% in 8/18 (44%), >25-50% in 7/18 and >50% in 3/18 patients with  
myeloma on a dose escalating study with one Complete Response and 2  
very close responses. 
Both analogues are clinically active and induce strong co- 
stimulation. The current study strongly suggests that the mechanism of  
clinical efficacy for CC-4047 in Myeloma is via immune stimulation and  
not by inhibiting angiogenesis or IL-6 production. 
P15
A NEW CLASS OF LIGAND FOR HIGH-ORDER DNA
STRUCTURE RECOGNITION.  Victoria A. Phillips,* Sharon A.
Jennings, Shelley L. Moores, Terence C. Jenkins, Roger M. Phillips, Richard
T. Wheelhouse. University of Bradford, BRADFORD, BD7 1DP, UK. 
N N
YY Z Z
Emax  (Θ = 0°)E min  (Θ = 
45°)
∆E
1,3-Biphenylbenzene E / kcal mol
-
1
75.21 73.28 1.93
4,6-
Biphenylpyrimidine
E / kcal mol
-
1
99.30 98.47 0.83
  The interaction of compounds with poly(dA)· [poly(dT)]2 triplex was assessed 
by thermal melting experiments. When Z is a simpledialkylamino group, there is 
a negligible effect on triplex melting (∆Tm1  ≤ 1 °C) and modest duplex 
stabilisation (∆Tm2 ≤ 5 °C). However, ligands bearing heterocyclic Z -groups 
show a marked stabilisation ofpoly(dA)· poly(dT) duplex (∆Tm2 ≤ 14 °C) and a 
specific destabilisation of the triplex structure (∆Tm1  ≈−8 °C).   Substituted 
biarylpyrimidines have intriguing binding preferences forunusual nucleic acid 
structures and the compounds examined allexhibited the desirable property of 
negligible cytotoxicity in a range of human tumour cell lines (IC50 ≥ 100 µM).
Tetraplex and triplex nucleic acids are important targets for anti-cancer drug 
design. Biarylpyrimidines bearingω-aminoalkyl substituents have been designed 
and synthesised as potentially-planar ligands capable of intercalating these high-
order structures.
The energy barrier to a planar conformation, ∆E, has been measured as a 
function of the torsion,Θ, around the inter-annular bond using semi-empirical 
molecular modelling techniques (Table), supported by X-ray crystallographic 
data. The influence of  functional group Y on electron distribution in the 
tricyclic system and the propensity to achieveplanarity has also been 
P16 
COMBRETASTATIN A-4-PHOSPHATE (CA-4-P) 
ACTIVATES NF  B IN HUMAN ENDOTHELIAL CELLS. 
A.C. Brooks*, C.S. Parkins, C. Kanthou, and G.M. Tozer.  
Tumour Microcirculation Group, Gray Cancer Institute, Northwood,
Middx., UK HA6 2JR.  
    The tumour vascular targeting agent CA-4-P inducesendothelial cellular 
adhesion molecule (CAM) expression, andsubsequent neutrophil adhesion. 
CAM expression is dependentupon the activation of transcription factors, 
including NF B,which is known to be activated by Rho GTPases. We 
haverecently demonstrated Rho GTPase activation by CA-4-P inhuman 
endothelial cells [Blood 99(6)2060 (2002)]. The aim ofthis study was to 
investigate CA-4-P-induced NF B activation.   
  Nuclearfractions wereobtained fromHUVEC incubatedwith TNF-  (100 
U/ml), or CA-4-P (0.001 – 0.1 µM). Todetermine the role of Rho in CA-4-
P-induced NF B activation,cells were pre-treated with the RhoA inhibitor, 
C3 exoenzyme,or the Rho kinase inhibitors Y27632 and HA1077. NF B-
DNAinteractions were examined using an EMSA, and NF Bcomponents 
identified using supershift assays.  
  Following treatment with TNF-  or CA-4-P, for 1 hour, twodensely 
labelled bands were observed on the EMSA blotcorresponding to NF B-
DNA complexes. These were inhibitedby excess unlabeled NF B probe, 
whilst supershift assaysrevealed NF B in the form of a p50·p65 
heterodimer. Pre-incubation of cells with C3 exoenzyme prior to CA-4-
Pexposure, prevented the formation of the NF B-DNA complexbands, 
while Y27632 or HA1077 were ineffective. These datasuggest that CA-4-P 
activates NF Bvia mechanisms involvingRho, but not Rho kinase.  This 
pathway is likely to be importantfor the expression of CAM following 
vascular targeted therapy.
Acknowledgements: The authors would like to thank Cancer Research UK for 
funding and OXiGENE Europe AB for supply of CA-4-P.
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APAG-1 DERIVATIVES AS ANTITUMOUR AGENTS 
Srinivas R. Jada*. Johnson Stanslas, Nordin H. Lajis, Said Saad,
Ahmad S. Hamzah, Andrew McCorroll, Charlie Mathews,
Malcolm F.G. Stevens, Department of Biomedical Sciences,
Faculty of Medicine and Health Sciences, Universiti Putra
Malaysia, 43400 UPM, Serdang, Selangor, Malaysia. 
APAG-1 is a diterpenoid lactone, isolated from a popular herb
found throughout the South East Asian region. Previously it was
shown that APAG-1 possesses antitumour activity against in vitro
and  in vivo breast cancer models (Stanslas et al. 2001 Eur J
Cancer, 37 (Suppl. 6): 169). Owing to the potential of APAG-1
as an antitumour agent, we synthesised simple derivatives
(SRJ01- 10) of this agent by acetylation, hydrolysis, oxidation,
condensation and Heck reactions. Using a 4-day MTT cytotoxic
assay we found that the derivatives had IC50 values in the
submicromolar concentration range in breast tumour cell line,
MCF-7, non-small cell lung cancer line, NCI-H460 and prostate
cell line, PC-3. Effect of these compounds on the cell cycle
progression showed that SRJ01 and SRJ03 induce G1 and G2/M
arrest in MCF-7 cells.
Screening of SRJ01 and SRJ03 against the 60 National Cancer
Institute (NCI) human cancer cell lines revealed that the 2
compounds failed to exhibit a pronounced antitumour selectivity.
We are currently synthesising newer derivatives of APAG-1 to
uncover agent(s) with increased antitumour potency and
selectivity. 
P18 
INHIBITION OF PROTEASOME FUNCTION AS A
MECHANISM OF ANTITU MOUR ACTIVITIES OF
NATURALLY OCCURRING  LACTONE RING-BASED
COMPOUNDS AND THEIR SYNTHETIC DERIVATIVES 
Johnson Stanslas*, Radin N.R. Yahaya and Srinivas R. Jada 
Faculty of Medicine and Health  Sciences, Universiti Putra
Malaysia, 43400 UPM, Serdang, Selangor, Malaysia. 
This study was conducted as an attempt to uncover themechanism of 
antitumour activities of naturally occurring APAG-1and goniothalamin 
(GTN) (Hawariah  & Stanslas, 1998,Anticancer Res., 18(6A): 4383; 
Stanslas et al. 2001, Eur J Cancer,37 (Suppl. 6): 169), and their synthetic 
derivatives. Usinglactacystin as a positive control, APAG-1 and its 
derivatives, SRJ01and SRJ03, and GTN were shown to significantly inhibit 
cell freeproteasome activity at concentrations of 25 microM and 50microM, 
accompanied with a strong association (r=0.75, p<0.05)with cytotoxic effect 
on breast cancer cell line, MCF-7. APAG-1 and SRJ03 were selected for 
evaluation of theirantitumour selectivity in a variety tumour cell lines based 
on theirpreliminary antitumour activity in MCF-7 cells. Using a 4-day 
MTTcytotoxic assay, parameters of growth inhibition GI50, TGI, LC50and 
IC50 were derived from dose-response growth inhibition curves.SRJ03 was 
found to be more active than APAG-1 in inducingcancer cell toxicity (mean 
IC50 of SRJ03 = 7.0 ± 1.7 microM vsmean IC50 of APAG-1 = 26.7 ± 5.8 
microM, p<0.05). Overall,SRJ03 was more selective in inhibiting growth 
and killing of breastcancer cells, MCF-7 and MDA-MB-231. On the 
contrary, APAG-1was not selective towards breast cancer cells; instead it 
displayedselectivity towards prostate (DU-145) and ovarian (SKOV-
3)cancer cell lines. However, the magnitude of selectivity was   1 logM 
concentration. The proteasome inhibitory property and the abilityto exert 
antitumour selectivity by APAG-1 and SRJ03 make thempromising new 
class of anticancer candidates. 
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PHARMACOKINETICS, METABOLISM & GLUTATHIONE
REACTIVITY OF SJG-136 
Gary P. Wilkinson*, Paul M. Loadman, Terence C. Jenkins, James
Taylor, Steve D. Shnyder, Patricia A. Cooper & David E. Thurston
Tom Connors Cancer Research Centre, University of Bradford,
All Saints Road, Bradford, West Yorkshire, BD7 3AY
SJG-136 is a novel DNA-crosslinking agent with sequence
selective properties. The PBD dimer shows potent in vitro
cytotoxicity and DNA-stabilising activity, and has been selected
for clinical development on the basis of impressive preclinical
activity. 
The aim of this study was to investigate the in vitro & in vivo
pharmacological characteristics of SJG-136 and to identify any
potential metabolites. The proposed reactivity of PBDs with thiol
containing macromolecules (e.g. GSH) was also investigated due
to the potential influence of this on the pharmacology of SJG-136.
An HPLC method was developed using fluorescence and
MS/MS detection. Intraperitoneal administration of SJG-136 to
NMRI mice at the MTD (0.2 mg/kg) gave peak plasma
concentrations of 336 nM after 30 min and an AUC of 0.34 uM. In
vitro metabolism studies of SJG-136 in the mouse liver S9 fraction
showed rapid drug depletion (< 10% at t0) likely to be due to GSH
conjugation. SJG-136 is freely metabolised to a demethylated form
in mouse liver microsomes & this metabolite was detected in in
vivo samples at low concentrations. This metabolite is not
detectible in the S9 fraction suggesting that GSH reactivity inhibits
metabolic degradation of the drug. SJG-136 reacts with GSH in a
concentration-dependant manner, suggesting increased adduct
formation at higher GSH levels. Analytically, these adducts appear
to be identical to those found in the S9 fraction. 
   Such low metabolic potential  in vivo simplifies the
pharmacology of the compound and enhances its therapeutic
potential. 
   All in vivo studies complied with UK home office regulations. 
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HYPOXIA INDUCED P53 ACTIVATION: THE ROLE OF THE 
REDOX-SENSING TRANSCRIPTIONAL CO-REPRESSOR 
CTBP2. 
Alexander. H. Mirnezami*; Sandra. J. Campbell; John. N. Primrose;
Peter. W. Johnson; Jeremy. P. Blaydes; Cancer Sciences Division, 
Southampton General Hospital. 
Background The p53 tumor suppressor protein has a critical role in the
cellular response to stress, and when activated, functions to
transactivate genes which induce apoptosis or growth arrest. The
oncoprotein Hdm2 is the most significant regulator of p53 activity, and
it achieves this partly through inhibition of p53 transactivating ability.
In order to investigate the mechanism by which Hdm2 brings about
this inhibition, we screened for novel Hdm2 interacting proteins and in
this process identified the redox-sensitive transcriptional co-repressor
CtBP2 as an Hdm2 binding partner. Methods The interaction was
verified using protein binding assays and deletion mutants used to
identify the interacting domains. The effect of the interaction on p53
activity was assessed using reporter gene assays. Results Hdm2
participates in a novel interaction with CtBP2 in vitro and in vivo. The
acidic domain of Hdm2 and the N-terminus of CtBP2 are necessary
and sufficient for this interaction. CtBP proteins undergo an NADH-
induced conformational change, which we show results in a loss of
Hdm2 binding ability. Recruitment of CtBP2 by Hdm2 results in a
promoter selective repression of p53-dependant transcription, and this
is abolished by hypoxia-mimicking conditions that increase NADH
levels. Conclusions We have identified a novel interaction between
Hdm2 and CtBP2, and identified that this interaction is regulated
through changes in cellular redox and functions to keep p53 activity in
check. This represents a novel mechanism whereby p53 activity can be
enhanced by hypoxia, and suggests that inhibition of the Hdm2-CtBP2
interaction may prove a useful target in hypoxia insensitive p53 wild-
type tumors. 
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USING HORSERADISH PEROXIDASE FOR GENE
THERAPY UNDER OXIC AND HYPOXIC CONDITIONS. 
Joanna Tupper*, Gillian M. Tozer, Gabi U. Dachs 
Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, 
Northwood, HA6 2JR, UK. 
   Hypoxic regions within solid tumours tend to be both radio and 
chemoresistant, resulting in adverse effects on locoregional 
control in a variety of human and experimental tumours. In this 
study we have used the horseradish peroxidase enzyme (HRP) 
for gene directed enzyme prodrug therapy (GDEPT). The HRP 
enzyme is capable of catalysing the 1 electron reduction of a 
variety of compounds including indole-3-acetic acid (IAA) and 
related indoles (Kenten, 1955, Biochem J, 59, 110). In addition 
HRP can catalyse the conversion of paracetamol to its 
semiquinone, resulting in formation of N-acetyl-p-benzoquinone 
imine (Potter, 1987, Biochem J, 262, 966). 
   Gene  modified  cells  were  grown  either  as  monolayers  or 
tumour cell spheroids, and exposed to prodrugs for 4 or 24h. 
After 24h exposure, 5mM IAA produced over 95% cell kill in 
HRP transfectants in both 300 and 700µm diameter spheroids. 
Similar results were seen with 1Me-IAA, whilst 5Br-IAA 
showed cell kill after 4h selectively in 700µm diameter 
spheroids, supporting previous data that it is rapidly activated 
under hypoxia (Greco, 2001, Mol. Cancer Ther, 1, 151). 
Paracetamol resulted in selective cell kill of HRP transfectants 
under both oxic and anoxic conditions. Clonogenic survival was 
reduced by 95% under anoxia at 5mM, and 8mM under 
normoxia. 
These data show that the use of the HRP enzyme for GDEPT 
shows continued promise for selective therapy in solid tumours, 
with a range of potential prodrugs suitable for hypoxia targeting. 
   This work was funded by Cancer Research UK. 
ENHANCEMENT BY INDOLE-3-ACETIC ACID (AUXIN) OF
OXIC AND HYPOXIC PHOTODYNAMIC  THERAPY  
Lisa K. Folkes* and Peter Wardman, Gray Cancer Institute, Mount 
Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK. 
Photodynamic therapy in cancer therapy generally requires the 
excitation of oxygen to highly reactive singlet oxygen to kill cells. 
Tumours commonly exhibit low oxygen tensions. Addition of 
indole-3-acetic acid (I) to mammalian cells photosensitised with 
phenothiazinium dyes dramatically increases toxicity compared to 
the dyes alone, both in aerobic and hypoxic systems.  
   Toluidine blue (TB
+), used in cancer diagnosis, and methylene 
blue (MB
+), used in experimental photodynamic therapy have been 
investigated. Tissue penetration of light occurs at the high 
wavelength at which these dyes absorb. Excitation of the dye 
results in a triplet state that oxidises I to a radical cation which 
rapidly decarboxylates to a skatoyl radical. In hypoxia this may be 
involved in toxicity whilst in aerobic conditions it adds oxygen 
leading to a variety of products. These include methylene oxindole 
a highly toxic species reactive towards cellular nucleophiles. 
Mouse fibroblast V79 and human breast MCF7 cells were 
incubated with 2 µM dye ± 0.1 mM I and illuminated at 630 or 660 
nm (LEDs) either in air or in 1% oxygen. Cells were allowed to 
grow into colonies and surviving fractions (SF) calculated.  
Dye Light 
dose 
 V79 cells 
SF in 1% O2
V79 cells 
SF in air 
MCF7  cells 
SF in air
TB
+ 1.6 J/cm
2 0.86±0.015 0.56  ±  0.12 0.91±0.005 
TB
+ + I  1.6 J/cm
2 0.011±0.003 0.005±0.003 0.007±0.003
MB
+ 1.1 J/cm
2 -  1.03 ± 0.002 1.06 ± 0.08 
MB
++ I  1.1 J/cm
2 - 0.05  ±  0.035 0.002±0.001
   The results show that addition of IAA at achievable non-toxic 
concentrations in man could markedly increase the efficacy of
some photodynamic therapy treatments. Rational design of 
photosensitizer and IAA analogues is possible based on 
thermodynamic and kinetic properties.     
This work is supported by Cancer Research UK
IMMUNODETECTION OF GLUT-1 AND NQO1 
(NAD(P)H:Quinone oxidoreductase) IN SUPERFICIAL BLADDER 
CANCER. 
Palit V* Basu S, Bibby MC,  Shah T,  Gill JH and Phillips RM. 
Cancer research unit, University of Bradford, Bradford  
Introduction: Elevated levels of reductase enzymes in conjunction with
tumour hypoxia are two key parameters that will influence the efficacy of
bioreductive drugs such as Mitomycin C. The enzyme NQO1 has been
implicated in the activation of Mitomycin C and the glucose transporter
GLUT-1 is known to be induced under hypoxic conditions. 
Aims: To determine the relationship between NQO1 and GLUT-1 protein
expression in superficial transitional cell cancer (TCC) of the bladder.  
Methods: Sections from 20 paraffin embedded tissues representing
superficial (pTa/pT1) and muscle invasive (pT2) TCC were cut and
stained for NQO1 and GLUT-1. Slides were scored by three independent
investigators and graded as low, moderate or high depending upon the
extent and intensity of staining. 
Results: Staining for NQO1 was cytoplasmic and confined to tumour
cells with superficial tumours (n=12) having higher levels than muscle
invasive (n=8) tumours. Staining for GLUT-1 was predominantly
membranous with moderate to high levels of GLUT-1 present in
superficial tumours (the majority of pT2 tumours have low levels of
GLUT-1). In papillary tumours, intense GLUT-1 staining was found on
the luminal surfaces of the tumour with no staining seen in cells residing
close to blood vessels. NQO1 was present in both GLUT-1 positive and
negative regions of the tumour.     
Conclusions: Elevated levels of both NQO1 and GLUT-1 were found in
superficial bladder TCC. The finding that many papillary type tumours
have intense regions of hypoxia (GLUT-1 positive) offers potentially
significant opportunities for hypoxia mediated therapeutic intervention. 
HYPOXIA UPREGULATES CYTOKINE-INDUCIBLE NOS
EXPRESSION IN HUMAN TUMOUR CELLS.
Simendra Singh*, Edwin  J. Chinje & Ian  J. Stratford 
School of Pharmacy, University of Manchester, Manchester (U.K.) 
  The hypoxic tumour microenvironment is responsible for the selection 
of malignant clones that overexpress hypoxia-inducible genes responsible 
for tumour angiogenesis. The cytokine-inducible form of nitric oxide 
synthase (iNOS) appears to respond to hypoxia stress since its activation 
is detected in solid tumours. Previous studies indicate that induction of 
iNOS by cytokines in murine tumour cells (EMT-6) trigger a NO 
production high enough to reverse hypoxia-induced radioresistance. The 
aim of this study was to examine the activity of iNOS in aerobic and 
hypoxic conditions after cytokine exposure in human breast tumour cells.
 MDA 231 cells grown to early confluence were exposed to a 
combination of LPS (50µg/ml) and IFN-γ  (100ng/ml) for 24 hr in air & 
hypoxia. Cultures were then washed out from cytokines and re-incubated 
for 24, 48, and 72hr. iNOS activity was estimated by conversion of 
radiolabelled arginine to citrulline and NO.
 Combination of LPSand IFN-γ  resulted in the up-regulation of iNOS 
activity up to 48 hr, which remained unchanged at 72 hr. The iNOS 
induction in air at 48 hr was 6-fold compared to untreated cells. In the 
absence of LPS and IFN-γ , hypoxia only marginally up-regulated the 
iNOS level; about 1.5-fold at 48 hr compared to the untreated cells in 
normoxia. LPS and IFN-γ , treatment in hypoxia resulted in maximal 
iNOS induction at 48 hr, which was 4-5 fold in comparison to hypoxia 
alone.
 We have demonstrated that hypoxia up-regulates cytokine-induced 
expression of iNOS in human breast tumour cells. This is of significance 
since some studies have indicated that NO produced intracellularly in the 
proximity of radiation targets can be more effective than chemically 
released NO. Therefore, cytokine modulation of iNOS activity in human 
tumours can potentially be exploited to increase radiation response. 
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AMINE REDUCTION PRODUCTS ARE KEY BYSTANDER
METABOLITES WHEN CB 1954 IS ACTIVATED BY E. coli
NITROREDUCTASE.  
Nuala A. Helsby*, Dianne Ferry, Adam V. Patterson and William
R. Wilson. Auckland Cancer Society Research Centre, University
of Auckland, Private Bag 92019, Auckland, New Zealand. 
  The dinitrobenzamide aziridine CB 1954 is metabolised by E. coli 
nitroreductase (NTR) to an equimolar mixture of the corresponding 2- 
and 4-hydroxylamines. The 4-hydroxylamine is a potent DNA 
crosslinking agent, and is considered to be the major cytotoxic metabolite 
when NTR/CB 1954 is used in GDEPT (1).  In this study we re-assess 
the bioactivity of CB 1954 metabolites, and examine their relative 
contribution to the bystander effect (killing of cells that lack NTR) when 
they are formed within 3D cell cultures (multicellular layers, MCL). 
NTR-transfected V79 cells were incubated with CB 1954, as single cell 
suspensions, and the extracellular medium was fractionated by HPLC 
and bioassayed against UV4 (ERCC-1 deficient) cells. This revealed four 
metabolites, identified by mass spectrometry as the 2- and 4-
hydroxylamine and their corresponding amines. As expected, the 4-
hydroxylamine was the major cytotoxic metabolite, but the other three 
species also showed significant bioactivity.  Single cell suspensions of 
NTR transfected SiHa cells gave a similar metabolic profile. When CB 
1954 was added to the donor side of the MCL (NTR transfected SiHa 
cells) the metabolites detected included the 4-hydroxylamine as well as 
the 2- and 4- amines. However, the only metabolites appearing on the 
other side of the MCL were the 2- and 4-amines. These results suggest 
that the amine metabolites are significant contributors to the bystander 
effects of CB 1954 following NTR activation in GDEPT, especially at 
long diffusion distances from NTR vectors.
  (1) Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ 
(1997). Hum Gene Ther 8: 709 
FACTORS INFLUENCING HUMAN CANCER CELLS
RESPONSE TO MITOMYCIN C. 
Milène Volpato*, Paul M. Loadman, Roger M. Phillips. 
Cancer Research Unit, Bradford University, BD7 1DP Bradford. 
Predicting tumour response to a specific treatment is an
important issue for clinicians and researchers. Mitomycin C
(MMC) is a bioreductive prodrug routinely used in clinic, which
requires enzymatic activation. Several reductases can metabolise 
MMC and DT-diaphorase was thought to be the main activating 
enzyme. Correlation between tumour response and enzyme activity 
remains controversial. But the mechanism of action of MMC
appears to be too complex to enable forecasting response on the 
basis of one enzyme activating system. The knowledge of drug
metabolism may provide a better indicator of response. The aim of 
this study is to investigate how factors such as MMC metabolism
rates and DNA damage induction and repair could influence 
response of cell lines to MMC. Cells lines have been characterised 
by their sensitivity to MMC and the activity of DTD and P450
Reductase. H460, HT29 and RT4 have respective IC50 values of
0.77, 4.60 and 30.20 µM and respective (DTD;P450R) activities of 
(353;37), (347;10) and (134;11) nmol/min/mg. MMC metabolism
rates were assessed (HPLC): MMC has a half life of approximately 
25 min in H460 cells, 33 min in HT29 cells and 17.8 min in RT4 
cells. The induction of cross-link and repair (COMET assay) was 
also analysed. 70% of DNA cross-links were obtained in H460
cells treated with 5 µM of MMC and 20% were repaired after 6h. 
Preliminary studies in A549 cells, which are as sensitive as HT29
cells the extent of damage was less (50%) and repair was faster and 
more extensive. In the resistant RT4 cells, no DNA cross-link was 
detectable. This study clearly suggests that at least two pathways 
could lead to MMC resistance: repair or detoxification
mechanisms. Ongoing studies are investigating these pathways 
further. 
QM/MM COMPUTATIONAL STUDY OF INTERACTION
OF NQO1 WITH BIOREDUCIBLE INDOLEQUINONES 
Shelley L. Moores*, Stephen W. Doughty, Roger M. Phillips,
Terry C. Jenkins 
YCR Laboratory of Drug Design, Tom Connors Cancer
Research Centre, University of Bradford, Bradford, West
Yorkshire BD7 1DP 
  NQO1 [NAD(P)H:  quinone  acceptor  oxidoreductase  1,  or
DT-diaphorase] can bioreductively activate prodrugs, including
quinones, to active drug species while using NAD(H) or
NAD(P)H as an electron donor (co-substrate). As levels of
NQO1 are elevated in tumours compared to normal tissues, this
system is currently being exploited for chemotherapeutic gain
in enzyme-directed bioreductive drug approaches, particularly
ADEPT, GDEPT and ENACT. 
  QM/MM modelling techniques and QSAR analysis have now
been used to examine linkages between molecular properties
(e.g. activation energy, LUMO) for a series of bioreducible
indolequinones [Phillips, R.M. et al. (1999) J. Med. Chem. 42
4071] and their substrate activity (kcat, Km) towards NQO1. This
relationship can be used to predict activity for other candidate
agents and thereby assist the overall drug design process. 
For the first time, (i) correlation between drug properties and
potency, and (ii) the use of molecular probes within the active
reducing enzyme pocket provide a firm structural basis for the
observed substrate preferences. This pharmacophore-based
approach offers a powerful tool for the rational identification of
new and active classes of bioreducible prodrugs for NQO1. 
CHARACTERISATION OF THE IN VIVO HOLLOW FIBRE
ASSAY FOR THE ANALYSIS OF DNA DAMAGE USING THE
COMET ASSAY. 
Marie Suggitt
*, Michael C. Bibby. Tom Connors Cancer Research
Centre, University of Bradford, Bradford, BD7 1DP.   
The  in vivo hollow fibre assay (HFA) is used as a screening
model by the National Cancer Institute (NCI) to prioritise potential
anticancer agents for secondary xenograft testing. This study
investigates whether the HFA can be used as a short-term assay to
demonstrate drug-target interactions in vivo, namely DNA damage.
Initially A549 lung carcinoma cells were seeded into hollow
fibres at various cell densities in order to characterise optimal cell
growth both in vitro and in vivo over 5 days. Following in vitro
studies of monolayer and hollow fibre cultures revealing DNA
crosslinking of A549 cells with mitomycin C (MMC), hollow
fibres were seeded with A549 cells (1 x 10
6cells/ml) and implanted
into NMRI mice. On day 4 MMC was administered
intraperitoneally (i.p) at its maximum tolerated dose (MTD)
(6mg/kg). Fibres were removed at 2 hours and cells retrieved for
DNA analysis using the comet assay.  
Methods of cell preparation for comet analysis were developed
throughout the study. Home Office guidelines for the welfare of
animals were adhered to throughout the study. 
Results revealed statistically significant differences between the
mean tail extent moment (TEM) values of treatment and control
groups at both i.p and s.c sites  (p = <0.001). These values revealed
MMC-induced DNA crosslinking in 55% and 49% of cells at i.p
and s.c sites respectively. 
In conclusion these data demonstrate that the HFA can be used as
an in vivo preclinical model in anticancer drug development for
studying the pharmacodynamic effects of the standard agent
MMC. This assay is now being used to investigate novel potential
DNA interactive compounds.   
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IMMUNOHISTOCHEMICAL ANALYSIS OF NQO1 AND
CYTOCHROME P450 REDUCTASE IN HUMAN
SUPERFICIAL BLADDER CANCERS: RELATIONSHIP WITH
CLINICAL RESPONSE TO MITOMYCIN C.
Basu S
  *, Martin SW, Seargent J , Loadman PM , Gill JH , Shah T, 
Puri R and Phillips RM 
Corresponding address: S. BASU; Cancer Research Unit, 
University of Bradford, Bradford BD7 1DP, UK  
  Introduction & aims: Mitomycin C (MMC) undergoes bioreductive 
activation by cellular reductases particularly by the enzymes NQO1 and 
cytochrome P450 reductase (P450R). Considerable controversy 
surrounds the issue of whether tumour response can be predicted on the 
basis of tumour enzymology. Our aim in the study was to predict the 
response of superficial bladder cancers (SBC) to MMC in the clinic on 
basis of the immunohistochemical distribution of NQO1 and P450R in 
the tumours.
     Methods: In this retrospective study, tumour response to MMC 
(time to first recurrence) was compared to immunohistochemical 
localisation of NQO1 and P450R in 102 human SBC (pTa & pT1) 
specimens. Sections were stained for human NQO1 and P450R and 
graded according to staining intensity and distribution by three 
independent investigators.
    Results: The majority of tumours (45%) had high levels of NQO1 
and staining was confined to the cytoplasm of tumour cells In contrast, 
P450R levels in all specimens examined showed moderate to high 
staining in both cytoplasm and stroma. Clinical response to MMC 
(either single dose or course) was independent of both NQO1 and 
P450R expression in tumours.
    Conclusion: The results of this retrospective study demonstrate that 
the response of SBC to MMC cannot be predicted on the basis of NQO1 
and P450R levels. This study has also demonstrated that NQO1 may be 
a good target for therapeutic intervention in SBC.   
DOES NQ01 [NAD(P)H QUINONE OXIDOREDUCTASE]
GENOTYPE INFLUENCE THE RESPONSE TO MITOMYCIN
C IN SUPERFICIAL BLADDER TUMOURS?
Basu S
* , Martin SW , Brown JE , Loadman PM  , Flannigan GM
Shah T  Puri R and Phillips RM  
Corresponding address: S. BASU; Cancer Research Unit,
University of Bradford, Bradford BD7 1DP, UK  
 Introduction & aims: The enzyme NQO1 has been suggested to
play a role in the bioreductive activation of Mitomycin C (MMC).
The gene encoding for NQO1 is polymorphic and a 609C>T
variant results in loss of NQO1 enzyme activity. In view of the
potential role of NQO1 in the mechanism of action of MMC, the
genotype of patients undergoing MMC therapy may have a
significant bearing on efficacy.  Our aim in this study was to
determine if the response of superficial bladder cancer to MMC
can be forecast on the basis of NQO1 genotype status.  
Methods: Following ethical approval, genomic DNA was
extracted from 84 paraffin embedded human bladder tumours
specimens. NQO1 genotype was determined by PCR-RFLP
techniques, which involved the use of two rounds of PCR
amplification using a nested primer strategy. PCR products were
digested with Hinf 1 and genotyped on the basis of the restriction
fragments produced. 
Results: Out of 84 patients, 51 (63.1%) were wild type, 29
(34.5%) were heterozygous, while 2 (2.4%) were homozygous
mutants. The clinical response to MMC (time to first recurrence)
failed to show any association with NQ01 genotype status. 
Conclusions: The response of bladder cancer patients to MMC
cannot be forecast on the basis of NQO1 genotype status. These
results suggest that NQO1 plays a limited role in determining the
final outcome of MMC chemotherapy. 
‘PING-PONG’ FLAVIN REDUCTION IN NQO2:
MECHANISM STUDIES AND BIOREDUCTION 
Terry C. Jenkins*, Shelley L. Moores*, Stephen W. Doughty,
and Richard J. Knox
1
YCR Laboratory of Drug Design, Tom  Connors Cancer
Research Centre, University of Bradford, West Yorkshire BD7
1DP; 
1Enact Pharma plc, Porton Down, Wiltshire 
Human NAD(P)H quinone oxidoreductase 2 (NQO2) is an
enzyme that is specifically elevated in most tumours and now
being exploited in new ENACT-based therapies. Using a redox
cycling reaction, FAD+ present in the active site transfers
hydrogen atoms from a co-substrate (cofactor) to a substrate
through a sequential ‘ping-pong’-type mechanism. This process 
can be used to reduce a prodrug substrate to a highly toxic
alkylating drug species inside a tumour – e.g. CB1954 is an
excellent prodrug substrate. NQO2 is unique in that it uses a
non-biogenic co-substrate (NRH) of bacterial origin. 
   Experimental  data  with  synthetic  nicotinamide-based  NRH
replacements show that simple derivatives are superior
co-substrates (“cofactors”) for NQO2 in the first half of its
redox cycle (oxidized→  reduced enzyme form). This finding
and the ‘ping-pong’ effect can be rationalized in terms of
molecular interactions; the use of NRH as co-substrate, rather
than the NAD(H) or NADP(H) used by NQO1, is also
explained. Correlation between activity and molecular character
has been established using QM/MM methods, and this linkage
can predict further NRH replacements. These findings have also
been used to predict activity in prodrug/drug substrate families
in the second reducing half of the NQO2 redox cycle. 
For the first time, the exacting requirements for substrate (and
co-substrate) activity by NQO2 can now be understood. 
MANIPULATION OF P450 GENE EXPRESSION IN 
TUMOURS; A NOVEL APPROACH FOR TARGETED 
ACTIVATION OF BIOREDUCTIVE PRODRUGS 
Robson T, Yakkundi A, McCarthy HO, McErlane V, Hughes 
CM, Hirst DG, *McKeown SR. Radiation Science group, 
University of Ulster, Jordanstown, N. Ireland. BT37 OQB
We are developing a gene-directed enzyme prodrug therapy
(GDEPT) strategy to enhance metabolism of a novel
bioreductive drug, AQ4N.  Bioreductive drugs are activated in
hypoxic cells allowing effective targeting of hypoxic,
radioresistant tumours. We aim to achieve additional selectivity
by using an X-ray inducible promoter linked to our therapeutic 
gene (cytochrome P450s). This should enhance drug metabolism
only in the radiation field and spare normal tissues. We have 
identified several human cytochrome P450s which are important 
for AQ4N prodrug activation, these include CYP3A4, 1A1 and 
2B6. RIF1 murine tumour cells transfected with cDNA from any
one of these CYPs displayed increased DNA damage and 
clonogenic cell kill following treatment with AQ4N under 
hypoxia compared to controls.  When tumours are transfected in 
vivo we have shown that a single CYP3A4 injection using a 
simple non-optimized approach can increase metabolism of 
AQ4N, and when used in combination with radiation 3 out of 9 
tumours are locally controlled for > 60 days. This implies that 
the bioreduction of AQ4N by CYPs in this tumour system is 
sub-optimal and this strategy could therefore be very promising 
for clinical use where CYP levels are known to be variable. We 
are also developing CYPs linked to the radiation inducible 
promoter WAF-1 to allow for selective activation in vivo.  
This work is funded by Cancer Research UK. In vivo studies are 
conducted under the Animals (Scientific Procedures) Act 1986.
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DEVELOPMENT AND USE OF AN IN-VIVO PHENOTYPING
TEST FOR CYTOCHROME P450 3A4 IN CANCER 
PATIENTS. 
*Simon J. Brown, Clive Y. Ward, Roland C. Wolf, Elaine M 
Rankin. Biomedical Research Centre, University of Dundee.
  The pharmacokinetics of most cytotoxic drugs show marked inter-
patient variability.  This may lead to unpredictability in the efficacy of 
the treatment or the degree of toxicity experienced by patients.   
Cytotoxic drug dosages are often based on an estimation of the patient’s 
body surface area.  This is now thought to be inaccurate as it is not 
related to physiological measures relevant to drug metabolism and 
disposition, such as hepatic or renal function. Oxidative metabolism of 
drugs such as taxanes and vinca alkaloids by the cytochrome P450 
(CYP) isoform 3A4, which shows marked variability, may explain some 
of the variation in pharmacokinetics. Assessment of CYP3A4 enzyme 
may give a more accurate way of determining the dose of cytotoxic 
drugs for individual patients.  To determine an individual’s CYP3A4 
activity we have carried out an in-vivo phenotyping test, where 
metabolism of a carefully selected probe drug is used to estimate the 
activity of the enzyme involved in its metabolism.  For CYP3A4 we 
have used a small dose of Midazolam (a benzodiazepine drug commonly 
used in conscious sedation) which is predominantly metabolised by 
CYP3A4.  As this method has previously been used in healthy 
volunteers, we have carried out a pilot study to see if it is safe and 
applicable to cancer patients, who may have liver disfunction and may 
be taking other medications which can induce or inhibit CYP3A4 
activity. We will extend this study to correlate in-vivo phenotyping data 
for CYP3A4 (using Midazolam and a limited sampling strategy) with 
drug handling (measured by pharmacokinetic sampling), drug efficacy 
(assessed by standard RECIST criteria), and drug toxicity (assessed by 
Common Toxicity Criteria) in patients receiving drugs which are 
metabolised by CYP3A4. 
CYTOCHROME P450 CYP1B1 VERSUS GLUT 1 PROTEIN 
EXPRESSION DURING THE DEVELOPMENT OF HEAD 
AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCs). 
Mhairi L Greer
1*, Francis M Daley
1, Paul Barber
1, Graeme I 
Murray
2, Laurence H Patterson
3, Steven A Everett
1, 
1Gray Cancer 
Institute, Mount Vernon Hospital, Middx HA6 2JR, 
2University of 
Aberdeen,
3TheSchool of Pharmacy, London
The trans-membrane glucose transporter protein (GLUT 1) is detectable in
pre-malignant squamous epithelia and squamous cell carcinomas of the head
and neck. The aim of this study was to compare the tissue distribution of 
CYP1B1 and GLUT 1 to ascertain their relative importance as diagnostic 
molecular markers. HNSCC sections were semi-quantitatively assessed
using monoclonal CYP1B1 and polyclonal GLUT 1 antibodies and
immunohistochemistry/light microscopy. Membrane-bound GLUT 1
expression in the carcinoma tissue was localised mainly in the tumour 
periphery but absent from the centre of well-differentiated tumour islands, in
contrast CYP1B1 was expressed throughout. CYP1B1 and GLUT 1 both
exhibited intra-patient heterogeneity. Protein expression of the two antigens 
in pre-cancerous tissue (n=17) showed that CYP1B1 was a better bio-
marker, as staining was stronger and detectable throughout the tissue (76% 
CYP1B1 vs. 24% GLUT 1). Membrane bound GLUT 1 protein was strong
only at the tip of the rete processes. 
Immunoreactivity in hyperplasia (%) 
Marker Weak Medium Strong
CYP1B1 (n=47) 0  40 36 24
GLUT1   (n=17)  6  29 24 41
The results indicate that CYP1B1 is a superior biomarker for the 
detection of pre-malignant lesions in HNSCC. The over-expression of 
CYP1B1 during HNSCC development may prove a useful therapeutic 
target for CYP1B1-activated prodrugs.  
This work is supported by Cancer Research UK and GLCRT. 
Negative
DMU135: A CYP1B1 ACTIVATED TYROSINE KINASE INHIBITOR 
PRODRUG WITH TUMOUR SELECTIVE ACTIVITY. P.C. Butler*, 
K.C. Ruparelia, T. Ijaz, H.L. Tan, N.E. Wilsher, P.J. Perry, M.D. Burke, 
and G.A. Potter, Cancer Drug Discovery Group, School of Pharmacy, De 
Montfort University, Leicester UK LE1 9BH
DMU-135 is a new anticancer prodrug that is activated by the tumour 
selective catalytic activity of the cytochrome P450 enzyme CYP1B1
1. 
Upon oxidative metabolism by CYP1B1 the low-toxicity prodrug DMU-
135 is bioactivated intra-tumourally to a potent tyrosine kinase inhibitor. 
The active metabolite DMU-117 is a potent broad spectrum TK inhibitor 
that is able to shutdown >30 % of total cellular tyrosine kinase activity. In 
normal cells DMU-135 typically showed low toxicity (e.g. in MCF-10A 
cells IC50 = 2 uM). However a marked increase in cytotoxicity was 
observed in cells expressing the CYP1B1 enzyme. Specifically, in MDA-
468 tumour cells the prodrug had very potent cytotoxic activity (IC50 = 
0.006 uM). In CYP1 inducible tumour cells, cytotoxicity increased 
dramatically upon enzyme induction, and was abrogated using enzyme
inhibitors. Furthermore, the prodrug had very low toxicity to primary
cultured normal human cells (IC50 = 30 uM), hence the tumour selectivity
factor is 5000-fold. These results suggest that DMU-135 is a tumour 
selective prodrug useful for the treatment of CYP1B1 expressing tumours. 
Moreover, because the active metabolite inhibits multiple tyrosine kinase 
pathways, resistance due to second messenger redundancy is unlikely.
1. G.A. Potter and P.C. Butler, 3,4-Methylenedioxy Chalcones (DMU-
135), British Patent Appl. GB 0123777, 2001. 
ABSTRACT WITHDRAWN
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CYP1B1 PROTEIN EXPRESSION IN PROSTATE CARCINOMA, 
DM Carnell
1,2*, FM Daley
1, RE Smith
3, P Hoskin
2, GI Murray
4, & 
SA Everett
1, 
1Gray Cancer Inst, 
2Marie Curie Res Wing, 
3Dept
Pathol, Mount Vernon Hosp, Northwood, Middlx 
1HA6 2JR or 
2,3HA6 2RN. 
4Dept Pathol, Univ Aberdeen, Aberdeen AB25 2ZD. 
Previous cDNA microarray and RT-PCR studies have demonstrated 
the expression of cytochrome P450 CYP1B1 in malignant prostate
and benign prostatic hyperplasia. Normal tissues including the liver 
can express the CYP1B1 gene without expressing the protein. The 
aim of this study was to compare CYP1B1 protein expression in 
prostate carcinoma with bladder carcinoma which over-expresses 
CYP1B1. Protein expression was detected immunohistochemically
using a monoclonal antibody specific for CYP1B1. Radical
prostatectomy specimens (n = 14) of moderate Gleason grade 3+3 
and 3+4 were compared retrospectively with biopsies taken from
patients with bladder carcinoma (n = 20). The intensity of 
immunoreactivity was assessed semi-quantitatively and graded as 
strong, moderate, weak, or negative against a positive control. The 
majority of the prostate carcinoma tissue was positive for CYP1B1 
although both inter- and intra-patient variability was evident; 2 
tumours (14 %) were negative, 1 tumour (7 %) was weak, 7 (50 %) 
tumours were moderate and, 4 tumours (28 %) exhibited strong 
CYP1B1 immunoreactivity. In both prostate and bladder carcinoma, 
CYP1B1 protein expression was localised in the cytoplasm of the 
tumour cells and was undetectable in the associated normal stromal
tissue. Bladder carcinoma exhibited greater CYP1B1 protein 
expression with moderate (45 %) to strong (55 %) immunoreactivity.
CYP1B1 protein expression was also detected in benign hyperplastic
prostate epithelium present in 13 (93 %) samples. In conclusion, 
human prostate carcinoma expresses the CYP1B1 protein with high 
frequency (n = 14, 86%) but lower immunoreactivity than bladder 
carcinoma. Future work will measure CYP1B1 functional activity in 
prostate carcinoma. This work is supported by Cancer Research UK 
INHIBITION OF THE MDM2-P53 INTERACTION AS A
POTENTIAL TARGET IN CANCER THERAPY 
Gillian Farnie, Shafiq Ahmed* and John Lunec 
Northern Institute for Cancer Research, University of Newcastle,
Medical School, Framlington Place, Newcastle NE2 4HH, United
Kingdom. E-mail: S.U.Ahmed@ncl.ac.uk 
      MDM2 gene amplification and/or overexpression in a range of
tumours causes inactivation of the p53 tumour suppressor protein.
Inhibitors of MDM2-p53 interaction are therefore therapeutic
candidates for activation of the p53 pathway in tumours. 
AP-B, an isomer of a previously published synthetic peptide (AP,
Chène et al 2000, J. Mol. Biol. 299. 245-253), structurally based on the
p53 binding domain for MDM2, was tested on wild type p53 cell lines
with amplified and overexpressed MDM2 (SJSA and LS) or normal
levels of MDM2 (HCT 116 and A2780).  A luciferase based gene
reporter assay was used to measure transcriptional activity of p53 and
Western blotting to determine protein levels of p53, MDM2 and
p21
WAF1 at 4, 9 and 24 hours.  Cell line growth and cell cycle
distribution was evaluated using Sulforhodamine B (SRB) assays and
FACS analysis. 
   The AP-B peptide (100µM) significantly increases p53 activity in
overamplified MDM2 cell lines (9 fold and 5 fold increases in SJSA
and LS cell line respectively).  This correlated with Western blot data,
which showed an increase in the levels of p53, MDM2 and p21
WAF1.
FACS analysis showed a significant increase in G1 arrest with the
SJSA cell line, in concordance with p21
WAF1 levels.  SRB data on
control cell lines SaoS-2, (p53 null) and HCT 116 N7 (p53 degraded)
showed no cell growth inhibition at 72 hours, indicating that growth
arrest is dependent on wild type p53 activation.  These findings
confirm and validate the MDM2-p53 interaction as a potential target in
cancer therapy, particularly for MDM2 overexpressing tumour. 
IN VITRO STUDY OF THE P53 PATHWAY IN PERIPHERAL
BLOOD MONONUCLEAR CELLS IN RESPONSE TO
DOXORUBICIN TREATMENT 
*Maged S. Nashed, George A. Thomson, Fiona E.M. Paulin, Julie 
Wardrop, Elaine M Rankin, David P Lane. Biomedical Research Centre, 
Department of Surgery and Molecular Oncology, University of Dundee.
Introduction and Aims   p53 is a tumour suppressor gene which is 
mutated in more than 50% of all sporadic cancers. The relationship 
between p53 status, response to treatment and the degree of side effects 
remains controversial. The aims of this study were to examine the pattern 
of changes in the key genes involved in the p53 pathway in normal 
tissues upon in vitro exposure to doxorubicin by means of western 
blotting (WB) and to examine the correspondence between 
immunohistochemistry (IHC) and WB findings in relation to the different 
levels of p53 protein. Materials and Methods   Peripheral blood 
mononuclear cells (PBMNC) were used as a surrogate marker of normal 
tissue response to chemotherapy. PBMNC were isolated from normal 
subjects by density gradient centrifugation. Parallel experiments were 
done using resting and phytohemagglutinin activated PBMNC where 
cells were treated in vitro with different doses of doxorubicin for different 
durations designed to simulate various in vivo situations. p53, p21 and 
caspase 3 monoclonal antibodies were used for WB. IHC was done from
formalin fixed paraffin embedded cell blocks of PBMNC. Results  The
overall pattern of p53 induction was similar among different individuals. 
However, the degree of its expression varied in relation to both the dose 
and the length of exposure to doxorubicin. p21 induction (as a marker of
p53 transcriptional activity) followed the same pattern as p53 in activated 
PBMNC. Early activation of caspase 3 (as a marker of effector stage of
the apoptotic pathway) in activated cells was also seen. The degree of p53 
induction detected by WB corresponded to that detected by IHC and the 
degree of caspase 3 and p53 induction detected by WB correlated with 
PBMNC morphological changes. Conclusions Different degrees of
induction of the key genes involved in the p53 pathway can be studied in 
PBMNC. This study opens an interesting field of in vivo experiments 
using IHC on PBMNC to identify molecular markers, which could 
potentially be used to predict chemotherapy toxicity to normal tissues. 
BCL-2 CONSTITUTIVELY SUPPRESSES P53-DEPENDENT
APOPTOSIS IN COLORECTAL CANCER CELLS 
Ming Jiang and Jo Milner* Yorkshire Cancer Research P53
Laboratory, Department of Biology,University of York, YORK YO10
5DD, UK 
To dissect apoptotic genes governing the survival of colorectal
carcinoma cells we employed RNAi to silence Bcl-2 and Bcl-xL in
isogenic clones of p53+/+ and p53-/- cells, and of Bax+/- and Bax-/-
cells. We identify a novel pro-apoptotic function of p53 that does not
require activation by genotoxic agents and that appears to be
constitutively suppressed by Bcl-2. Silencing of Bcl-2 induced massive
p53-dependent apoptosis. The “Bcl-2/p53 axis” requires Bax and
caspase 2 as essential apoptotic mediators. This newly discovered Bcl-
2/p53 functional interface represents a key regulator of apoptosis
which can be activated by targeting Bcl-2 in colorectal carcinoma
cells.  
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INK4a and P15
INK4b ALTERATIONS IN VULVAL AND
ENDOMETRIAL CANCER 
Yuzhu Cheng* and Anthony D Blackett 
Sheffield University Department of Obstetrics & Gynaecology, 
The Jessop Wing, Sheffield S10 2SF  
 P16INK4a and p15INK4b are tumour suppressor genes located on 
chromosome 9p21.  These two genes regulate the cell cycle pathway by 
inhibiting the cyclin D/CDK4/6 mediated phosphorylation of pRb.  In 
human neoplasms, the p16INK4a and p15INK4b genes may be silenced in 
the following ways: homozygous deletion, promoter methylation and 
point mutation. The 9p21 gene cluster has been implicated in a variety 
of tumour types and derived cell lines.  Although p16INK4a and p15INK4b 
genes are known to play a role in many malignancies, their significance 
in vulval cancer (VC) and endometrial cancer (EC) was uncertain, and 
their physiological role remained unclear.
 To clarify the mode of inactivation of these genes in primary cancers, 
we performed multiple molecular analyses on samples of 34VCs and 20 
ECs.  A comparative multiple PCR assay was used for the detection of 
homozygous deletions.  The methylation status of samples was assessed 
using sodium bisulphate modification prior to PCR amplification.  
Protein expression was detected by western blotting and 
immunohistochemistry.
The findings indicated that in vulval cancer inactivation of p16INK4a is 
predominantly caused by promoter methylation, whereas in activation 
of p15INK4b is frequently caused byaberrant promoter methylation along 
with some homozygous deletion. Promoter methylation of p16INK4a but 
not p15INK4b occurred in endometrial carcinoma.  Our results show that 
the mode of alteration at 9p21 was not uniform but was selective, 
dependent upon histological type. The two genes are inactivated by 
different mechanisms during primary VC and EC development.
EXAMINATION OF THE RESPONSE OF BREAST CANCER 
CELLS, ALTERED IN P53 STATUS, TO DOXORUBICIN
Fiona E. M. Paulin*, Julie Wardrop, Clive Ward, David P. Lane, 
Elaine M. Rankin, Alastair M. Thompson & C. Roland Wolf. 
University of Dundee, Biomedical Research Centre, Level 5, 
Ninewells Hospital and Medical School, Dundee, DD1 9SY.  
Doxorubicin is widely used in the treatment of many cancers, 
however the clinical response and side effects differ considerably 
between patients. In part, the genotypic and phenotypic 
characteristics of a tumour may explain this phenomenon, but 
differences in patient drug metabolism may also be important. One 
key gene involved inthe cytotoxic response is the tumour suppressor 
gene p53.  It is frequently mutated in cancers but the relationship 
between p53 mutational status and response to chemotherapy 
remains unclear.
   To address this question in more detail we created two dominant 
negative (DDp53) breast cancer cell lines. The parental cell line, 
MCF7(p53 wildtype), and the DDp53 cell lines (p53 non-functional) 
were then treated with different doses of doxorubicin in vitro.  Drug 
levels were quantified over time by HPLC-MS/MS and cytotoxicity 
assays were performed.  In addition, gene expression was analysed 
by microarray technologies and quantitative PCR techniques.   
Protein levels of key factors were also examined by western blotting.
   The DDp53 cell lines showed a greater resistance to doxorubicin 
and displayed a different basal gene expression pattern compared to 
the parental cell line.  In addition the gene expression pattern 
induced was dependent on the dose of doxorubicin given.  These 
results clearly demonstrate the important role of p53 in response to 
doxorubicin and imply that drug doses delivered to a tumour may be 
critical in determining the tumour response.  
COMPARISON OF THE EFFICACY OF ANTIBODY
DERIVATIVES CARRYING DIFFERENT NUMBER AND 
GEOMETRY OF Fc IN GUINEA PIG LEUKAEMIA THERAPY. 
*Kwok S. Kan, Andrew M. Smith, George T. Stevenson. Institute
for Health Policy & Research, London Metropolitan University, 
Holloway, London N7 8DB.   
  Aim  We studied two different factors which might affect the 
efficacy of antibody derivatives in leukaemic guinea pigs. We
investigated the therapeutic effects of (i) increasing the number of 
Fc( conjugated to antibody derivatives, (ii) conjugating two Fc(
either randomly to Fab2 or specifically to the hinge of Fab2. 
  Methods All human Fc( were used. Fab2Fc1, Fab2Fc2, and
Fab2Fc3 were synthesised from Fab( of 5G10 murine monoclonal 
antibody. A thiolating agent N-succinimidyl-S-acetylthioacetate 
(SATA) was used to randomly introduce sulfhydryl (SH) groups to
murine RJD Fab2 followed by crosslinking between Fc( and Fab(
via phenylenedimaleimide (OPDM) to yield Fab2 Fc2. Another 
Fab2Fc2  was produced by specifically crosslinking two Fc( to the 
SH groups in the hinge of RJD Fab2 via OPDM. Strain 2 guinea 
pigs were inoculated i.p. with 5 x 10
4 L2C leukaemic cells. After 
24 hours, 4 mg of each antibody derivative was injected
intravenously.
  Results  and  conclusion Firstly, Fab2Fc2 produced a higher 
therapeutic response than Fab2Fc1 or the control animals.
However, Fab2Fc3 performed no better than Fab2Fc2. Therefore, a 
higher number of Fc( than 2 within an antibody derivative may
lead to steric hindrance which hampers antibody binding and
recruitment of effectors. Secondly, SATA-linked Fab2Fc2 showed
a better therapeutic response than hinge-linked Fab2Fc2. However, 
SATA-linked Fab2Fc2 produced greater breakdown products in
vivo than hinge-linked Fab2Fc2. Increased in vivo breakdown of 
SATA-linked Fab2Fc2 may generate more univalent FabFc2
remnants which would outperform hinge-linked Fab2Fc2  due to
antigenic modulation 
IDENTIFICATION AND REPLICATION OF REACTIVE T-
CELLS SPECIFIC AGAINST RENAL CELL CARCINOMA 
Ciaran B Lynch,* Paul A Moss, Nicholas D James.
CR UK Institute of Cancer Studies, University of Birmingham.
Edgbaston. Birmingham B15 2TH.
   Aims: This project attempts to identify cytotoxic T-lymphocytes 
found within the tumour substance which are reactive against Renal 
Cell Carcinoma (RCC). RCC is a highly immunogenic tumour and
has a large number of Tumour Infiltrating Lymphocytes (TILs).  
   Procedure: Patient volunteers undergoing nephrectomy for RCC 
are identified, consent obtained and a sample of tumour and 
matched normal kidney obtained. Ethical approval for this has been
granted. Primary tissue is mechanically disaggregated and TILs are 
extracted from the tumour tissue by density gradient centrifugation. 
Standard methods of tissue culture are then used. T-cells, when 
stimulated by antigen, release cytokines and recent technological 
advances allow these cells to be identified and isolated. Standard 
methods of T-cell cloning are then used to expand and clone these 
tumour-specific cytotoxic T-lymphocytes. 
   Major findings: It has been possible to identify and grow 
tumour-specific T-cells in vitro. These cells are rare, amounting to 
approximately 1 in 100 000 TILs. IL-2 expands this population 
further, but at the expense of tumour specificity.  
   Conclusions: The above results are promising in the
development of anti-tumour T-cells. Work is ongoing in T-cell 
cloning and measurement of anti-tumour activity against
autologous tumour targets. These cells, if expanded sufficiently,
would offer therapeutic opportunities in a Clinical Trial setting for 
T-cell adoptive immunotherapy. 
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CD20 INDUCED APOPTOSIS IS AN ANTIBODY DEPENDENT 
PHENOMENON WHICH DOES NOT REQUIRE
REDISTRIBUTION INTO TX-100 INSOLUBLE MEMBRANE 
RAFTS 
H T Claude Chan, David Hughes, Ruth R French, Alison L Tutt, 
Claire Walshe, Martin J Glennie, Mark S Cragg* 
*Tenovus Research Laboratory, Cancer Sciences Division, School 
of Medicine, General Hospital, Tremona Road, Southampton, 
SO16 6YD United Kingdom
Rituximab (Ritux) is in prevalent use in the clinic for the treatment of 
neoplasia and is currently being evaluated for use in autoimmune disorders. 
Although depletion of CD20 expressing cells occurs in both cases, the 
mechanism remains uncertain. Apoptosis may be one means through which 
depletion is achieved. Here, CD20 apoptosis was investigated with a panel of 
anti-CD20 mAb in a wide range of cell-lines. Although CD20 apoptosis was 
dependent on the target cells a hierarchy of mAb activity was apparent, with 
the B1 mAb generally the most potent.  Interestingly, apoptosis was 
dependent upon the nature of binding employed by the different anti-CD20 
mAb and correlated with the extent of homotypic cell adhesion caused. 
However, using previously characterised anti-CD20 mAb which vary in the 
extent to which they translocate CD20 to membrane rafts and a range of 
mutated CD20 molecules with diminished ability to redistribute to membrane 
rafts, we were able to determine that CD20 apoptosis is independent of 
translocation to TX-100 insoluble rafts. Further investigation of CD20 
mutant molecules revealed that the apoptosis inducing function of CD20 
does not appear to reside in the C terminus. We conclude that CD20 induced 
cell death is an antibody dependent process which is linked to the mode of 
mAb binding and does not require redistribution into TX-100 insoluble 
membrane rafts. 
P47
MANIPULATION OF MACROPHAGE POPULATIONS CAN 
ENHANCE LOW DOSE RADIATION PLUS ANTI-CD40 MAB 
THERAPY. Jamie Honeychurch*, Martin J. Glennie, Peter W.M. 
Johnson, Timothy M. Illidge. Cancer Sciences Division, 
Southampton General Hospital, Southampton University, SO16 
6YD, UK  
   We have demonstrated that combining total body irradiation (TBI) and 
anti-CD40 monoclonal antibody (mAb) can result in long-term protection 
in murine B-cell lymphoma and this protection is mediated by CD8+ T-
cells (CTL). Therapeutic efficacy directly correlates with radiation dose, 
and we believe that this reflects a threshold of induced tumour cell death 
needed to provide critical amounts of antigen for uptake by “licensed” 
antigen presenting cells (APC) capable of priming CTL.
 Which APC are most effective at processing and presenting antigen from 
dying cells is controversial. Evidence suggests that whilst macrophages 
(Mφ) are the primary scavenging cell, they are unable to cross-present 
efficiently. Thus, we investigated if manipulation of Mφ  populations could 
enhance radiation therapy. Using flow-cytometry and fluorescent 
microscopy we have shown that tumour cells are rapidly engulfed by Mφ  
following TBI, and that the degree of engulfment directly correlates with 
both the dose of radiation delivered and the amount of apoptosis observed. 
Treatment of mice with silica to selectively deplete Mφ prior to TBI results 
in reduced tumour cell clearance in secondary lymphoid organs. 
Conversely, treatment with thioglycollate to increase Mφ numbers results in 
a more rapid, and extensive clearance of dying tumour. Interestingly, these 
differences in antigen longevity and availability in the major sites of 
tumour growth post-irradiation are reflected in therapeutic efficacy. The 
degree of protection observed following low-dose radiation and anti-CD40 
mAb therapy was significantly increased in animals depleted of Mφ . This 
work was supported by CR UK.
ANTI-CD40 MONOCLONAL ANTIBODY THERAPY:
TREATMENT TOXICITY AND IMPLICATIONS FOR
CANCER IMMUNOTHERAPY 
Thomas Geldart*, Melanie Harvey, Norman Carr, Martin Glennie
Peter Johnson, Cancer Research UK Oncology Unit, Southampton 
General Hospital, Southampton, SO16 6YD. 
Background   The critical importance of CD40 signalling in the 
development of CD8+ cytotoxic T cell responses and the 
expression of CD40 on a broad range of malignancies make CD40 
an attractive target for immunotherapy. Published data has 
demonstrated that anti-CD40 therapy provides significant 
therapeutic effects and protects against tumour re-challenge in a 
syngeneic mouse model of malignancy
1. 
Aims   To establish the toxicity profile of anti-CD40 monoclonal 
antibody (mAb) treatment in an animal model. 
Methods   Rat anti-mouse CD40 mAb (3/23) was administered at 
a variety of dose levels to cohorts of BALB/c and C57BLK/6 
mice. Biochemical, haematological and histopathological data was 
gathered over a period of three months.  
Results   There was no treatment related mortality. Anti-CD40 
mAb therapy caused a dose dependent but fully reversible lympho-
granulomatous hepatitis. Mild, reversible tubulo-interstitial
lymphocytic nephritis and dose related splenomegaly were also 
noted. 
Conclusion   Anti-CD40 mAb treatment in mice is limited by dose 
dependent but reversible hepatic toxicity, a result in keeping with 
the published dose limiting toxicity of recombinant human CD40 
ligand in humans
2. These results have implications for the 
treatment of human cancers with anti-CD40 mAb immunotherapy. 
References
1. French RR et al. 1999. Nature Medicine 5:548-53. 
2. Vonderheide RH et al. 2001. J Clin Oncology 19:3280-7. 
DESIGNER T CELLS FOR THE IMMUNOTHERAPY OF
CANCER. 
David E. Gilham*, Ryan D Guest, Eleanor J Cheadle, Chris 
Hughes, Natallia Kirillova, Allison O’Neill, Joely Irlam and
Robert E Hawkins.
Cancer Research UK Department of Medical Oncology, Paterson
Institute, Christie Hospital NHS Trust, Manchester, M20 4BX. 
T cells can be an effective treatment for malignant disease.
However, tumours can avoid immune recognition through a variety
of mechanisms including the down-regulation of important T cell
recognition molecules.  Chimeric Immune Receptors (CIR’s)
consisting of antibody fragments (scFv) fused to the CD3ζ   chain
effectively re-direct T cell activity to protein antigens directly
thereby circumventing tumour avoidance of T cell recognition.  
T cells from healthy donors transduced with recombinant
retroviruses encoding an anti-carcinoembryonic antigen (CEA)
scFv.CD3ζ CIR effectively respond to and lyse antigen-specific
target cell lines in vitro.  Protection against tumour cell growth in
vivo was observed when the gastric carcinoma cell line MKN45K
was co-administered sub-cutaneously in NOD/SCID mice with
CIR expressing human T cells (3/5 animals surviving at 78 days)
while mock treated cells offered no additional protection over
tumour only controls (0/5 animals surviving at 78 days).
Importantly, a dose-dependent effect was observed when higher
levels of transduced T cells present within the population
generated correspondingly increase delays in tumour growth.
Further experiments have indicated that the methods of pre-culture,
and, in particular, the concentration of cytokines used to grow the
T cells, can have a major influence upon the activity of the T cells
This work demonstrates that gene-modified T cells can challenge
the growth of CEA expressing tumour cells in vitro and in vivo. 
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DESTRUCTION OF CD19
+ LYMPHOMAS BY T CELLS
EXPRESSING A CHIMERIC RECEPTOR
Eleanor J Cheadle*, Anne Armstrong, John Radford, David E 
Gilham, Robert E Hawkins. 
Department of Medical Oncology, Paterson Institute for Cancer 
Research, Christie Hospital, Manchester, M20 4BX. 
Chimeric T cell receptor technology enables the coupling of an 
antibody scFv to TCR signalling molecules such as CD3ζ, thus 
enabling the targeting of cytotoxic T cells to tumour without the 
need for MHC restriction. 
CD19 is a signal transduction molecule expressed on the surface 
of all mature B cells and lymphomas but lost upon maturation to 
plasma cell phenotype.  Chimeric receptors were constructed that 
expressed either an anti CD19 scFv coupled to the transmembrane 
and cytosolic domain of the CD3ζ molecule (CD19.CD3ζ), or an
anti CD19 scFv coupled to the CD3ζ molecule via the human IgG1
CH2CH3 Fc spacer region (CD19hFc.CD3ζ).  Constructs were 
cloned into retroviral vectors, which enabled efficient transduction 
of proliferating T cells. 
Retroviral transduction of healthy donor T cells with chimeric 
receptor genes expressing CD19.CD3ζ or CD19hFc.CD3ζ, 
receptors led to comparable specific killing of a CD19
+ Burkitt 
lymphoma cell line and IFNγ release upon culture with the Raji 
cell line.  However, IFNγ release from CD19hFc.CD3ζ transduced 
T cells was significantly reduced compared to that from
CD19.CD3ζ transduced T cells.  Importantly, transduced patient T 
cells specifically killed autologous tumour cells derived from
lymphoma biopsy samples.  
The efficacy of T cells expressing a CD19.CD3ζ chimeric 
receptor is currently being evaluated in a murine model system. 
THE EFFECT OF ADEPT, AS A SINGLE OR COMBINED
THERAPY,  IN TWO COLORECTAL XENOGRAFTS.
Surinder K Sharma*, R Barbara Pedley, Helen L Irwin, Ethaar
El-Emir, Geoffrey M Boxer, Robert W Boden, Kerry A Chester & 
Richard H J Begent, 
CR UK Targeting & Imaging Group, Dept. of Oncology,  RF & 
UCMS, UCL,Royal Free Campus, Rowland Hill Street, London 
NW3 2PF, UK. 
The out come of antibody-directed therapies is related to the 
morphology and pathophysiology of the tumor.
  Antibody directed enzyme prodrug therapy (ADEPT) has therefore 
been studied in  two CEA-producing human colorectal tumour 
xenografts, differing in both these aspects. The LS174T model is a 
moderate to poorly differentiated adenocarcinoma. The SW1222 is 
organized into well-defined glandular structures around a central 
lumen. Biodistribution studies of  a recombinant fusion protein (MFE-
CP) comprising an anti-CEA single chain Fv (MFE-23) fused to the 
bacterial enzyme carboxypeptidase G2 (CPG2) showed  localization of  
CPG2 activity in tumours and clearance from normal tissues, within 6 
hours after injection. A single cycle of MFE-CP in combination with 
prodrug resulted in reproducible growth delay for both LS174T and 
SW1222 colorectal tumor xenografts without systemic toxicity, but 
was more effective in the SW1222 (10v15 days growth delay). 
Repeated ADEPT cycles gave significantly extended growth delay in 
LS174T but produced regressions in the SW1222model, with minimal 
toxicity. The microscopic effects of ADEPT on tumour biology have 
also been studied using  quantitative digital microscopy.
  Agents which enhance the effect of ADEPT when used in 
combination are being investigated, and will be discussed.
In-vivo work in compliance with UKCCCR guidelines.
Supported bythe Cancer Research Campaign, AstraZeneca and the 
Association for International Cancer Research.  
 ISOLATION OF  TUMOUR CELLS FROM PERIPHERAL 
BLOOD FOR POTENTIAL ASSESSMENT OF RESPONSE
TO ANTIBODY DIRECTED ENZYME PRODRUG THERAPY
(ADEPT). Helen L Irwin
1*, Frances Corcoran
1, Geoffrey M Boxer
1, 
R. Barbara Pedley
1, Jason Dearling
1, Janet M Hartley
2,  
Richard H J Begent
1 and Surinder K Sharma
1. 
1CRUK Targeting and Imaging Group, 
2Molecular and Cellular 
Pharmacology Group, Dept.of  Oncology, RF & UCMS, UCL, Royal 
Free Campus, Rowland Hill Street, London NW3 2PF. 
The detection of circulating tumour cells from peripheral blood is of 
clinical importance in terms of monitoring disease progression, response 
to therapy and determining the mechanisms by which treatments exert 
their effect.
  Two techniques (StemSep™ and RosetteSep™) were investigated 
whereby the haemopoietic cells are removed, leaving the enriched 
tumour cell population unaltered. Both methods were applied to separate 
spiked CEA-positive human colorectal tumour cells, SW1222, from 
whole blood obtained from healthy donors after written consent.  
RosetteSep™ was determined to be the better  and more sensitive of the 
two techniques and was investigated further. Immunohistochemistry 
showed  isolated tumour cells to be CEA positive, Cytokeratin positive 
and LCA (leucocyte common antigen) negative thus demonstrating the 
specificity of the separation technique. SW1222 tumour cells were then 
treated in vitro with the components of  ADEPT, spiked into healthy 
whole blood and separated out using RosetteSep™. COMET assays 
were performed on  tumour cell samples to determine the extent of DNA 
cross-linking caused by the ADEPT system.
 The results indicated that the negative cell separation procedure could 
isolate ADEPT treated cells from peripheral blood. This implied that 
RosetteSep™  has  potential application in isolating circulating tumour 
cells in peripheral blood of cancer patients. These cells can then be 
characterised further to determine the level of cellular damage caused by 
cancer therapy and yield data to inform design of future therapeutic 
strategies. 
IDENTIFICATION OF CTL EPITOPES FROM TUMOUR 
ANTIGENS IN HUMAN LUNG CANCER 
Angela J Darby*, Peter W M Johnson and Tim J Elliott
Cancer Sciences Division, University of Southampton, UK 
Aims:  To identify CTL epitopes from novel tumour antigens in 
human lung cancer to lead to new targets for clinical trials of
immunotherapy. 
Background:  Lung cancer is the commonest cause of cancer
death in the United Kingdom and, despite advances in
conventional chemotherapy and radiotherapy, only 5% of patients
are alive at 5 years.  CTL-based immunotherapy is based on the
observation that cytotoxic T lymphocytes (CTL) can make an
effective response to specific autologous tumour antigens.   
Methods:  Web-based algorithms were used to identify nonamer 
peptides with potential to act as CTL epitopes for nine tumour
antigens with expression in lung cancer.  Binding to HLA-A*0201
was measured with a T2 stability assay and experimental results 
for each antigen were ranked and compared to predictive results
from the algorithms.  Peptides shown to bind to HLA-A*0201
were used to prime CTL responses in a human ex-vivo system. 
Results: Approximately 1/3 of peptides predicted to bind to
HLA-A*0201 demonstrated no binding in a T2-stabilisation assay.
Two of 5 peptides used in the ex-vivo system produced CTL that
released peptide-specific interferon-γ in an ELISPOT assay.
Conclusions: While predictive algorithms can guide epitope 
identification, experimental validation is required.  We are 
generating peptide specific CTL to test cytotoxicity using tumour 
antigen-bearing cancer cell lines. 
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PHASE I/II STUDY OF FRACTIONATED
RADIOIMMUNOTHERAPY (RIT) IN RELAPSED LOW
GRADE NON HODGKIN’S LYMPHOMA (NHL). 
Mike Bayne*, Maureen Zivanov ic, Val Lewington, Yong Du,
Christine Harrison, Liz Hodges, Peter Johnson, Tim Illidge.
CR UK Wessex Medical Oncology Unit, University of
Southampton, Southampton General Hospital, SO16  6YD, UK. 
  Despite highly promising results with RIT in “low grade” NHL there 
remains uncertainty as to the optimal treatment approach. Currently a single 
myeloablative dose of radiolabelled anti-CD20 monoclonal antibody (mAb) 
is given. Both commercially developed radioimmunoconjugates, 
131I-
Tositumomab (Bexxar) and 
90Y-Ibritumomab tiuxetan (Zevalin) use murine 
mAbs and the development of human anti-mouse antibody responses may 
prevent more than one administration. Impressive durable responses from 
clinical studies using higher myeloablative dose RIT followed by peripheral 
blood stem cell transplant (PBSCT) suggest that there may be a radiation 
dose response for RIT. With the development of Rituximab, a chimeric 
mAb, multiple or fractionationed treatments are possible, which in turn may 
enable higher cumulative doses of RIT to be delivered without the need for 
PBSCT. The primary goal of this study is to test the safety and efficacy of 
fractionated RIT in relapsed CD20 positive NHL in a dose escalation study 
using two fractionated doses of labelled Rituximab. Eligible patients will 
receive two fractions of 
131I labelled Rituximab given with an eight weeks 
interval. Clinical, radiological, molecular response and toxicity data are 
being prospectively collected. In addition an analysis of serum rituximab 
levels during the course of the therapy is being performed and a novel 
technique for measuring the radiation dose delivered during RIT using the 
cytogenetic analysis of cultured peripheral blood lymphocytes is being 
developed. We report on the feasibility of this approach as well as toxicity 
and early response data on the first 6 patients. 
LONG TERM CLEARANCE OF TUMOUR IN
RADIOIMMUNOTHERAPY (RIT) OF B-CELL LYMPHOMA
REQUIRES TARGETED RADIATION AND  MONOCLONAL
ANTIBODY (mAb) INDUCED CELL SURFACE SIGNALLING
Yong Du, Jamie Honeychurch, Peter Johnson, Martin Glennie,
Tim Illidge* Cancer Sciences Division, Southampton University
School of Medicine, Southampton, UK. SO16 6YD 
…RIT has emerged as a new treatment option for the treatment of 
lymphomas however the mechanisms underlying the tumour responses 
are poorly understood. We have therefore investigated the relative 
contributions of mAb effector mechanisms and targeted radiation to the 
clearance of tumour in vivo using two different murine syngeneic B cell 
lymphoma models (A31 and BCL1). In this study we initially 
demonstrate an additive effect of external beam irradiation (EBRT) and 
anti-Id mAb, which for the BCL1 tumor model was a modest 
improvement in tumour protection of around 15 days over control 
animals. However when we used 131I anti-MHCII mAb to target radiation 
in combination with unlabelled anti-Id mAb higher tumour doses could 
be delivered (18Gy per 18.5 MBq 131I anti-MHCII) and this resulted in 
100% prolonged disease free survival in both tumor models at 100 days 
as well as prolonged survival with 131I anti-MHC and anti-CD19. Using 
in vivo tumour tracking and we have demonstrated that this additive 
cytoreductive effect is dependent on both targeted radiation and 
signaling mAb. Finally we have shown that the clearance of tumour 
appears to correlate with the ability of mAb (anti-Id, anti-CD19) to 
initiate cell surface signalling as measured by intracellular tyrosine 
phosphorylation on western blot analysis and intracellular calcium 
influx. In conclusion we have shown that the long term clearance of 
tumour in vivo critically depends upon the ability of mAb to target 
radiation to tumour as well provide cell surface signalling to downstream 
apoptotic pathways.  
DESIGNER T CELLS: ROLE IN THE TREATMENT OF 
HEPATIC COLORECTAL METASTASES 
Daren. A. Subar*, David. E. Gilham, David. J. Sherlock and 
Robert. E. Hawkins
Cancer Research UK Department of Medical Oncology, 
Paterson Institute for Cancer Research, Christie Hospital, M20 
4BX 
  T lymphocytes genetically engineered to target tumour cells 
are attractive as a potential immunotherapy.  Previous work has 
shown that T cells isolated from patients with advanced 
colorectal disease can be effectively targeted to kill 
carcinoembryonic antigen (CEA) expressing cell lines through 
the expression on the T cell of chimeric receptors composed of
an anti-CEA single chain antibody (scFv) fused to the CD3 ζ
chain. It is of great importance to determine if these modified T 
cells maintain specific targeted activity after transduction and 
expansion in conditions relevant to clinical protocols. To 
investigate this we used media suitable for clinical practice; 
(AIM V) with mixed human AB serum in the presence of
clinical grade interleukin-2 (IL-2). 
  T cells isolated from patients with colorectal liver metastases 
were transduced and expanded in these clinically relevant 
conditions.  Greater than ten fold expansion of T cells was 
observed during a two week time frame when cultured with 100 
IU/mL IL-2. These cells were shown to be functionally active in 
in vitro assay. To improve the overall yield of T cells for clinical 
use, we are investigating the effects of varying culture
conditions upon T cell expansion and function. These 
experiments will provide information concerning the kinetics of 
gene modified T cell growth, which has important ramifications 
upon the transfer of this technology into an effective clinical 
therapy.
DNA-Fc FUSION VACCINE TARGETING THE
ENDOTHELIAL ANTIGEN TIE-2 
Judith Ramage*, Rachael Metheringham, Robert S Moss,  
 Ian Spendlove, Robert Rees and Lindy Durrant
CRUK Clinical Oncology, Nottingham University, Nottingham.
Tie-2 stabilised pericyte/endothelial interactions during
angiogenesis and is highly expressed on tumour endothelium. A
vaccine that targets endothelium over-expressing Tie-2 may result
in vessel damage and stimulate an inflammatory cascade resulting
in disease regression. We have previously identified an enhanced
HLA-A*0201 peptide in Tie-2 which can stimulate CTL responses
that recognise T2 cells pulsed with either enhanced or wild type
peptide. Incorporation of this enhanced epitope within a Tie-2
DNA construct stimulated poor CTL responses in HLA-A2
transgenic mice. Recent studies have shown that targeting the high
affinity Fc receptor results in dendritic cell activation and
presentation of both class I and class II epitopes.  Fc- vaccines have
been used successfully to stimulate both CD8 and CD4 responses
to MAGE-3, HBV, CEA and CD55. Human Fcγ1 was therefore
incorporated into the Tie-2 DNA vaccine. A dramatic increase in
the frequency of γ IFN secreting cells that were specific to both
native and wild type peptides were demonstrated by ELISPOT in
the mice immunized with the Tie-2Fc construct. Moreover these
CTL recognise endothelial cells over-expressing Tie-2. This Tie-2
vaccine is currently being screened for toxicity and efficacy in
tumour models. The human Fc region is probably providing both
foreign T cell help and also allowing receptor mediated uptake and
activation of dendritic cells in vivo. To assess the relative
contribution of these mechanism of action a Tie-2 mouse Fc
construct is currently being evaluated. These studies provide a
novel approach to cancer vaccination. 
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A MONOCLONAL ANTIBODY DIRECTED AGAINST SCR1-2 
OF COMPLEMENT CONTROL PROTEIN, CD55 ENHANCES 
C3 DEPOSITION AND TUMOUR CELL LYSIS  
R G Bradley*, J Morgan, I Spendlove and L G Durrant.  CRUK
Academic Unit of Clinical Oncology, Nottingham university,
Nottingham City Hospital. 
CD55 (Decay Accelerating Factor) is a glycophosphatidylinositol
(GPI) anchored membrane bound complement control protein
expressed on most cells including endothelial cells and leukocytes.
CD55 accelerates the decay of both complement activation 
pathways, specifically C4b2a or C3bBb and corresponding C5
convertases, thus protecting cells from complement mediated
bystander attack.  Structurally, CD55 contains four Short
Consensus Repeat domains, SCR 2-4 possessing decay
accelerating activity, while SCR3 mutations have shown to disrupt 
both alternative and classical complement pathways. 
  Complement Deposition assays have shown that using the CD55
over-expressing osteosarcoma, 791T, cell line that mAb 791T/36, 
directed at SCR1-2, produces increased C3b/c deposition 
compared to BRIC 216 (SCR3 directed). 791T/36 also showed 
effective DAF blockade when compared to 1C6 and 1H4 
monoclonal antibodies (also SCR3 directed).  In order to assess the 
effectiveness SCR1-2 blockade, Chromium
51 release assays have 
been performed to determine whether inhibition of CD55 activity
leads to tumour cell lysis and how this compares to lysis induced 
by alternative SCR blockade. 
This novel approach for a SCR1-2 targeted monoclonal antibody, 
blocking CD55 function and generating potential therapeutic 
effects may be further analysed.   
INVESTIGATION OF THE HUMAN TELOMERASE RNA
GENE CORE PROMOTER IN BASAL TRANSCRIPTION
Jiangqin Zhao*, Alan Bilsland, Stacey F. Hoare and W. Nicol
Keith. Cancer Research UK Department of Medical Oncology,
University of Glasgow, Cancer Research UK Beatson Laboratories,
Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD,
UK.  
The telomerase RNA gene, hTR, is regulated by a variety of
transcription factors including NF-Y and Sp1. The hTR proximal
promoter contains four Sp1 sites and one CCAAT-box. We have
carried out a functional analysis of the proximal promoter region in
order to fully understand the role of the sequence elements present
and to define the core promoter region. Two Sp1 sites downstream
of the CCAAT-box mediated negative regulation, while the other
two Sp1 sites were positive regulators with the strongest effect
mediated by the negative regulatory Sp1 site closely flanking the
CCAAT box. Basal transcriptional activity is maintained via the
CCAAT-box even when all four Sp1 sites are mutated, suggesting
NF-Y is a fundamental regulator of hTR promoter function.
Chromatin immunoprecipitation revealed binding of NF-Y, Sp1
and TFIIB to the promoter in vivo, providing the first direct
evidence that a component of the Pol II transcriptional machinery is
involved in telomerase RNA gene transcription in human cells.
Thus the interaction of NF-Y at the CCAAT-box is pivotal to hTR
gene transcription and surrounding sequence elements may provide
an environment for the regulation of activity through recruitment of
additional protein complexes. 
HYPOXIC REGULATION OF TELOMERASE GENE EXPRESSION
Claire J. Anderson*, Margaret Ashcroft, W. Nicol Keith 
Cancer Research UK Department of Medical Oncology, University
of Glasgow, Cancer Research UK Beatson Laboratories, Garscube 
Estate, Switchback Road, Bearsden, Glasgow, G61 1BD
  Expression of the telomerase RNA (hTR) and protein (hTERT) 
component genes is greatly up regulated in cancer cells when
compared to normal cells and this up-regulation occurs at the level
of transcription.  To determine how this occurs we are investigating 
a number of transcriptional regulatory elements within the 
telomerase gene promoters.  Bioinformatic analysis of the 
telomerase promoter sequences identified potential hypoxia 
inducible sequence elements:  2 within hTERT overlapping the E-
box consensus sequences and 1 within hTR.  Gel retardation assays 
using labelled oligonucleotides encompassing these putative 
hypoxia response elements (HRE) revealed protein binding. 
Competition studies showed specific binding of HIF-1 and myc to
these sites.  Transfection of A2780 ovarian carcinoma cells with 
the telomerase promoters linked to luciferase reporter constructs 
allowed for functional analysis of these sites.  Co-transfection of 
telomerase promoter vectors with a titration of HIF-1α   expression
vector gave a 2-fold increase in expression when compared to 
telomerase promoters alone.  This effect is specific, as co-
transfection of HIF-1α  with hTERT promoter mutated in both 
consensus HRE sites produces no effect.  These results suggest that 
telomerase gene expression is inducible by hypoxia, which may
have implications for tumour development and gene therapy. 
CISPLATIN INDUCED NEUROBLASTOMA CELL DEATH 
AND THE INVOVLEMENT OF TELOMERES
Jessie C. Jeyapalan *
1,2, Michael J. Tilby
2, Thomas von Zglinicki 
1
1Department of Gerontology SCMS, University of Newcastle upon 
Tyne, Newcastle General Hospital, NE4 6BE 
2Northern Institute of Cancer Research, University of Newcastle 
upon Tyne, Medical School NE2 4HH 
Background:  Neuroblastoma is chemotherapeutically treated by
cisplatin whose major DNA adduct is the intrastrand crosslink
between adjacent guanines. Human telomeric DNA is partially
composed of guanines as its sequence is TTAGGG. Telomere
damage accelerates shortening which may signal growth arrest
and/or apoptosis. A specific role of telomeres in mediating
cisplatin cytotoxicity has been proposed. 
Aim:  To establish the significance of the telomere-cisplatin
interaction in the neuroblastoma cell line SHSY5Y. 
Methods: Cytotoxic effects of cisplatin were assessed by the SRB
assay, cell cycle analysis and apoptosis measurements using flow
cytometry. Telomere and single stranded G rich overhangs were
detected using an in gel hybridisation technique. 
Results:  A 2 hour exposure to cisplatin at concentrations at or
below the IC50 value (15µM) induced low levels of apoptosis.
Following exposure to high concentrations of cisplatin (>350µM)
apoptosis increased dramatically by 24 hours after treatment. Also
there was no net growth of cells and telomerase inhibition
occurred. There was no change in telomere lengths or single
stranded overhangs after a two hour exposure to cisplatin
following any of the cisplatin concentrations tested. 
Conclusions: Telomere lengths do not decrease after a two hour
exposure or a continuous treatment to cisplatin. SHSY5Y
apoptosis induction after cisplatin treatment is not mediated by
telomere shortening. 
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SYNTHESIS, MODELLING AND BIOPHYSICAL STUDIES 
OF AMINO-ANTHRAQUINONES AS TELOMERASE 
INHIBITORS 
Toni Brown*, Roz J. Anderson, Don Cairns, Terry C. Jenkins. 
YCR Laboratory of Drug Design, Tom Connors Cancer 
Research Centre, Bradford, West Yorkshire BD7 1DP.
  Functionalised  amino-anthraquinones  (AAQ)  are  being
examined as selective ligands to stabilise four-stranded
(tetraplex) DNA structures. Such complexes would prevent
access of telomerase to its linear DNA substrate and thereby
elicit a possible chemotherapeutic response for tumour control.
Certain AAQs have previously been examined as intercalators
for duplex DNA in the quest for cytotoxic agents. 
Uncyclised and cyclised 1-mono-, 1,5-di- and 1,8-di-AAQs of
different complexion have been synthesised with differing side-
chains: -NH(CH2)2OH, -NH(CH2)2NH(CH2)2OH and
-NH(CH2)2N(CH2CH3)2. A cleaner, flexible route to these
compounds has been developed and will be presented.
  Binding  energies  for  novel  cyclised compounds  have  been
calculated using molecular modelling with two reported [NMR
and crystal] DNA-tetraplex structures. Early results show that
energies appear to be superior for the NMR rather than the
crystal structure (~-700 vs ~-400 kcal mol
-1) using one selected
quinoxaline-functionalised AAQ ligand. 
Preliminary DNA melting experiments show stabilisation of
calf thymus DNA, (DNA duplex-drug ratio 10:4) for uncyclised
compounds with negligible effect for the cyclised AAQ series.
e.g.1-[2-(2-hydroxyethylamino)ethylamino]anthraquinone;  ∆  Tm
=10  ºC and 4-(2-hydroxyethyl)-1,2,3,4-tetrahydro-1,4-diaza-
benzo[a]anthracene-7,12-dione; ∆  Tm  ≤  1 ºC. Full DNA-binding
profiles and biological data will be presented. 
QUANTIFICATION OF CTL RESPONSE AGAINST hTERT IN 
BREAST CANCER
Shoba M.P. Amarnath*, Charlotte E. Dyer, Aswatha Ramesh, Obi 
Iwuagwu, Liviu V. Titu, Philip J. Drew, John Greenman.    
Postgraduate Medical Institute, University of Hull. 
Telomerase is expressed in approximately 90% of breast cancers but
not in most normal somatic cells. The enzyme plays a key role in
maintaining chromosomal telomere integrity. The catalytic subunit of
telomerase, human telomerase reverse transcriptase (hTERT), is a
widely expressed tumour associated antigen against which specific
cytotoxic T lymphocyte (CTL) responses have been identified. Human
CD8
+ CTL have been shown to recognise hTERT synthetic peptides in
both an HLA-A2 and HLA-A3 restricted manner, and to lyse hTERT
+
tumour cells of multiple histologies. 
   This study has investigated the specific CD8
+ CTL response in breast
cancer patients against 3 synthetic hTERT peptides. PBMC were
isolated from blood samples by Ficoll-density centrifugation and
screened for HLA subtype by flow cytometry. The HLA-A2 or HLA-A3
positive PBMC samples were analysed using a standard IFNγ   ELISpot
assay.
   The results showed that 11/15 cancer patients (HLA-A2
+ or HLA-A3
+)
had a specific CD8
+ CTL response against one of the synthetic hTERT
peptides; five of these patients responded to both HLA-A2 peptides. In
contrast, 4/11 normal healthy female controls responded against a single
peptide only.  This suggests that a specific immune response exists
against hTERT peptides in breast cancer patients when compared with
normal healthy controls. Such functional immune response assays
indicate that hTERT deserves further investigation as a target for
anticancer immunotherapeutic strategies in breast cancer patients. 
Financial support provided by RCS(Eng) and an Overseas Research
Scholarship (S. Amarnath) 
THE DEVELOPMENT OF NOVEL TELOMERASE 
INHIBITORS: STRUCTURE-ACTIVITY RELATIONSHIPS 
Mai-Kim Cheng*, Chetna Modi, Christina R. Grindon, Malcolm
F.G. Stevens and Charles A. Laughton. Cancer Research 
Laboratories, School of Pharmaceutical Sciences, University of 
Nottingham, NG7 2RD.
We have discovered and are developing a novel class of
polycyclic acridines that show great promise as inhibitors of
telomerase. The hypothesis is that these molecules act by
stabilizing the G-rich single-stranded overhang of the telomere in a
four-stranded (quadruplex) form, in which it is unable to function
as a substrate for elongation by the telomerase enzyme. 
  Therapeutically acceptable  telomerase inhibitors  that  function
through this mechanism must show a high specificity for the
quadruplex form of DNA. Otherwise, they will be expected to also
show the undesirable cytotoxic characteristics of conventional
antitumour agents that target normal genomic (duplex) DNA. 
We have studied the binding of a wide range of our polycyclic
acridines to both duplex and quadruplex DNA, and correlated the
results with their telomerase inhibition (TRAP assay) and
cytotoxicity (GI50 data from the NCI 60 cell panel). Binding
affinities of the molecules to salmon testis DNA (fluorescence
titration experiments) correlate excellently with the GI50 data (R
2
0.925) but not at all with telomerase inhibition. Conversely, the
ability of the molecules to stabilize quadruplex DNA (FRET-based
melting studies) correlates fairly well with the TRAP assay data
(R
2 0.677) but not at all with the GI50 data. Associated molecular
modelling studies suggest that quadruplex versus duplex selectivity
is controlled by a subtle balance between many factors, including
solvation, electrostatics, and DNA flexibility. These results support
the proposed mechanism of action of these compounds and are
guiding their further development. 
ZONATION OF MUCOSAL PHENOTYPE, DYSPLASIA 
AND THEIR RELATIONSHIP WITH TELOMERASE
ACTIVITY IN BARRETT’S OESOPHAGUS
Aileen J. Fletcher-Monaghan
*, James J. Going,  Lisa Neilson, Bea
A. Wisman, Ate van der Zee, Robert C. Stuart, W. Nicol Keith
Cancer Research UK Department of Medical Oncology, University
of Glasgow, Cancer Research UK Beatson Laboratories, Garscube
Estate, Swittchback Road, Bearsden, Glasgow, G61 1BD
Unchecked neoplastic growth requires telomerase enzyme
activity. We have investigated the  zonal distribution of different
mucosal types  and dysplasia in Barrett’s oesophagus in relation to
telomerase activity. Patients and methods  Biopsies (n 256) from
squamous oesophagus, columnar-lined oesophagus every 2 cm,
oesophago-gastric junction, gastric corpus and antrum were
evaluated from 32 patients with ≥ 3cm Barrett’s oesophagus by
telomerase repeat assay protocol (TRAP) and reviewed for mucosal
phenotypes and severity of dysplasia.  Results   Intestinal-type
Barrett’s mucosa was consistently present at all levels in Barrett’s
oesophagus, and at least one Barrett’s biopsy was TRAP+ in 22/32
patients.  The data were consistent with a proximal-to-distal
gradient of increasing TRAP-positivity of intestinal-type Barrett’s
mucosa, possibly related to mucosal exposure to acid or bile reflux.
Native gastric mucosa was rarely TRAP+ (1/31 corpus, 2/32
antrum), whereas native squamous mucosa was almost always
TRAP+ (31/32).    A non-significant association between TRAP
positivity and dysplasia existed, but the TRAP assay could be
positive without dysplasia and negative even in extensive, high-
grade dysplasia.     
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A PRELIMINARY EVALUATION OF THE POTENTIAL ROLE
OF FDG-PET TO ASSESS RESPONSE TO GLIVEC
ΤΜ   IN
GASTROINTESTINAL STROMAL TUMOURS (GISTS) 
Jackie Harney
*, Way lup Wong, Susan Short. MCRW, Paul
Strickland Scanner Centre, Mount Vernon Hospital, UK. 
  Introduction: GIST's are the commonest mesenchymal tumours of the 
GIT. They are characterised by over-expression of KIT, the protein 
product of the c-kit proto-oncogene, & unresponsiveness to any type of 
systemic chemotherapy. GlivecTM (Imatinib) is a new type of tyrosine 
kinase inhibitor that selectively inhibits various tyrosine kinases 
including KIT. GlivecTM shows a remarkable efficacy in the treatment of 
GIST's [1]. It is currently available in theUKon a named patient basis for 
advanced GISTs. If metabolic change occurs before morphologic change 
following treatment, traditional imaging modalities (CT & MRI) cannot 
detect it. FDG-PET has been shown to highlight early functional changes 
in glucose metabolism that correlate with metabolic tumour response to 
GlivecTM [2].  Methods: 4 patients with advanced, metastatic GISTs 
presenting to MVH between March 2002 and March 2003 were 
commenced on GlivecTM 600 - 800mg/day. MRI and FDG-PET scans 
were performed prior to treatment. FDG-PET was repeated after 2-4 
weeks of treatment to assess early response. MRI scanning was 
performed at regular intervals thereafter.
Results: In this group of patients FDG-PET at 2-4 weeks demonstrated 
marked metabolic improvement, which correlated well with 
symptomatic improvement. MRI scanning at 6-8 weeks demonstrated 
partial response to treatment in all patients.
 Conclusions: Reduced FDG uptake on PET scanning at 1 month 
appears to predict responses on MRI and herald clinical improvement in 
this small group of patients. References:
1. Demetri GD et al N. Eng. Med. 2002; 347:472-480.
2. Van den Abbeele et al. ASCO 2001. Sarcoma abstract1444. 
EVALUATION OF MULTI-FUNCTIONAL DYNAMIC CONTRAST-
ENHANCED MRI TO PREDICT RESPONSE TO NEOADJUVANT
CHEMOTHERAPY IN PRIMARY BREAST CANCER
Mei-Lin W. Ah-See*, N. Jane Taylor, Andreas Makris, Russell J. Burcombe,
James J. Stirling, Helen J. Cladd, Martin O. Leach, Anwar R. Padhani; Mount
Vernon Hospital, Northwood, Middlesex, HA6 2RN.* 
Introduction: Neoadjuvant chemotherapy (NAC) is increasingly
used for treating primary breast cancer. The ability to identify non-
responders early during treatment will enable the use of alternative
therapies that may be more beneficial. Here, we assess the role of
multi-functional dynamic contrast-enhanced magnetic resonance
imaging (MRI) to identify these non-responders. Materials &
Methods: 10 patients with primary breast cancer (median age 44
years, range 33-59) were imaged prior to & following two cycles of
5-fluorouracil, epirubicin & cyclophosphamide chemotherapy.
Dynamic MRIs were obtained following contrast-medium
administration (Gd-DTPA) & parameters reflecting microvessel
permeability (Ktrans), blood flow (rMSD), leakage space (ve) &
oxygenation (R2*) were measured. Median & 5-95th centile values
for each parameter were derived from tumour regions of interest.
Pre-treatment parameter values & treatment changes were
correlated with clinical response following 6 cycles of NAC.
Results: Pre-treatment Ktrans, rMSD, ve & R2* did not predict for
response. Percentage change in median Ktrans & rMSD correlated
with response (p=0.04 & p=0.04 respectively) as did percentage
change in the Ktrans 5-95th centile range (p=0.04). Changes in ve
& R2* were not significant. Conclusion: These early data indicate
that MRI parameters reflecting blood flow & vascular permeability
may act as early response parameters for NAC in breast cancer. A
large patient cohort is currently being studied to quantify the
magnitude of this effect. 
MAGNETIC RESONANCE SPECTROSCOPY (MRS) STUDY OF 
17AAG IN HT29 XENOGRAFTS 
Helen Troy
1*, Yuen-Li Chung
1, Udai Banerji
2, Ian R Judson
2, Martin O 
Leach
2, Marion Stubbs
1, Sabrina Ronen
2, Paul Workman
2 and John R
Griffiths
1
1St George’s Hospital Medical School, London, UK,
2Institute for Cancer 
Research, Sutton, UK. 
Aims: 17AAG is an anti-cancer drug that inhibits heat shock protein 90 
(Hsp90) which results in proteasomal degradation of oncogenic client 
proteins.  The aim of this work was to develop a non-invasive 
pharmacodynamic (PD) marker for 17AAG.
 Methods: HT29 xenografts were grown in nude mice to a size of
484+36 mg. In vivo localized 
31P MRS was carried out on day 1 (pre-) 
and 5, on tumours treated with 17AAG (n = 14, 80mg/kg i.p., 4 days) or
EPL vehicle (n = 5). In vitro
1H and 
31P MRS and Western blots for Raf-
1 and Hsp70 were carried out on tumour extracts to complement our in 
vivo MR data.
 Results: 17AAG inhibited tumour growth (97 + 2%), while control 
tumours increased by 120 + 7% of pre-treatment volume.  In vivo
31P 
MRS showed a significant reduction in β  -NTP/total phosphorus signal
(TotP) (p <0.03) and elevation in phosphocholine and
phosphoethanolamine (PC+PE)/TotP (p <0.05) ratios in 17AAG-treated 
tumours.  No significant changes were found in controls. In vitro
31P and 
1H MRS of the 17AAG-treated tumour extracts confirmed our in vivo
findings, showing a significant increase in the levels of PC (p <0.04) and 
PE (p <0.03) when compared with controls. Western blots showed 
induction of Hsp70 and reduced Raf-1 in the 17AAG-treated group,
confirming the expected action of the drug.  
Conclusions: 17AAG inhibited Hsp90 and altered tumour
bioenergetics and phospholipid membrane metabolism, as well as 
decreasing tumour growth rate.  MRS may provide a non-invasive PD 
marker for use in clinical trials. 
DETERMINATION OF THE ANTI-CANCER DRUG
ACTINOMYCIN D IN HUMAN PLASMA BY LIQUID 
CHROMATOGRAPHY-MASS SPECTROMETRY, Julie 
Errington*, Gareth J. Veal, Julieann Sludden, Melanie J. Griffin,
Lisa Price, Annie Parry, Juliet Hale, Andrew D.J. Pearson and 
Alan V. Boddy. Northern Institute for Cancer Research, University
of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH. 
Actinomycin D is an anticancer drug commonly used in the
treatment of paediatric malignancies such as Wilms tumour and
Ewing’s sarcoma.  Despite its long history of clinical use, little is
known about the pharmacokinetics of actinomycin D in humans.
As actinomycin D treatment in children with cancer is associated
with veno-occlusive disease, and as dose intensity has been
defined as a significant risk factor for the development of this
potentially life-threatening toxicity, pharmacokinetic studies of
actinomycin D may be beneficial in optimizing treatment with this
drug. 
   We have  developed an  accurate  and  sensitive  liquid
chromatography-mass spectroscopy method for the determination
of actinomycin D in human plasma samples.  Extraction of
analytical samples was carried out with acetonitrile and analysis
performed on a C8 column with an API 2000 LC/MS/MS using an
internal standard of 7-aminoactinomycin D.   
The method showed good reproducibility with intra- and inter-
assay precision CVs of 2.7-11.3% and 2.3-7.8% respectively.
Actinomycin D recovery rates varied from 83.5 to 89% and the
limit of detection was determined to be 1ng/ml.  Analysis of
plasma samples obtained from 2 patients receiving actinomycin D
treatment, indicated that the assay could successfully be used to
quantify actinomycin D in clinical samples. Peak plasma
concentrations of 7.71 and 41.3ng/ml were observed following
doses of 0.75 and 1.5mg/m
2 respectively. 
Poster Presentations
S41
British Journal of Cancer (2003) 88(Suppl 1), S25–S54 & 2003 Cancer Research UKP69 P70
P71 P71a
SENSITIVE DETERMINATION OF BBR 3464 AND
CISPLATIN DNA ADDUCT LEVELS IN CLINICAL SAMPLES
USING ICP-MS and PIMMS 
Tyrone John
* 1, Chris Ottley
2, Graham Pearson
2, Geoff Nowell
2, 
Hilary Calvert
1 & Michael Tilby
1.  
1NICR, Newcastle University, 
Framligton Place, NE2 4HH.  
2Durham University, Geology
Department. 
Introduction. Blood samples from recent clinical trials of the novel 
trinuclear platinum anti-cancer drug BBR3464 provide the 
opportunity to determine the levels of Pt-DNA adducts achieved in 
patients with this drug. Since immunoassays are not available for 
these adducts, highly sensitive inductively coupled plasma mass
spectrometry (ICP-MS) methods have been developed for Pt on 
DNA. 
Methods Whole blood was incubated with BBR 3464, 1hr, 37
oC, 
and lmphocytes isolated (lymphoprep). A2780 ovarian cells were 
exposed to BBR 3464 and cisplatin (1h, 37
oC). IC50 values were
determined by XTT. DNA was extracted (Qiagen tips) and Pt 
levels determined with ThermoFinnegan Neptune (PIMMS) and 
Perkin Elmer Elan 6000 quadrapole ICP-MS instruments. 
Results and conclusion Adduct levels at IC50 exposures of BBR 
3464 and cisplatin in A2780 were 2.5 and 2.8 nmoles /gDNA
respectively and gave signals >100x above background. DNA
adduct levels detected in blood incubated with levels of BBR3464 
observed in patients (0.03 µM) were about 0.18 nmoles/gDNA.
PIMMS gives >50x Pt sensitivity than ICP-MS allowing the 
accurate analysis of blood DNA adducts. If BBR 3464 adducts are 
formed in patients at biologically effective levels they should be 
detectable by these techniques. 
METHIONINE DEPENDENCY OF TUMOURS: A
BIOCHEMICAL STRATEGY FOR OPTIMIZING
CHEMOSENSITIVITY. V Pavillard*, DJ Swaine, AA Drbal, RM
Phillips, A Nicolaou, & JA Double. Tom Connors Cancer Research
Centre and School of Pharmacy, University of Bradford, Bradford
BD7 1DP, UK. 
The aim of our study is to explore the effect of MET depletion on
viability, cell cycle kinetics, sulfur amino acid metabolism in MET-
dependent cancer cells for optimizing in-vitro chemosentivity. The
cells used were rat hepatocarcinoma HTC (MET-dependent), Phi-1
(partially MET-independent), transformed mouse fibroblasts 3T3
(MET-dependent) and human skin fibroblasts Hs-27 (MET-
independent). Cells were grown in Control medium (containing
MET) and MET depleted medium (containing HCY); viability was
tested by supplying MET after 5 days of MET depletion. In MET
depleted medium, MET-dependent cells did not proliferate and
were accumulated in S/G2 phases of the cell cycle compared to
controls. They remained viable after MET depletion that resulted in
cell proliferation, transient burst of cells in S and G2/M phases and
normalization of cell cycle parameters few days later. Cysteine was
taken up by HTC while 3T3 exported HCY. MET independent
cells were able to grow MET depleted medium without significant
changes in cell cycle parameters compared to controls. Cysteine
was taken up by Phi-1 while Hs-27 exported HCY. The amino-acid
metabolism seemed to be cell-type dependent. The cells treated
with vinblastin and taxol (targeting cells in G2/M phase) were all
more resistant to both drugs under MET depletion compared to
controls (treatment in control medium). Only MET-dependent cells
were more sensitive to both drugs while recovering after MET
depletion compared to controls and MET-independent cells. The
potential of synchronizing MET-dependent cells in a specific phase
of the cell cycle is rendering cells more susceptible to cell cycle
phase specific agents and produces a therapeutic gain. This work
was supported by Cancer Research UK.  
DEXRAZOXANE (DXRz) DOES NOT REDUCE THE
RESPONSE RATE TO DOXORUBICIN (ADRIAMYCIN)   Kurt 
Hellmann* Windleshaw House, Withyham, East Sussex, TN7 4DB, 
UK
Reduction of side effects of antitumour drugs with-outloss
of activity has been explored for many years. Although highly
active, doxorubicin's full potential is restricted by a dose limiting 
cardiotoxicity. DXRz is highly effective in preventing this
potentially lethal side effect.  It is not accompanied by any new
adverse reaction apart from a reduction in WBC.  One of 16 
randomised, controlled clinical trials reported a reduced response 
rate.  It could not be repeated in an identical trial.  Survival has not 
been reduced in any of the 16 trials.  In an attempt to find an 
explanation for the apparent reduction in response, we examined the 
effects of DXRz on K562 cells. 
We found that as with razoxane, incubation in IC50 levels of 
DXRz (70uM) led to G2/M arrest within 8h.  At 24h, 35± 6% of 
cells had tetraploid or higher DNA content, suggesting DNA
rereplication.  The cells were also significantly larger (mostly twice 
as large).  If this occurred in a solid tumour, it would be possible for 
a tumour to increase in size without any increase in number of cells
and thus give the illusion of not having responded. 
Differences of response rate between controls and treated as
in the 1/16 trials (above) cannot be taken at face value, but should 
be rigorously examined, particularly where differences are small (as 
above) and in accordance with FDA ruling that response rate is just 
a surrogate for the all important median survival time. 
COMPARISONS OF HISTOPATHOLOGY, MOLECULAR GENETICS AND
SINGLE VOXEL 
1H MR SPECTROSCOPY IN OLIGODENDROGLIAL
NEOPLASMS
Carol Walker
+*, Trevor Smith
#, Kathyrn A. Joyce
+, Daniel DuPlessis
# and Peter
C. Warnke
#+ Clatterbridge Cancer Research Trust, Clatterbridge Hospital,
Bebington, Wirral, CH63 4JY;
#Walton Centre for Neurology and
Neurosurgery, Liverpool, UK.
The diagnosis of gliomas is particularly challenging with the
histopathological classification frequently differing from a
classification based on molecular genetics.  
1H-MRS is capable of
non-invasively determining intracellular metabolite concentrations,
which in brain tumours differ from normal brain, but it is not
known whether this technique can distinguish the different
subtypes of glioma based on either a molecular or a
histopathological classification. 
In this study, 28 tumours were investigated and laser capture
microdissection and microsatellite analysis was used to determine
allelic losses. Loss of both 1p36 and 19q13, typical of
oligodendrogliomas, was found in 8/12 OII, 3/10 OAII, 2/3 OIII
and 1/3 OAIII.  
1H single voxel spectra were obtained using a G.E.
Signa 1.5T NVi MR Scanner running PROBE P (PRESS) SV
MRS TR 1500 TE 35. Peak areas of NAA, Cho, Cr, myoinositol
and lipid/lactate were calculated and normalised to the Cr peak.
No significant difference in NAA, Cho, myoinositol, lipid/lactate
or NAA/Cho was observed in oligoastrocytomas vs
oligodendrogliomas, or tumours with 1p36/19q13 loss vs those
without, when the data was analysed in the series as a whole or in
low-grade tumours only.  Despite the small number of high-grade
cases, Cho and lipid/lactate signals were significantly greater in
high-grade vs low-grade tumours. 
In gliomas with an oligodendroglial component, single voxel
1H-
MRS may be useful to determine malignancy, but in this study did
not permit distinction between histological or molecular subtypes.  
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PROGNOSTIC SIGNIFICANCE OF OESTROGEN
RECEPTOR BETA IN USUAL DUCTAL HYPERPLASIA OF 
THE BREAST 
Abeer M. Shabaan , Penny A. O’Neill* and Christopher S. Foster  
Department of Cellular and Molecular Pathology, The University
of Liverpool, L69 3GA, UK 
 ERβ   is thought to have prognostic significance in breast cancer. 
However, little is known about its role in benign proliferative 
breast lesions. We designed case-control study on 120 cases who 
had benign breast biopsies that progressed to breast cancer and 
382 matched controls that did not develop breast cancer (follow-
up: 20yrs). Foci of usual ductal hyperplasia, (UDH, n=154) and 
adjacent normal lobules (n=116) were identified and stained with 
monoclonal ERβ   and ERα   monoclonal antibodies. The majority
of normal lobules from cases that developed breast cancer and 
controls expressed ERβ   with a significantly higher level in 
control subjects (P=0.04). ERβ   expression in UDH from cases
(67.50%) was lower than that of matched controls (80.50%). 
This difference, however, was not statistically significant, 
whereas ERα   level was higher in cases than in controls 
(P=0.008). A significantly lower median expression of ERβ   was 
seen in UDH foci from control patients when compared with
adjacent morphologically normal lobules (P<0.001).  ERβ  :ERα 
ratio was significantly lower in UDH from cases than in controls
(P=0.008). Our date indicate that the level and distribution of 
ERβ   are distinct from those of ERα  . Concurrent low levels of 
ERβ   and high levels of ERα   characterise potentially high-risk 
patients. The relative occurrence and/or interaction of these two 
types of oestrogen receptor might help predict the phenotypical 
behaviour of UDH. 
INFLUENCE OF CYTOKINE GENE POLYMORPHISMS ON
SUSCEPTIBILITY TO AND PROGNOSIS IN BREAST 
CANCER 
W. Martin Howell*, Katherine C. Smith, Helen M. Fussell, Adrian 
C. Bateman. Departments of Molecular Pathology, Cellular 
Pathology and University Human Genetics, Southampton General 
Hospital, Southampton, SO16 6YD, UK.   
Single nucleotide polymorphisms (SNPs) in the promoter regions 
of a number of cytokine genes are associated with differential 
levels of cytokine expression in vitro. In accordance with our 
findings in other malignancies, we hypothesised that these SNPs 
might influence breast tumour development and progression by
affecting the efficiency of the anti-tumour immune response and/or 
pathways of angiogenesis.  
144 female breast cancer patients and 263 cancer-free controls
were genotyped for selected pro- and anti-inflammatory and 
angiogenic cytokine SNPs, including IL-1β –511 (T/C), IL-6 –174 
(G/C), TNFα –308 (A/G), IL-10 –1082 (A/G), IL-8 –251 (A/T) and 
VEGF –1154 (A/G), using ARMS-PCR and TaqMan® 5’ nuclease 
assays for allelic discrimination. Patient-control comparisons
revealed that the TNFα –308 GG genotype was increased in 
patients v controls (79.7% v 68.2%, P=0.03, OR=1.83, 95% 
CI=1.08-3.09).  Stratification of the patient group according to the 
Nottingham Prognostic Index revealed a number of significant 
associations, including IL-8 –251 AA and poor prognosis disease 
(35.3% v 12.7%; P=0.02) and IL-6 -174 GC and Grade 2/3 v Grade 
1 disease (51.3% v 31.4%; P=0.04).  
    These  results  provide  preliminary evidence  that 
polymorphisms in the promoter regions of cytokine genes may
affect both susceptibility to and prognosis in breast cancer, 
although causality cannot be directly inferred. Confirmation of 
these findings is currently being sought in an expanded patient 
and control group, with full SNP exclusion for selected genes.
CORRELATION OF WILD TYPE OESTROGEN 
RECEPTOR BETA (ERβ  1) mRNAAND PROTEIN EXPRESSION 
WITH PROGNOSIS IN TAMOXIFEN TREATED BREAST
CANCER. 
Penny A.O’Neill
1*, Abeer M. Shaaban
2, Christopher S.Foster
2, Helen 
Innes
1, D. Ross Sibson
1, andMichael P.A. Davies
1 
1Clatterbridge Cancer Research Trust, J. K. Douglas Laboratories, 
Wirral, and 
2Dept. of Cellular and Molecular Pathology, University of 
Liverpool, Merseyside. 
  ERα   status is important for predicting response to hormonal 
therapies but the role of ER β is less clear. We studied expression of 
ERα    and ERβ  1 proteins in 167 patients with invasive breast cancers 
treated with adjuvant endocrine therapy. We used a previously
validated PPG5/10 monoclonal antibody to detect full length, wild type 
ERβ  1.  The results were compared with mRNA expression of the same
genes by RT-PCR.  
  ERα protein expression was closely associated with RNA expression 
detected by RT-PCR (p< 0.001). However ERβ1 protein was expressed 
at a variety of levels and did not correlate with RNA expression. 
Associations were seen between expression of both receptors by RT-
PCR (p < 0.001) and between ERβ RT-PCR and ERα IHC (p < 0.027), 
but not between the ERα   and ERβ  1 proteins detected by IHC. It is 
therefore possible that translational or post-translational control plays a 
significant part in ERβ  1 expression. There was no significant 
association between ERβ   1 IHC status and  PgR status, tumour stage or 
grade, axillary nodal status, presence of lymphovascular invasion, size 
of tumour or proliferation. There was a trend for ERβ  1 IHC negative 
cases to have a better outcome both within the group as a whole and 
within ERα   positive Tamoxifen-treated cases.   
DETECTION OF CIRCULATING TUMOR CELLS IN BLOOD
AND BONE MARROW OF PATIENTS WITH
GASTROINTESTINAL CANCERS 
Sergej P. Osinsky*,  Vitalij V. Lukyanchuk, Antoine Roggo, Jorg
Kleeff, Daniil F. Gluzman, Vyacheslav A. Chorny, Dmitry S.
Osinsky, Daniel Candinas, and Helmut Friess. 
Institute of Exp. Pathol. Oncol. Radiobiol.,  Kiev, Ukraine; Bern
University, Switzerland; Heidelberg University, Germany.
   Aim: to examine whether cytokeratin 20 (CK-20) and prostate
stem cell antigen (PSCA) are useful markers for the detection of
disseminated cancer cells.  
   Patients and Methods: nested RT-PCR was used to determine
the expression of  CK-20 and PSCA in peripheral blood (PB) from
47 patients (pts.) with pancreatic carcinoma (PC) (11), gastric
cancer (8), colorectal carcinoma (15), and miscellaneous tumors
(13). Immunocytochemical method was used to detect the
expression of CK in bone marrow (BM) from patients with PC
(11). All patients and healthy volunteers (18) gave written consent
before samples were obtained.  
   Results: CK-20 expression was observed in PB of 19/47
(40.4%) pts. with malignant tumors (MT). PSCA expression was
present in PB of 22/47 (46.8%) pts. MT, and particularly in 7/11
(63.6%) patients with PC. CK-20 and PSCA expression was not
observed in blood samples from healthy donors. CK- or PSCA-
positive cells were found in 40% of  Stage II-III patients. There
was a relationship between PSCA expression and tumor stage.
Correlation between findings of cancer cells in BM and survival
was shown. Reactive changes of immunocompetent and stromal
cells in BM  of patients with CK
+ cells were observed. 
   Conclusion: Detection of cancer cells in PB and BM can be
useful both to identify the patients of high risk for early metastases
and prognosis of clinical outcome. 
The study was supported by SCOPES (Grant No 7 IP 62587).
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INTERLEUKIN 10 POLYMORPHISM MAY INFLUENCE RENAL
CANCER DEVELOPMENT.
Erik G. Havranek *, Mike Whelan
a, Joseph Whelan
a, Angus Dalgleish
b,
Chris Anderson, Hardev Pandha
b
Department of Urology, St. George’s Hospital, London.
a Onyvax Ltd, St. George’s Hospital Medical School, London. 
b Department of Clinical Oncology, St. George’s Hospital Medical
School, Cramner Terrace, London SW17 ORE.
Introduction: Interleukin-10 (IL-10) is a T-helper 2 cytokine with known
anti-inflammatory properties. A gene polymorphism of the IL10-1082
promoter region causes low expression of IL-10. This study aimed to
determine whether there is an association between this IL-10
polymorphism and renal cancer.
Patients and Methods: The single nucleotide polymorphism in the
IL10-1082 gene was detected by TaqMan real-time PCR using probes
labelled with FAM or VIC dyes. Genotypes were assigned to DNA
extracted from paraffin embedded archival tissue from patients (n=147)
with known renal adenocarcinoma. These were then compared to DNA
extracted from peripheral blood lymphocytes of control patients (n=149)
without cancer.
    Results: Of the renal cancer patients, 44% (n=26) had the AA
genotype, 38% (56) AG and 18% GG. Of the control patients 30% (45)
were AA, 46% (69) AG and 23% (35) GG. Chi square test showed a
significant difference between cancer and control patients (p<0.05). The
odds ratio (1.83) shows that the AA genotype is over-represented in
renal cancer patients with a 95% confidence interval 1.14-2.95.
Conclusions: The results suggest that there is a significantly larger
proportion of low IL-10 (AA) producing homozygotes amongst renal
cancer patients than would be expected in a normal population. This
data is in agreement with the findings in prostate cancer patients.  
Wen G. Jiang
1, Anthony Douglas-Jones
2 and Robert E. Mansel
1,
1Metastasis Research Group and 
2Department of Pathology,
University of Wales College of Medicine, Heath Park, Cardiff, The
United Kingdom
Peroxisome-proliferator activated receptor-gamma (PPARγ  ) belongs
to a family of nuclear receptors and acts as receptor for peroxisome-
proliferators, steroids, retinoc acids, and polyunsaturated fatty acids.
The current study examined the transcript levels of peroxisome-
proliferator activated receptor-gamma (PPARγ  ) and its co-activator
(PGC-1) in a cohort of patients with breast cancer. An invasive
breast cancer cell, MDA MB 231 exhibited lower level of expression
of PPARγ  , compared with non-invasive MCF-7. Both cells
expressed PGC-1. Breast cancer tissues (n=120) exhibited a lower
level of PPARγ  mRNA compared with normal tissues (n=25,
p=0.05). However, no difference of PGC-1 was seen between normal
tissues and tumour tissues. Although the levels of PPARγ   and PGC-
1 did not correlate with nodal involvement and grade, significantly
lower levels of PPARγ were seen in TNM3 and TNM4 tumours and
from patients with local recurrence and those who died of breast
cancer.  Lowest level of PGC-1 was also seen in TNM3 and TNM4
tumours and patients who died of breast cancer. It is concluded that
there is aberrant expression of PPARγ   and its co-activator, PGC-1, in
human breast cancer, and that low levels of these molecules in
cancer tissues are associated with poor clinical outcomes. 
PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR-
GAMMA (PPARG) AND THE PPARG CO-ACTIVATOR, PGC-1,
AND THEIR CORRELATION WITH AGGRESIVENESS OF
HUMAN BREAST CANCER.
EVALUATION OF PLASMA & SERUM VASCULAR
ENDOTHELIAL GROWTH FACTOR (VEGF) DURING
NEOADJUVANT CHEMOTHERAPY FOR PRIMARY BREAST
CANCER. 
PROGNOSTIC VALUE OF COMPLEMENT REGULATORY
PROTEINS CD55 AND CD59 IN BREAST CANCER 
Zahra Madjd
1*, Sarah E Pinder
2, Ian Spendlove
1 and Lindy  G
Durrant
1 1CRUK Clinical Oncology and 
2 Dept. of Histopathology,
University of Nottingham, City Hospital, Nottingham, NG5 1PB 
Introduction: Cells express complement regulatory proteins CD55, CD59 
and CD46 to protect them from bystander attack by complement. Our 
previous immunohistochemical study showed that in breast carcinoma loss 
of CD59 correlated with poor survival.
Aim and methods: The prognostic significance of CD55 was investigated 
in 480 patients with primary operable breast cancer, using an anti-CD55 
monoclonal antibody (mAb) RM1 (developed in the department) with a 
standard immunohistochemistry method. The anti-CD55 mAb (RM1) was 
raised against a synthetic peptide and stained formalin-fixed, paraffin 
embedded sections stronger than the commercial mAb to CD55 (clone 67). 
As there are no commercially available anti-CD46 antibodies suitable for 
use on paraffin sections we are developing a peptide specific antibody to 
CD46. This will be used to complement the antibodies to CD55 and CD59 
in screening the breast microarrays.
Results: 95% of the breast carcinomas expressed CD55 (RM1) with 
intensity ranging from weak (51%) to strong (6%). High expression of 
CD55 was significantly associated with low grade (G1, G2) (p=0.001), 
lymph node negativity (p=0.031) and good prognosis tumours 
(Nottingham Prognostic Index <3.4) (p<0.001). Significant correlation was 
also found between expression of CD55 and overall survival, loss of CD55 
in breast tumours being associated with poor survival (p=0.001).
Conclusion: Our data indicated that unexpectedly loss of CD55 and CD59 
is associated with aggressive breast tumours. However, it has been 
speculated that loss of CD55 and CD59 may be compensated by increased 
expression of CD46, which inhibits the complement cascade at an early 
stage. Analysis of CD46 expression in these breast microarrays will 
complete the picture of the role of these complement inhibitory proteins in 
tumour prognosis.  
Mei-Lin W.Ah-See*, Andreas Makris, Russell J. Burcombe, Charlotte 
Davies, Helen J. Cladd,Anwar R. Padhani & Adrian L. Harris. Mount 
Vernon Hospital,Northwood, Middlesex, HA6 2RN.*
   Background: There is a need for surrogate markers of angiogenic 
activity. VEGF is an important regulator of angiogenesis & elevated 
tumour VEGF is a poor prognostic factor in breast cancer. We 
measured plasma & serum VEGF (pVEGF,sVEGF) during 
neoadjuvant FEC chemotherapy (NAC) for primary breast cancer in 
order to evaluate its role as a predictor of tumour response to NAC.  
Materials & methods: Serial measures of pVEGF & sVEGF were 
performed in 22 patients (median age 47, range 34-67) undergoing 
NAC for T2-4 biopsy-proven breast carcinoma. Samples were 
collected before cycle 1, 2, 4 & 6 of treatment and measured using an 
ELISA immunoassay. Baseline & changes in pVEGF & sVEGF were 
correlated with clinical, radiological & pathological response. Results: 
Little inter-or intra-patient variability was observed in pVEGF or 
sVEGF & no consistent variation with time could be demonstrated. 
There was no significant difference in baselineor change in pVEGF or 
sVEGF afterone cycle of treatment between responders & non-
responders classified by clinical, radiological or pathological criteria. 
Conclusions: Given that baseline & changes in pVEGF & sVEGF are 
of limited value in predicting response to neoadjuvant chemotherapy 
alone in breast cancer, changes following combination therapy 
(chemotherapy & antiangiogenic therapies) may be of value as a 
surrogate marker of angiogenic activity specifically inresponse to 
antiangiogenic therapies. 
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HEPATOCYTE GROWTH FACTOR ACTIVATORS (HGFA AND
MATRIPTASE-1) AND HGF INHIBITORS IN HUMAN BREAST 
CANCER. Christian Parr*, Gareth Watkins, Robert E. Mansel and
Wen G. Jiang. Metastasis Research Group, Department of Surgery, 
University of Wales College of Medicine, Cardiff, U.K.
 Hepatocyte growth factor (HGF) stimulates cancer cell dissociation, 
migration, invasion and angiogenesis. This factor is synthesised as an 
inactive precursor called pro-HGF. HGF activator (HGFA) and matriptase-1 
are two serine proteases responsible for converting pro-HGF to active HGF, 
and have been implicated as pro-invasion and metastasis factors. HAI-1 and 
HAI-2 possess the ability to inhibit the action of both HGFA and matriptase-
1. This study determined the expression of HGFA, HAI-1, HAI-2, and 
matriptase-1 in breast cancer. 
 Breast cancer tissue (n=100) and normal background tissue (n=20), was 
obtained immediately after surgery. The median follow-up for the patients 
was 72 months. Matriptase-1, HGFA, HAI-1 and HAI-2 expression was 
determined using RT-PCR and Q-RT-PCR. 
 HGFA was expressed at a higher level in node positive tumours compared to 
specimens from patients without nodal involvement (59±124 copies/µl vs. 
38± 72 copies/µl, respectively). However, HAI-2 was expressed to a lower 
degree in node positive tumours (341±368 copies/µl), than that in the node 
negative breast cancer tissues (440±5685 copies/µl). Our results showed that 
grade 3 tumours produce statistically lower levels of HAI-1 (821±1183 
copies/µl) and HAI-2 (237±358 copies/µl), compared to grade 1 tumours 
(1898±3800 and 479±522 copies/µl, respectively). HAI-2 was also found to 
be statistically lower in the TNM 3 breast cancer group when compared to 
TNM groups 1 & 2 (p<0.001), thus associated with a poor prognosis. No 
significant correlation was found between matriptase-1 and nodal status or 
tumour grade.  
 This is the first study to quantitate HGFA, matriptase-1 and HAI expression 
in human breast cancer tissues. The aberrant levels of HGFA, HAI-1 and 
HAI-2 have important bearing to the grade and stage of human breast cancer.  
LOBULAR CANCER- THE MARKER FOR BRCA 3 AND 4?
E F Shah*, L Barr, A D Baildam and D G R Evans 
Specialist Breast Unit and Academic unit of Medical Genetics,
South Manchester University Hospitals NHS Trust and St Mary's
Hospital, Manchester
Aims: To demonstrate the likelihood of lobular carcinoma in
individuals with LCIS who have a strong family history of lobular
breast cancer, the lack of BRCA1 and 2 mutations in these families
and the possibility of a link with other putative breast cancer
susceptibility genes such as BRCA 3 and 4. 
Procedures: Women attending the family history clinic with a 1:4
or greater lifetime risk of breast cancer were considered eligible for
bilateral risk reducing mastectomy. 136 women from different
breast cancer families underwent preventative surgery and follow-
up thereafter in a dedicated out-patient setting. They went through
the phases of a rigorous prophylactic mastectomy protocol
1 prior to
surgery. All the families underwent extensive testing for BRCA1
and 2. 
Findings: Six patients were found to have LCIS and/or invasive
lobular cancer on definitive histology. All of them had a family
history of lobular cancer. Testing for BRCA1 and 2 was negative in
all cases, including one patient from a family with a BRCA1
mutation, which was discovered later.  
Conclusions: LCIS in a BRCA1 or 2 family could be a
coincidental finding. Lobular cancer may be the marker for BRCA
3 and 4. 
   Reference: 
1. Lalloo F, Baildam A, Brain A, Hopwood P, Evans DGR, Howell
A. A protocol for preventative mastectomy in women with an
increased lifetime risk of breast cancer. Eur J Surg Oncol 2000; 26:
711-713. 
INDUCTION OF INSULIN-LIKE GROWTH FACTOR
BINDING PROTEIN-3 BY HYPOXIA AND INCREASED
URINARY EXCRETION IN BLADDER CANCER. Jonathan J.
Ord* Edward H. Streeter David Cranston Adrian L. Harris Address
for correspondence – Room 405 Institute of Molecular Medicine,
John Radcliffe Hospital, Headington Oxford. j.ord@cancer.org.uk 
Using 10000 gene Sanger cDNA chips we analysed gene
expression; in an aggressive bladder cancer cell line EJ28 under
normoxia and hypoxia (0.1%); and on 38 bladder cancers compared
to a panel of 11 cancer cell lines. One of the most strongly
differentially expressed genes in both arrays was the mRNA for
Insulin-like growth factor binding protein 3 (IGFBP-3). This was
upregulated 6-fold by hypoxia and 2 to 100-fold in 33/38 tumours.
Vascular Endothelial Growth Factor mRNA by comparison was
upregulated 2-fold by hypoxia and 2 to 18-fold in 27/38.  
Urine from 157 bladder cancer patients and controls were
collected prospectively and IGFBP-3 levels measured by ELISA.
There were 71 superficial cancers, 18 invasive, 4 carcinoma-in situ,
30 patients clear of disease, and 30 controls. 
There was a significant increase in urinary IGFBP-3 from
control/clear groups to superficial cancers to invasive cancers,
p<0.01 for superficial vs. control/clear, p<0.01 for invasive vs.
control/clear [IGFBP-3 ng/ml mean (standard deviation); controls
15.2ng/ml (7.55); clears 14.6ng/ml (8.1); superficial 27.7ng/ml
(29); invasive 55.1ng/ml (40)]. After correction for urinary
creatinine significance (p<0.01) was retained for invasive tumours
not with the superficial group. 
   Previous in vitro experiments on cell growth and IGFBP-3 make
it very likely that the levels of IGFBP-3 seen here are of clinical
significance reflecting the hypoxia in the primary tumour and
contributing to cell viability
ELUCIDATION OF THE MOLECULAR MECHANISMS OF
CYTOTOXICITY AND PATHOGENESIS IN NON-SMALL
CELL LUNG CANCER (NSCLC) USING GENE EXPRESSION
PROFILING 
Russell D Petty
*1,2&3, Marianne C Nicolson
2, Keith Kerr
3, Graeme
Murray
3. and Elaina Collie-Duguid
11  Dept of Medicine and
Therapeutics, Univ. of Aberdeen, 
2 Dept of Oncology, 
3 Dept of
Pathology, Aberdeen Royal Infirmary, Aberdeen, UK. 
A better understanding of the molecular mechanisms of action and
resistance to cytotoxic drugs and the mechanisms underlying
NSCLC pathogenesis will lead to more effective therapies.
Effective anti- cancer therapy involves the selective killing of
tumour cells, therefore cell death pathways are of particular
interest. Unfortunately the complexity of  the molecular
abnormalities present has hindered progress. We have used the
model of neoadjuvant chemotherapy in NSCLC in conjunction with
gene expression profiling (Affymetrix HG-U133A genechips-
22283 transcripts) to elucidate the molecular determinants of  drug
cytotoxicity and pathogenesis in NSCLC. To date tumour:normal
paired tissues from  3 patients who have received platinum based
neoadjuvant chemotherapy have been profiled. Data has been
analysed using Affymetrix MASv5.0  and DMTv3.0.  We have
identified 2599 genes with significantly altered expression in at
least one of the tumours and 768  (401 decreased and 367
increased) with significantly altered expression in all three tumours
compared to normal tissue (Mann-Whitney p<0.05).  This analysis
identified 20 cell death associated genes with significantly altered
expression in all three tumours- these include TRADD, IAP, DAP-
3, DAPK-2, FLAME-1 (average fold change 2.5, 3.0, 1.7, -8.0,
and -2.0 respectively). Further  work is ongoing and updated results
including gene expression profiles in relation to pathological
response will be presented at the meeting. 
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EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH
FACTORS (VEGFS), THEIR RECEPTORS AND ANGIONESIS
MARKERS (TEMS) IN HUMAN COLORECTAL CANCER 
Khaled Rmali*, Malcolm CA Puntis, Wen G Jiang, Department of
Surgery, Univ. of Wales College of Medicine, Cardiff, CF14 4XN.
Introduction
  Angiogenesis is an essential step in tumour growth and metastasis. We 
studied the expression of VEGFs, their receptors and their connection with 
angiogenic markers, both specific (TEMs)1 and non-specific (PECAM) to 
tumour related angiogenesis in a group of patients with colorectal cancer
Methodology:   RT-PCR and quantitative RT-PCR were used to assess the 
expression of VEGF, -B, -C and -D, their receptors Flt-1,KDR and Flt-4, as 
well as Tumour Endothelial Markers (TEM1-8) and PECAM in tumour 
(n=21) and normal colon tissues (n=28), and colorectal cancer cell lines 
(HT115, HRT18 & HT55).
Results: VEGF was expressed in HT115, VEGF-B and -D in HT115 and 
HRT118, and VEGF-C in HT55 & HRT118cells. VEGF-B expression was 
significantly higher in colon cancer tissues than in normal (p=0.001, χ2 test). 
The level of VEGF-C was significantly greater in tumour tissues than in 
normal  (p=0.02), but the level of VEGF and VEGF-D remained the same. 
While Flt1 and KDR were highly expressed in tumour tissues (p=0.019 and 
p=0.003 respectively), Flt4 was detected equally both in colonic tumours 
and in normal (p=0.13). TEM-1, -2, -7, -7R, & TEM8 were at a higher level 
in colonic cancer than in normal mucosa. No significant difference between 
the levels of TEM4, TEM6 and PECAM found in cancer and normal 
mucosal tissues.
Conclusion:  VEGF-B and VEGF-C, their receptors (Flt1&KDR) and 
TEM1, 2,7,7R and TEM8 highly expressed in human colorectal cancer 
tissues, which may contribute to the development of colon cancer, and may 
constitute a putative target for anti-angiogenic drug therapy. 
1. Croix BS, Rago C, et al,. Science 2000, 289, 1197 
MUCIN GENE EXPRESSION IN SUPERFICIAL BLADDER 
CANCER: IDENTIFYING NOVEL MUCIN TUMOUR 
MARKERS 
Sze M. Yong*, Keith N. Stewart, Anne M. Pollock, James 
N’Dow, Andrew C. Schofield 
(Correspondence: Department of Surgery, University of 
Aberdeen Medical School, Aberdeen, AB25 2ZD.) 
Introduction  Mucins are found in mucus secretions including the 
urinary bladder and their expression is frequently altered in cancer.  We 
studied the expression of MUC1, 2 and 5AC in carcinoma in-situ (CIS), 
papillary urothelial carcinomas (pTa) and normal bladder specimens to 
examine their use as tumour markers in superficial bladder cancer. 
Methods  Samples from 65 bladder cancer patients were investigated 
including CIS samples (n=25), pTa samples (n=40; Grade1=6, 
Grade2=30, Grade3=4) and normal bladder specimens (n=14). 
Immunohistochemistry was performed using antibodies NCL-MUC1, 
MUC2 and MUC5AC.  Specimens were scored for presence or 
absence, proportion and depth of staining.  Statistical analysis was 
performed using the chi-squared test with the level of significance at  p 
< 0.05.  
Results MUC1, 2 and 5AC wereexpressed in 96% (24/25), 32% (8/25) 
and 8% (2/25) of CIS specimens respectively (p<0.001).   pTa 
specimens expressed MUC1 and MUC2 in 92.5% (37/40) and 33% 
(13/40) respectively, with no expression of MUC5AC (p<0.001).  CIS 
specimens expressed MUC1 in a higher proportion of cells (p=0.004) 
and stained deeper (p=0.041) compared to pTa specimens.  Normal 
urothelium expressed MUC1 but not MUC2 or 5AC. 
Conclusion  MUC2 and 5AC were expressed in superficial bladder 
cancer but not in normal bladder specimens. These 2 mucins may 
therefore be potentially useful tumour markers in superficial bladder 
cancer. 
IN VITRO ACTIVITY OF S-THALIDOMIDE AGAINST 
MULTIPLE MYELOMA CELLS: A GENE AND PROTEIN
EXPRESSION PROFILE.
Jim Malpas*
1,2, Tracy Chaplin
2, Anita Sanmugathasan
2 and Wai 
Liu
1. 
1New Drug Study Group and 
2Dept Medical Oncology, St
Bartholomew’s Hospital, London, UK. 
Background: Thalidomide (Th) has proven efficacy in multiple 
myeloma (MM). However, its mode of action is unclear, and it 
may be anti-angiogenic or may promote apoptosis. We have 
investigated the changes to the expression of genes involved with
these cellular processes following culture with Th in the U266
MM cell line. Methods: Cells were cultured with s-Th (0 - 1000
µM: Cellgene Corp., USA), and cell parameters, including
apoptosis, were assessed on day 3. RNA was extracted from cells 
cultured for 24 hr with IC50 of s-Th, and gene expression profiles 
established by microarray methodologies. Results: Reductions in
cell viability was observed in U266 cells cultured with s-Th
(IC50: 357 µM), which were mirrored by significant increases in
apoptosis (day 3: 9.3 ± 0.6% vs. 3.3 ± 0.9% on day 0; p<0.001).
The table below shows the changes in expression of the key genes 
involved with apoptosis (apo) or with angiogenesis (ang). 
ang VEGF  FLT-1  β-FGF FGF-r  MMP IL-6  myc 
∆(fold) 0  5 ↓ 3 ↑ 0             0  0  10 ↓
apo p53 ras bcl-2  bcl-xl  TNF-α I κβ NF-κβ
∆(fold) 2 ↑ 10 ↑ 0              0  9 ↓ 29  ↓ 4  ↓
Immunoblotting analyses of treated cells revealed that changes in
protein levels did not always correlate with gene expression. As 
an example, s-Th resulted in a reduction in IL-6 protein level but 
no change to the gene expression. Conclusion: Our data suggests 
that both angiogenic and apoptotic genes and proteins are affected
by s-Th. There is evidence that microarray analyses should not be 
used alone, as epigenetic factors, not considered by the technique,
may eventually alter protein level and functionality. 
EXPRESSION OF TRANSGLUTAMINASES IN HUMAN BREAST 
CANCER AND THEIR POSSIBLE CLINICAL SIGNIFICANCE. 
Wen G. Jiang
1; Richard J. Ablin
2; Anthony Douglas-Jones
3; Robert E. 
Mansel
1. 
1Metastasis Research Group and 
3Department of Pathology, 
University of Wales College of Medicine, Cardiff CF14 4XN, UK;
2Innapharma, Inc., Park Ridge, NJ 07656, USA. 
Implicated in several physiologic processes, including tumour-host 
responsiveness (Ablin/Gonder. Protides Biol. Fluids, 32:271, 1985), 
some transglutaminases (TGase) have been noted to play a regulatory
role in the extracellular matrix in cell adhesion and migration of cancer 
cells. This study sought to determine the level of expression of TGases 
and their possible clinical significance in a cohort of human breast 
cancer patients (pts.) using RT-PCR and quantitative RT-PCR. Normal 
breast tissues generally expressed low levels of TGases-1, 2, 3 and 7, 
and higher levels of TGases-4, 5 and plasma TGase (FXIII). 
Significantly increased levels of transcripts of TGases-4 and 7, and 
significantly lower levels of FXIII were seen in tumour tissues (n=110) 
compared with normal mammary tissues (n=27), p=0,05, 0.04, 0.05, 
respectively. Node positive tumours exhibited significantly higher 
levels of TGase-2 and lower levels of TGase-3 (p=0.05 and 0.046, 
respectively).  The lowest levels of TGases-3 and 7 were seen in pts. 
with metastatic disease, and TGase-3 in pts. who died of breast cancer, 
compared with those who remained disease free (median follow up 72 
months).  Higher levels of TGases-4 and 5 were noted in pts. with 
local recurrence.   Breast cancer displays an aberrant expression of 
TGases, wherein the levels of TGases-2, 3 and 7 have a relationship 
with node involvement and patient outcome.
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THE EXPRESSION OF IGF-1 IN NORMAL AND MALIGNANT 
BREAST TISSUE AND ITS ASSOCIATION WITH TUMOUR
SIZE 
Christiana A Laban*
1, Paul J Jenkins
2, Rob Carpenter
1. 
Departments of Breast Surgery
1,and Endocrinology
2, Bart’s and
The London, London UK. 
  Background:  The growth hormone/insulin-like growth factor-I 
(GH/IGF-I) axis has been increasingly implicated in the development 
of breast cancer. However the correlation of its local expression with 
clinical factors has not fully been investigated. 
  Aims:(i) To quantify the mRNA levels of IGF-I in normal and 
malignant breast tissue and (ii) to identify any correlation between 
level of expression of IGF-I and clinical parameters.  
  Methods: Total RNA was extracted from 29 samples of paired 
normal and malignant breast tissue. mRNA levels of IGF-I were 
quantified using a real time RT-PCR assay ('Taqman'). Full clinical 
details were available for each patient.  
   Results: (i) IGF-I was expressed in 27 of 29 normal samples and 26 
of 29 malignant breast tissue samples. IGF-I expression was 
significantly downregulated in the malignant tissue compared to 
normal tissue (median log copy number/microgrammes total RNA 
4.8E+06 vs 2.0E+07 respectively; P<0.0005). (ii) IGF-I mRNA 
expression was significantly increased in the larger cancers (>20mm) 
compared to smaller cancers (<20mm) (1.2E+07 vs 2.9E+06 
respectively; P<0.02). There was no association between IGF-I 
expression and tumour type, grade, nodal status or ER and PR status. 
  Conclusion: IGF-I mRNA is expressed locally in normal and 
malignant breast tissue. The upregulation in larger cancers is in keeping 
with its mitogenic role and suggests it might play an important role in 
tumour invasiveness and angiogenesis.
CHARACTERISATION OF AN ALTERNATIVE
TRANSCRIPT OF MURINE B29 
*Matthew D. Fox, Mark S. Cragg, and Martin J. Glennie. 
Directors Group, Tenovus Research Laboratory, Southampton
General Hospital, Southampton, SO16 6YD. 
B29 (Igβ, CD79b), and mb-1 (Igα, CD79a) form the CD79 
heterodimer, which is crucial for the expression of surface 
immunoglobulin (sIg), and formation of the B cell Receptor (BCR).  
An alternative transcript of B29 has been reported in normal and 
malignant human B cells (h∆B29) where exon 3 is deleted, resulting 
in a truncated extracellular domain. This transcript appears to regulate 
apoptosis through the BCR. We have recently discovered a 
homologous alternative transcript of B29 in normal and malignant 
murine B cells (m∆B29).  Sequence analysis of this transcript 
confirms that exon 3 has been deleted and that mB29 shares the same 
splice region as h∆B29.  All B cell lines so far assessed express this 
alternative transcript as judged by RT-PCR and its expression appears 
to correlate with a diminished sensitivity to apoptosis signalled 
through the BCR. To address the function of the alternative transcript 
more directly m∆B29 was cloned into the pCI-puro expression vector. 
Following transient expression in COS-7 cells and western blot 
analysis, it was revealed that the mB29 transcript successfully 
encodes for protein.  Furthermore, cellular localisation of m∆B29 
prior to and after ligation of the BCR was studied using YFP-tagged 
m∆B29, indicating that m∆B29 is expressed at the cell surface.  
Subsequently, various techniques such as over-expression and siRNA 
have been used to up- or down-regulate expression of mB29, 
respectively, in a variety of murine B cell lines to directly examine its 
effect on apoptotic signalling through the murine BCR.  
TNF-α GENE INDUCTION IN A MODEL OF HUMAN 
MELANOMA INVASION 
David P Jackson, Effie Katerinaki, Paul Berry*, Paul C Lorigan, Sheila
MacNeil, Poulam M Patel. 
Cancer Research UK Clinical Centre, St. James’s University Hospital,
Beckett Street, Leeds, LS23 6RZ.
Recent in vitro and animal studies suggest that an inflammatory
microenvironment may promote melanoma invasion. We recently
reported that the invasiveness of the human melanoma cell line HBL
through fibronectin is increased by 27% by the pro-inflammatory
cytokine TNF-α (1). The aim of this study was to use this model of
invasion to investigate TNF-α gene up-regulation in the HBL cell line
using cDNA microarrays. 
HBL cells were treated with TNF-α at 200 U/ml for 4, 8 or 24 hours.
Fluorescent labelled poly A+ RNA, from untreated and TNF–treated
cells was hybridised to a 10K cDNA microarray. 
Over this time course 21 genes were shown to be up-regulated greater
than 2-fold in response to TNF-α and 22 genes were down-regulated.
Of these a number of genes have been previously implicated in the
TNF-α response, including Glutathione peroxidase and SOD2,
scavengers of reactive oxygen species; NF-κB and I-REL, components
of the NF-κB transcription complex; and TNFAIPA20. In addition we
have identified a number of genes not previously known to be TNF-α
regulated.
cDNA microarrays have identified TNF-α regulated genes that may
play a role in the TNF-α response. We conclude that a combination of 
this technology with functional assays assessing the effects of TNF on
e.g. cell invasion and migration, applied to a panel of melanoma cell 
lines with differing invasive potential will be a valuable approach to
identifying genes relevant to inflammation associated metastasis.
(1) Zhu N et al. J Invest Dermatol 2002; 119:1165-1171
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GENE EXPRESSION PROFILING OF APOPTOSIS AND CELL 
CYCLE CONTROL IN DUKES’ C COLON TUMOURS.  Elaina
S R Collie-Duguid
1*, Diane S Stewart
1, James Cassidy
3, Graeme I
Murray
2.  Depts of Medicine and Therapeutics
1 and Pathology
2, 
University of Aberdeen, Aberdeen.  CRUK Dept of Medical 
Oncology, University of Glasgow, Glasgow. 
    Dukes’ C colon cancer patients with potentially curative resection 
and apparently the same histological stage and grade of tumour have 
vastly different clinical outcomes. Further insight into the molecular 
networks controlling tumorigenesis, response to therapy and survival in 
these cancer patients is required to allow more effective treatment. Cell 
cycle and apoptotic pathways are commonly disrupted in solid 
tumours, and this altered cellular profile may support tumour growth 
and chemoresistance. Microarray technology now allows, the many 
factors comprising these complex networks to be analysed 
simultaneously. 
  Gene expression levels were measured in tumour resection specimens 
from 4 patients with Dukes’ C colon cancer, using Affymetrix HG-
U133A GeneChip microarrays.   
    Analysis using Affymetrix MASv5.0 and DMTv3.0, revealed that 
862 transcripts were either increased or decreased in all tumours 
(3.9%).  Expression of 15 apoptosis associated transcripts (including 
MYC, TNFRSF6b, TRAIL-R2 [TNFRSF10b], DAP3 [2.0-3.8 median 
fold increase]; NFΚB1α, Apo2 ligand [TNFSF10], PDCD4 and 
caspase 7 [1.8-3.8 median fold decrease]) and 33 cell cycle transcripts 
(including NEK2, DKC1, CDC20, cyclinD1,CDK7, CDC2δT, PCNA, 
CDC25B, CDK4 and CDKI3 [2.3-15.0 median fold increase]) was 
altered in all tumours compared to the paired normal tissue (Mann 
Whitney p<0.05).  Expression profiles associated with prognosis and/or 
chemoresistance are currently being evaluated in a larger patient group. 
MOLECULAR MECHANISMS OF CYTOTOXICITY AND PATHOGENESIS
IN  NON-SMALL  CELL LUNG CANCER  (NSCLC)  USING  GENE
EXPRESSION PROFILING.  Russell D Petty*
1, Marianne C Nicolson
3,
Keith Kerr
2, Graeme I Murray
2 and Elaina Collie-Duguid
1.
Departments of Medicine and Therapeutics
1 and Pathology
2,
University of Aberdeen, Aberdeen, UK; Department of Oncology,
Aberdeen Royal Infirmary, Aberdeen, UK
3. 
 A better understanding of the molecular mechanisms of action and 
resistance to cytotoxic drugs and the mechanisms underlying NSCLC 
pathogenesis will lead to more effective therapies. Effective anti-
cancer therapy involves the selective killing of tumour cells, therefore 
cell death pathways are of particular interest. Unfortunately the 
complexity of the networks controlling chemoresistance and/or 
tumorigenesis has hindered progress.  
 We used the model of neoadjuvant chemotherapy in NSCLC in 
conjunction with gene expression profiling (Affymetrix HG-U133A 
GeneChips; 22283 transcripts) to elucidate the molecular determinants 
of drug cytotoxicity and pathogenesis in NSCLC. Tumour:normal 
paired tissues from 3 patients who received platinum based 
neoadjuvant chemotherapy were profiled. Data was analysed using 
Affymetrix MASv5.0 and DMTv3.0 software.  
 A total of 768 (401 decreased and 367 increased) genes had 
significantly altered expression in all three tumours compared to the 
uninvolved tissue (Mann-Whitney p<0.05). This analysis identified 20 
apoptosis-associated transcripts with significantly altered expression 
in all three tumours, including TRADD, IAP, DAP-3, DAPK-2 and 
FLAME-1. These results illustrate the ability of this technology to 
unravel the complexity of the molecular abnormalities present. Further 
work is ongoing to elucidate the gene expression profiles associated 
with pathological response. 
QUANTITATIVE RT-PCR TO INVESTIGATE THE EFFECT 
OF PROTEOLYSIS INDUCING FACTOR (PIF) ON THE
EXPRESSION OF  UBIQUITIN-PROTEASOME
PROTEOLYTIC PATHWAY. Jwan Khal*, Anna V. Hine and 
Michael J. Tisdale. Pharmaceutical Sciences Research Institute, 
Aston University, Birmingham, UK, B4 7ET.  
Cancer cachexia is characterized by selective depletion of 
skeletal muscle protein reserves. The ubiquitin-proteasome 
proteolytic pathway has been shown to be responsible for muscle 
protein degradation and muscle wasting in cancer cachexia. To 
establish the importance of this pathway in the action of PIF in 
inducing protein catabolism in skeletal muscle a quantitative 
competitive RT-PCR method was developed to measure the 
mRNA levels of the proteasome subunits C2 and C5 and the 
ubiquitin-conjugating enzyme E214k. In addition this method was 
used to determine the effect of the arachidonic acid metabolite 15-
hydroxyeicosatetraenoic acid (15-HETE), which is thought to be 
the intracellular transducer of PIF action. Using a surrogate model 
system for skeletal muscle, C2C12 myotubes in vitro, it was shown 
that both PIF and 15-HETE increase proteasome subunit 
expression (C2 and C5) as well as the E214k enzyme by
approximately 74% (p<0.05), 76% (p<0.01) and 63% (p<0.001) 
respectively, when cells were incubated for 4 hrs with PIF and by
51% (p<0.05), 85% (p<0.05) and 64% (p<0.05), respectively,
when treated with 15-HETE for 4 hrs. These effects were 
attenuated with 50µM EPA, suggesting that EPA may act to inhibit 
several steps in PIF-induced proteasome expression. These results 
suggest that 15-HETE is the intracellular mediator for PIF induced 
protein degradation and the elevated muscle catabolism is
accomplished through up-regulation of the ubiquitin-proteasome 
proteolytic pathway. Furthermore, EPA has shown anti-cachectic 
properties, which could be used in the future for the treatment of 
cancer cachexia.
ETS TRANSCRIPTION FACTORS IN HUMAN BREAST CANCER 
Yvonne. Buggy* 
1, Teresa.M. Maguire
1, Gerald. McGreal 
1, Arnold.D.K
Hill
1+2,Enda. McDermott
1, Niall. O’Higgins
1, Michael.J. Duffy 
1+2+3 
1Department of Surgery, University College Dublin, St Vincent’s
University Hospital, Dublin 4, Ireland. 
2Conway Institute of Biomolecular and Biomedical Research, Dublin 4,
Ireland. 
3Department of Nuclear Medicine, St Vincent’s University Hospital,
Dublin 4, Ireland
Proteins of the Ets family of eukaryotic transcription factors are
involved in a number of fundamental physiological processes, such as
organogenesis, haematopoiesis and signal transduction. In particular,
specific Ets factors have been implicated in angiogenesis, tumour cell
invasion and metastasis.
 This  study investigated  the  ex vivo expression patterns of four Ets
family members, i.e., Ets-1, Ets-2, PEA3/E1AF and ESX in an attempt to
establish a link between these factors and the formation and progression
of human breast cancer. Following ethical approval messenger RNA
levels of all four Ets factors were determined by Reverse Transcriptase
Polymerase Chain Reaction (RT-PCR) All four transcripts were increased
in tumour tissue compared to either normal breast tissue or
fibroadenomas. Transcripts for PEA3/E1AF were not found in normal
breast tissue. In the carcinomas, correlations were observed between Ets-
1 and HER-2/neu and uPA.
In conclusion, this is the first large scale study implicating Ets
transcription factors in human breast cancer.
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GENE EXPRESSION ANALYSIS USING SERIAL STEREOTACTIC 
BIOPSIES FROM GLIOMAS 
Elisabeth J. Shaw*
+, Michael P.A. Davies
+, Peter C. Warnke
# and Carol 
Walker
+  
+Clatterbridge Cancer Research Trust, Clatterbridge Hospital, Bebington, 
Wirral CH63 4JY;
#Dept. of Neurological Science, Liverpool 
University, Liverpool. 
Gene expression analysis has an important role in the investigation of 
factors that influence therapeutic response in gliomas. However, 
minimally invasive surgical procedures, such as serial stereotactic 
biopsy, limits the tissue available for such study.
In practice, after histopathological diagnosis, 1-6 biopsies per case 
each containing 70-500ng total RNA may be available for analysis. 
Expression of the p16 gene relative to the HPRT gene has been
successfully demonstrated by RT PCR using 50ng total RNA from such
biopsies. However, for microarray analysis RNA amplification is 
required. The U373 glioma cell line was used for methods development. 
>From 50ng total RNA, linear amplification by T7 IVT (RiboAmp, 
Arcturus), cDNA synthesis and indirect labelling gave greater yields
than exponential amplification using the Atlas SMART Fluorescence 
Amplification kit, but showed increased bias toward the 3’ end. 
Hybridisation of Cy3/Cy5 labelled probes onto cDNA microarrays 
(HGMP) showed reproducible representation of gene expression in
experiments using:- different quantities of total RNA in the initial 
amplification, identical samples processed in parallel, and in self-self 
hybridisation experiments.  RNA from a small series of stereotactic 
biopsies has been amplified by the T7 IVT method and hybridised on
cDNA microarrays and cluster analysis performed. 
These results suggest that RNA amplification and microarray analyses 
may be used to investigate factors that influence response to therapy in
gliomas diagnosed by serial stereotactic biopsy.
DIFFERENTIAL GENE EXPRESSION IN BLADDER CANCER
Heba Sh. Kassem*, Jonathan H. Shanks, Noel W. Clarke, Richard Cowan, 
Geoffrey P. Margison 
Cancer Research UK Carcinogenesis Group, Paterson Institute for Cancer 
Research (H.S.K & G.P.M), Christie Hospital, NHS, Trust Manchester, M20 
4BX (J.H.S., N.W.C. & R.C.) Pathology Department, Faculty of Medicine, 
Alexandria University, Egypt (current address of H.K)
mRNA expression patterns were studied in the bladder transitional cell 
carcinoma (TCC) cell lines RT4, RT112 and T24 that represent the 
progression model of bladder cancer (G1,G2 and G3, respectively) and 5 
paired bladder cancer/non involved mucosa samples using Atlas human 
oncogene/tumour suppressor cDNA arrays
TM (BD Clontech,
UK).Adjusted autoradiographic signal intensities were compared using 
the lower grade cell line or the mucosa as the reference in pair-wise 
analyses 
Twenty-four genes (of 190, 13%) were differentially expressed among 
the 3 TCC cell lines with a consistent pattern of up or down-regulation in 
at least 2 comparisons. Fifteen genes (8%) were differentially expressed 
in the tumours relative to the mucosa counterparts in at least 3 paired-
samples. 
Comparing the differential expression analysis of the TCC samples and 
that of the cell lines, some genes revealed a consistent pattern of up or
down regulation in the tumour relative to the non-involved mucosa and 
in the higher grade relative to the lower grade cell lines, indicating their 
potential role in TCC progression. Differential expression of some genes 
e.g. EGFR and PCNA, revealed similar patterns of alteration to those 
previously reported in the literature. Ezrin and neurogenic locus notch 
protein homologue1 (Notch1) were down-regulated in the high grade cell 
line (T24) relative to the lower grade cell lines (RT4 and RT112) and 
also in 4 and 3 tumours relative to the non involved mucosa counterparts, 
respectively, indicating a potential role in bladder cancer. To the best of
our knowledge, this is the first report of the involvement of ezrin and 
Notch1 in bladder cancer and further analysis is warranted to define their 
role and potential use as diagnostic and prognostic markers in bladder 
cancer.  
DOES THE UP-REGULATION OF GASTRIN AND 
GASTRIN RECEPTOR GENE EXPRESSION IN 
BARRETT’S OESOPHAGUS RESULT IN AN INHIBITION 
OF APOPTOSIS?
*Joseph C. Harris
1, Altaf Awan
1, Janusz Jankowski
2, Susan A.
Watson
1
1Cancer Studies Unit, D Floor, West Block, QMC, Nottingham
NG7 2UH  
2Dept. of Cancer Biomarkers, University of Leicester, Leicester 
 Introduction: Barrett’s Oesophagus (BE) is a pre-malignant 
condition of the lower oesophagus characterised by a metaplastic 
change from squamous to columnar intestinal-type epithelium. This 
study aimed to identify a role for gastrin,gastrin receptor (CCK2R) 
and CCK2Ri4sv (splice variant) in the progression of BE via 
circumvention of apoptosis.  
  Methods: Gastrin, CCK2R and CCK2Ri4sv gene expression was 
quantified in paired human normal and Barrett's biopsy samples via 
real-time PCR. Western blotting studies characterised the effect of 
exogenous gastrin on PKB phosphorylation in three CCK2R positive 
oesophageal cell lines; OE19 (adenocarcinoma), OE21 (squamous 
carcinoma)and OE33 (Barrett’s metaplasia derived adenocarcinoma).  
  Results:  Real-time PCR showed gastrin (p=0.0076), 
CCK2R(p=0.0068) and CCK2Ri4sv (p=0.0077) to be significantly 
up-regulated in the BE samples compared to paired normals. 
Exogenous amidated gastrin increased PKB phosphorylation in OE21 
and OE33 cells, whilst PKB was constitutively phosphorylated in 
OE19 cells. Additionally CCK2Ri4sv-transfected OE33 cells showed 
increased basal PKB phosphorylation compared to wild type cells. 
  Conclusion: Gastrin may play a role in progression to oesophageal 
adenocarcinoma through its activation of PKB.
THE EFFECTS OF ESTRADIOL AND ICI 182,780 
TREATMENT OF PRIMARY BREAST CANCER CELLS ON
GENE TRANSCRIPTION AND COMPARISON TO EFFECTS
IN ESTABLISHED CELL LINES. 
Nicola Brookman-Amissah*, Robert K. Price, Richard Foxon, Alan 
Mackay, Michael J. O’Hare and Robert C. Stein. Department of 
Oncology, and Ludwig Institute of Cancer Research, University 
College London, 91 Riding House Street, London W1W 7BS. 
A gene transcription study of the effects of estradiol (E2) and the 
steroidal antiestrogen, ICI 182,780, was carried out on primary
breast cancer cells.  These were isolated from a pleural effusion 
obtained from a woman with metastatic breast cancer who 
subsequently responded to endocrine manipulation.  After 
incubation in low estradiol medium for 6 days, the cells were 
treated with saturating doses of E2, ICI 182,780, E2 and ICI 
182,780 in combination or vehicle control.  Transcriptional 
profiling was performed on samples after 4, 24 and 72 hours. 
cDNA samples from each culture were reciprocally hybridised 
against reference RNA, from a pool of breast cancer cell lines, to 
microarrays of 10,000 ESTs representing mostly known cDNAs. 
Images were analysed using GeneSpring software. 
Genes up-regulated by E2 treatment included cytokeratin 15 and 
the estrogen responsive genes pS-2, cathepsin D and LIV-1.  The 
combination of E2 and ICI 182,780 abrogated these responses. 
Cells treated with ICI 182,780 alone showed no significant 
difference from the cells treated with the vehicle control. 
Results were compared with data obtained from three estrogen 
responsive cell lines - MCF-7, T47D and ZR75.1, and an estrogen 
independent cell line - MDA-MB-453.  Preliminary data from
T47D cells shows surprisingly little overlap with the primary cells. 
Further data and validation of the results will be presented. 
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GENE EXPRESSION PROFILING OF SUPERFICIAL
BLADDER CANCER.  Jeetesh M Bhardwa*, Mahesh Kumar, D 
M Berney, Joanne Martin, Finbar Cotter, Vinod Nargund. 
Bladder cancer (TCC) is the sixth most frequent malignancy 
occurring worldwide. Superficial TCC accounts for 75-85% of all 
TCC. 70% of patients with superficial TCC have one or more 
recurrences after initial treatment, and about one third of these 
patients have progression of disease. Markers are needed to identify 
those most at risk of developing invasive disease.  
  A retrospective study of 128 patients with superficial TCC matched 
for age/ sex/ smoking habits and number of tumours on presentation 
were divided into 2 categories, those that had tumours that progressed 
into invasive disease and those which did not recur nor progress. 
mRNA extracted from archival material on these patients (n=4) was 
used to perform Gene expression analysis using the Affymetrix® 
Human Genome HG U-95A Gene Chip. Out of a total of 12,500 
genes on the chip, 10% were called present. We have filtered these 
genes down to a total of 6 candidate genes, MMP11, ETV6, TFAP2, 
TNFRSF6B, TGFBIF2, ING1L that were over expressed in TCC that 
became muscle invasive, other solid tumours are also known to over 
express these genes There were also 7 genes ACVR1B, CDC2L2, 
SFN, RBBP8, BECN1, RPS29 and ABL1 that were under expressed 
in specimens that turned invasive, implying that these genes may 
have a role in tumour suppression.  
   We will validate our results by performing Real Time Quantitative 
PCR on the above-mentioned genes (n=20). We hope to be able to 
prove that the overexpressed genes play an oncogenetic role in 
invasive TCC while the under expressed genes are involved in 
tumour suppression and prevention of muscle invasion. 
A COMPARATIVE APPROACH TO CANCER CYTOGENETICS 
* Rachael Thomas, Ken C. Smith, Matthew Breen 
Animal Health Trust, Newmarket, Suffolk UK
   The clinical presentation, histology and biology of many canine 
cancers closely parallels those of human malignancies, and their 
extensive genome homology is well established. Comparative studies 
of related human and canine malignancies can make a significant 
contribution towards the understanding of tumour development in 
both species, and to improving tools for diagnosis, prognosis and 
therapy.Our ongoing studies focus on the molecular cytogenetic 
evaluation of canine cancers, the characterisation of non-random 
genomic abnormalities, and comparison with knowledge gained from 
more widely studied human counterparts. Ultimately this will lead to 
a greater ability to extrapolate data and resources between species, 
with potential benefit to both human and veterinary medicine.  
  As an example of this approach, data will be presented on 
preliminary comparative genomic hybridisation analysis of 25 cases 
of canine malignant multicentric lymphoma. This represents the most 
frequent life threatening cancer in dogs, comprising approximately 
20% of all canine malignancies. Aberrations involved 32 of the 38 
canine autosomes, with a maximum of 12 per case and a mean of 
three. Genomic gains were almost twice as common as losses. A 
subset of frequently encountered aberrations was detected. Potential 
correlations with immunophenotype and histological subtype have 
been observed. We aim to develop this approach for cytogenetic 
subdivision of this heterogeneous canine disease, and to correlate 
findings with clinical outcome. Comparisons may also be drawn with 
homologous aberrations observed in human lymphoma, suggesting 
that a related genetic aetiology maybe involved. This will form the 
framework for more detailed comparative studies. 
FUNCTIONAL ANALYSES OF ALTERNATIVE ISOFORMS
OF PAX3 IN MELANOCYTES 
Qiuyu Wang
1*,Craig Parker
1,Shant Kumar
2,  Pat Kumar
1 
1. Manchester Metropolitan University, Chester St., Manchester M1 5GD.
 The paired box gene, PAX3 encodes a transcription factor, 
importantin cell proliferation, migration and survival during early 
embryonic neural and muscle development. Until recently, five 
different isoforms had been identified, while their functions remain 
unknown. We have discovered two new isoforms, g and h, lacking 
complete coding for exon 8. We have confirmed their sequences 
and subcloned seven isoforms, PAX3a-h into  pcDNA4 expression 
vector. The constructed plasmids and empty vector pcDNA4 were 
stably transfected into a non-tumorigenic  murine melanocyte cell 
line, Melan-a, using Transfectam. Transfected colonies wereanalysed 
for PAX3 isoform expression using specific primers bysemi-
quantitative RT-PCR.  
  Promega Cell Proliferation Assay:  melan a-PAX3h cells 
proliferated more rapidly than mock transfectants over 72h (P<0.01), 
while Melan a-PAX3a, -PAX3b cells proliferated more slowly 
(P<0.01 )and Melan a-PAX3c, PAX3d, PAX3e, PAX3g showed 
similar rates of proliferation. A cell growth curve analysis over 7 days 
confirmed this, except that PAX3e grew more slowly than mock 
transfectants. Cell transformation assay: mock transfectants and cells 
containing PAX3a, PAX3b or PAX3e failed to form colonies in soft 
agar, whereas cells expressing PAX3c, PAX3d, PAX3g, and PAX3h 
formed colonies. PAX3d expressing cells formed larger colonies than 
the others, while cells having PAX3h produced more colonies. 
Together, our results suggest that alternative isoforms of PAX3 have 
different effects on melanocyte growth and transformation. Further 
studies are needed to determine whether there is a causal relationship 
between PAX3 isoforms and tumorigenesis in melanoma or whether 
one spliced isoform can regulate another, and to determine the 
molecular mechanisms involved.  
MOLECULAR CYTOGENETIC ANALYSIS OF A COHORT OF
MEDULLOBLASTOMAS 
Jayne M. Lamont*, Charles S. McManamy, Andrew D. J. Pearson, 
Steven C. Clifford, David W. Ellison.Northern Institute for Cancer 
Research, University of Newcastle-upon-Tyne, UK
Although improvements in diagnosis and treatment of
medulloblastoma (MB) have increased five-year survival to 50-
60%, it is recognised that a clearer understanding of genetic 
alterations in MB may allow improved treatment stratification and 
suggest novel therapies.  Using fluorescence in situ hybridisation, 
44 MBs, histopathalogically classified as classic (CL;70.5%), 
anaplastic/large cell (A/LC;25%) or desmoplastic (DES;4.5%), 
were analysed for several genetic abnormalities known to occur in 
MB. 35% (15/43) showed a significant degree of polyploidy at 
more than 4 of 8 loci (47% being A/LC).  Investigation of trisomy
7 indicated copy numbers between 3 and 7+ in 41% (18/44), while 
8q24 (MYC), showed gain/amplification in 22% of cases. Analysis
of 9q22.3 (PTCH), revealed 1 gain (DES) and 2 losses (CL and 
DES), while 10q23.3 (PTEN) and 10q24.31 (SuFu) showed 
paralleled losses in 3 cases (7%). Isochromosome 17q (i17q), the 
commonest aberration in MBs, occurred in 43% of cases and in 
55% of A/LC.  This is in agreement with previous reports. 
However, i17q was not preferentially clustered in A/LC MBs, as
previously suggested, because 39% of CL MBs also showed this
feature. In addition, 5 MBs had 17q gain alone.  Although no clear 
associations between histopathology and molecular cytogenetics 
are immediately apparent, the results at present do confirm and 
question previous data.  In particular, there is no close association 
between chromosome 17 abnormalities and the anaplastic 
phenotype. 
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ROLE OF MISMATCH REPAIR IN DETERMINING
SENSITIVITY TO THE TOPOISOMERASE II POISONS.
Lisa C. Bloodworth*, Linda A.Hogarth, Andrew G. Hall. 
Northern Institute for Cancer Research, Medical School,
University of Newcastle Upon Tyne, NE2 4HH. 
 Conflicting evidence exists as to whether mismatch repair (MMR) 
affects sensitivity to topoisomerase II (topo II) poisons.The topo II 
gene may be a target for mutagenesis in MMR deficient cells.  Drug 
resistance to topo II poisons in vitro has been associated with 
mutations mainly in 7 exons of the topoIIα gene. To determine if 
topo IIα  is mutated in MMR deficient cells we have screened 12 cell 
lines of lymphoid and myeloid origin, with known MMR status, for 
single nucleotide polymorphisms (SNPs) in these 7 exons using 
denaturing HPLC.  Many detected SNPs were intronic. However, in 
JURKAT and NALM-6 cell lines missense mutations were 
identified.  The JURKAT acute lymphoblastic leukaemia (ALL) cell 
line showed a novel mutation corresponding to a R815Q amino acid 
change in the catalytic domain of the protein.  The potential 
functional consequence of this is yet to be determined. MMR 
proficient and deficient cell lines were compared and there was no 
significant difference in the number of mutations. 31 relapsed and 35 
presentation unpaired childhood ALL samples were analysed for 
SNPs in the same manner.  SNPs detectedwere similar to the cell line 
screen.  However, one relapse sample showed loss of heterozygosity 
(LOH) at 3 exons which has been confirmed by sequencing.  In 
contrast this was not seen in the presentation and remission samples 
from the same patient.  It is possible that LOH at this locus may be a 
more common phenomenon in leukaemia than can be detected by 
dHPLC.  Thus further investigation using microsatellite markers is 
being undertaken. 
P106
THE USE OF REAL-TIME PCR TO VALIDATE 
METHYLTHIOADENOSINE PHOSPHORYLASE AND p16 
DELETIONS AS A NEW DRUG TARGET IN CHILDHOOD 
ACUTE LYMPHOBLASTIC LEUKAEMIA
Nadia Thornton*, Andy Hall and Sally Coulthard 
Northern  Institute for Cancer Research, Medical School, 
University of Newcastle upon Tyne, NE24HH.
  Previous research has shown methylthioadenosine phosphorylase 
(MTAP), an enzyme involved in purine metabolism, and p16 are 
frequently co-deleted. As MTAP deficient cells are more sensitive 
to inhibition of de novo purine synthesis, this may offer an 
important new drug target in childhood acute lymphoblastic 
leukaemia 
  A Real-Time PCR assay, which can detect p16 and MTAP co-
deletion, has been established in a panel of 28 cell lines, and in
childhood ALL patients. Of the 28 cell lines, the MTAP status of 
21 cell lines, have not previously been reported.
  6/28 (21.4%) of the cell lines had deletions of the MTAP gene, 
and 7/28 (25%) of the cell lines had a deletion of the p16 gene. Of
these, 27/28 (96.4%), had both MTAP and p16 co-deleted, and in 
only 1/28 (3.6%), p16 deleted but MTAP non-deleted.  Of 5 
patients studied so far, none have shown deletions in either loci.  
  Although deletions have been shown in a panel of cell lines, and 
not in the patients so far, this is most likely due to the small number
of patients studied. Real-Time PCR is a robust and reliable method 
to establish the MTAP and p16 status of cell lines, which can be 
applied to clinical material. 
POTENTIAL USE OF ASPARAGINE SYNTHETASE 
LEVELS IN THE INDIVIDUALISATION OF
L-ASPARAGINASE THERAPY 
Mark Leslie*, Marian C. Case, Andrew G. Hall, Sally A.
Coulthard.   Leukaemia Research Group, Northern Institute of
Cancer Research, University of Newcastle upon Tyne, U.K. 
L-asparaginase (l-asp) is a potent chemotherapeutic agent used
in the treatment of acute lymphoblastic leukaemia (ALL). As it
is associated with potentially severe side effects, it would be
beneficial for treatment to be targeted to patients who will
respond. Understanding the molecular pharmacology of this
drug will be advantageous in the individualisation of l-asp.  
   Cytotoxicity of L-asp results from the depletion of circulatory
asparagine. Lymphoblasts lack activity of asparagine synthetase
(AS) compared with normal cells. Resistance to L-asp is due to
increased cellular AS activity in lymphoblasts.  
Although lymphoblast AS levels are generally low at
presentation, some patients may express higher levels. These
patients might not benefit from L-asp. Some patients with acute
myeloid leukaemia (AML) have also responded favourably to
L-asp; limited results have been published regarding AS
expression in these patients. 
Using real-time PCR, we have observed large variation in
normalised AS mRNA levels (RAS) in ALL and AML. For
ALL, RAS values vary from 0.013 to 1.55 (median=0.18, n=68)
and AML 0.2 to 11.6 (median=0.72, n=20). Little variation in
expression was detected in mononuclear cells from healthy
individuals (0.29 to 0.70, median=0.42, n=14). These results
reached significance (one way ANOVA, P<0.0001);
mononuclear v ALL (SNK, P<0.01); mononuclear v AML
(SNK, P<0.05); ALL v AML (SNK, P<0.001). These results
may have implications for patients being treated with L-asp.
  
  WITHDRAWN
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IDENTIFICATION OF TUMOUR SUPPRESSOR LOCI ON
CHROMOSOME 10q IN MEDULLOBLASTOMA 
Debbie K. Scott*, Janet C. Lindsey, Meryl E. Lusher, Andrew D.J. 
Pearson, David W. Ellison and Steven C. Clifford. 
Northern Institute for Cancer Research, University of Newcastle, 
Newcastle-upon-Tyne, U.K. 
We have previously demonstrated that deletions involving the 
long arm of chromosome 10 (10q) are a frequent event in 
medulloblastoma (MB), the most common malignant brain tumour 
of childhood.  To map these deletions in detail and identify
potential MB tumour suppressor gene (TSG) loci, we performed 
deletion mapping analysis on eleven MB cell lines using a panel of 
polymorphic markers at 10cM intervals across chromosome 10.  
This analysis revealed two key findings. Firstly, that the highest 
rates of homozygosity were observed at 10q24.3-10q26.1, 
indicative of a common region of deletion. Secondly, a 
homozygous deletion involving the 10q23 region was detected, 
indicative of a MB TSG locus.  Detailed mapping of this locus 
delineated a ~200kb deletion encompassing the PTEN TSG and 
further novel predicted transcripts. PTEN coding region mutations 
are rare in MB, occurring in <5% of tumours.  We therefore 
investigated epigenetic PTEN inactivation in a series of MBs.
Methylation-specific PCR analysis revealed tumour-specific 
hypermethylation of the PTEN CpG island in 38% (16/42) primary
tumours. Work is currently underway to determine whether this is
associated with transcriptional silencing and gene inactivation.   
These data indicate (i). that the PTEN TSG and/or genes at 
10q24.3-10q26.1 may represent critical targets of 10q deletions in 
MB, and (ii). that PTEN hypermethylation is a common event in 
this disease.
  EPIDEMIOLOGICAL EVIDENCE FOR AN INFECTIOUS
ORIGIN FOR CHILDHOOD LEUKAEMIA 
Richard J.Q. McNally*, Osborn B. Eden, Jillian M. Birch. 
*Cancer Research UK Paediatric and Familial Cancer Research 
Group, Stancliffe, Royal Manchester Children’s Hospital, Hospital 
Road, Manchester M27 4HA. 
The Manchester Children’s Tumour Registry (MCTR) is
population-based and has been collecting case data from a 
geographically defined region of North West England since 1954 
with almost total ascertainment. The aim of the report is to interpret 
the results of several recent analyses of childhood leukaemia data 
from the MCTR to test current hypotheses posing an infectious 
element of the aetiology of leukaemia. Trend tests, space-time 
clustering (Knox and K-function tests), ecological regression and 
geographical mapping were used to study the data on all 
leukaemias broken down by sub-type into ALL and ANLL. For the 
most recent period since 1980 ALL was further examined by
immunophenotype. There was an increasing incidence of ALL due 
mainly to precursor B-cell sub-type. Space-time clustering was
evident for cases of ALL aged 0-4 years for the time period 1954-
85 based on date of diagnosis and place of birth. For the time 
period 1980-2001 space-time clustering was confined to cases of 
precursor B-cell ALL aged 18-54 months based on date and place 
of birth. The incidence of ALL was greater in more densely
populated wards due to increased incidence of non-precursor B-cell 
ALL. The studies present a complex picture, but are supportive of 
an infectious element in aetiology particularly for precursor B-cell 
ALL. However there may be at least two infectious mechanisms
operating, one predominating in the earlier years of the study
period and another in the later years of the study period.   
GLUT-1, A MARKER FOR TUMOUR HYPOXIA, IS 
EXPRESSED IN CHILDHOOD NEUOROBLASTOMA AND 
RHABDOMYOSARCOMA 
Edward J Estlin*,  Marie Grady,  Anna Kelsey, Ian Stratford, 
Rachel Airley
*Department of Paediatric Oncology, Royal Manchester Children’s Hospital, 
Pendlebury, Manchester M27 4HA, UK 
In several adult cancers, tumour hypoxia is associated with a poorer 
prognosis, possibly as a result of the induction of hypoxia-regulated genes. 
The facilitative glucose transporter Glut-1, which promotes a compensatory 
switch to anaerobic glycolysis and adaptation to hypoxia, is a validated 
surrogate marker for tumour hypoxia. However, there is a paucity of 
information regarding the prevalence and influence of hypoxia in paediatric 
cancers.  To address this, expression of the hypoxia-regulated gene Glut-1 
and the relationship with the prognostic indicators such as stage and MYCN 
amplification, are currently being investigated in studies involving patients 
with paediatric neuroblastoma and rhabdomyosarcoma. In a preliminary 
study, Glut-1 protein expression was investigated in archival formalin-fixed, 
paraffin-embedded biopsy material from a series of 20 patients presenting 
with each of neuroblastoma and rhabdomyosarcoma.  For neuroblastoma 
samples, Glut-1 was present in 10/20 cases. Although in this small series of 
patients, there was no apparent link between lack of survival and either Glut-
1 or MYCN amplification, there were non-significant trends whereby Glut-1 
was associated with MYCN amplification (r = 0.316, P =0.201) and patients 
showing concurrent Glut-1 expression and MYCN amplification were less 
likely to have survived (r = 0.329, P = 0.183). Glut-1 expression was found 
in 30% of rhabdomyosarcoma cases.  Upon examination, virtually all 
tumours had large areas of abundant vascularisation. However, Glut-1 
expression, if present, mostly occurred in patches of poor vascularisation 
around areas of necrosis.  In conclusion, Glut-1 expression may be an 
indicator of hypoxia in paediatric neuroblastoma and rhabdomyosarcoma. 
Further study of an expanded series of patients for each tumour type is 
planned to define the relationship between Glut-1 expression and tumour 
stage, biology and outcome.   
SUSTAINED ACTIVATION OF RAS AND THE MAP KINASE 
P38 ARE EFFECTORS OF BASIC FIBROBLAST GROWTH
FACTOR (bFGF)-INDUCED DEATH IN THE EWING’S
SARCOMA FAMILY OF TUMOURS (ESFTs). 
Andrew J. K. Williamson*, Ben C. Dibling and Susan A. Burchill. 
Cancer Research UK, St James’s Hospital, Leeds, LS9 7TF. 
   The aims of this study were to examine the effects of bFGF on
cytoskeletal organisation and to determine whether bFGF-induced
cell death was initiated following activation of the MEK-ERK and
p38 pathways. Phalloidin and confocal microscopy were used to 
examine the effect of bFGF on the organisation of the cytoskeleton. 
Cell cycle profile was examined by fluorescent associated cell 
sorting (FACS) and Western blot. Expression and activation of 
Ras, ERK and p38 were examined by Western blot, ELISA, 
immunoprecipitation and GST- Ras binding domain binding 
assays. The effect of bFGF in the presence and absence of 10 µM 
PD98059 (ERK inhibitor) or 20 µM SB202190 (p38 inhibitor) on 
cell death was examined by FACS. TC-32 cells accumulated in G1 
and produced neurite-like extensions after 24 hours exposure to 
bFGF. However A673 cells, which do not die, did not. Exposure of 
TC-32 cells to bFGF induced rapid and sustained phosphorylation 
of Ras, ERK and p38. Phosphorylation was seen five minutes after 
addition of bFGF and was sustained up to two hours. Sustained 
activation of p38 MAPK was extended to seventy-two hours. 
Incubation of TC-32 cells with PD98059 or SB202190 rescued TC-
32 cells from bFGF-induced cell death, suggesting that ERK and 
p38 play a role in the signalling for cell death following exposure 
to bFGF. However ERK activation was also sustained in A673 
cells, although Ras and p38 were not activated. This suggests that
sustained activation of p38 and/or Ras are the major effectors of 
bFGF induced cell death in ESFT cells. 
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OXIDATIVE METABOLISM OF 13-CIS-RETINOIC ACID IN
CHILDREN WITH NEUROBLASTOMA 
Gareth J. Veal*, Julie Errington, Karin E. Koller, Ann M. Elsworth, 
Andrew D.J. Pearson and Alan V. Boddy on behalf of the 
UKCCSG Pharmacology Working Group. Northern Institute for 
Cancer Research, University of Newcastle upon Tyne, Newcastle 
upon Tyne NE2 4HH. 
   13-cis-retinoic acid (13cisRA) plays a key role in the treatment of 
high-risk neuroblastoma (nbl) in children. However, whereas a high-dose 
intermittent schedule of13cisRA has proved to be clinically beneficial, a 
lackofefficacy was observed with low-dose continuous 13cisRA, 
suggesting that 13cisRA systemic exposure may be a key factor in 
determining clinical efficacy.  In addition, oxidative metabolism of the 
retinoids has previously been shown to be clinically important, with 
ATRA metabolism being correlated with drug resistance in acute 
promyelocytic leukaemia.   
  We are investigating the pharmacokinetics of 13cisRA in nbl patients 
receiving a dose of 80 mg/m2 b.d. (14 days consecutively out of 28; 6 
courses).  10 patients have currently been studied with pharmacokinetic 
sampling carried out at 0,1,2,4 and 6 hrs post- 13cisRA administration on 
days 1 and 14 of treatment.  Retinoid concentrations in plasma were 
determined by HPLC.   
  Peak 13cisRA concentrations of 0.4-9.2µM were observed between 1 
and 6hrs in patients studied on course 2, with an approximate 15-fold 
inter-patient variation in exposure.  Extensive accumulation of 4-oxo-
13cisRA occurred between days 1 and 14, with plasma concentrations of 
this metabolite being greater than those of 13cisRA by day 14 in 7/10 
patients.  Metabolite concentrations returned to baseline on day 1 of each 
treatment course. These data show significant inter-patient variation in 
13cisRA exposure and demonstrate that intermittent scheduling of 
13cisRA limits the accumulation of its oxidative metabolites. 
GLUTATHIONE IN CHILDHOOD ACUTE LYMPHOBLASTIC 
LEUKAEMIA (ALL)-PREDNISOLONE RESISTANCE AND 
RATE OF BLAST PROLIFERATION-DOUBLE TROUBLE?
G. A. Amos Burke*, Sarah J. Townend, Dharmesh B. Patel, 
Nicholas J Goulden, Pamela R. Kearns. 
Department of Child Health, School of Medical Sciences, 
University of Bristol, UK
   Raised blast glutathione (GSH) levels in childhood ALL are
correlated with high presenting white cell counts (WCC) and an 
increased risk of relapse but the relationship to drug resistance 
remains unclear. Using the T lineage leukaemia cell line CCRF-
CEM C7, we demonstrate that increased total GSH is associated 
with resistance to prednisolone and that GSH levels are related to
proliferation rates in vitro. 
   Total GSH levels were measured using the recycling assay of 
Tietze. In vitro cytotoxicity was assessed using the sulforhodamine 
B (SRB) colorimetric assay and proliferation was measured using 
incorporation of 
3H thymidine.
   Cells grown in the absence of serum had 2-fold higher GSH
levels (34.9 v 17.6; p<0.001) and peak GSH concentrations were 
related to peak incorporation of 
3H thymidine. Higher GSH content
resulted in decreased sensitivity to prednisolone (p<0.05).
Reducing GSH levels in serum-free culture using buthionine 
sulfoximine resulted in partial restoration of prednisolone 
sensitivity (p <0.05 at effective dose combinations). Paradoxically, 
10 mM N-acetylcysteine increased the sensitivity to prednisolone.  
   Our data supports the concept that redox status is one of the 
molecular determinants of prednisolone sensitivity with the 
potential for therapeutic modification.  The correlation of GSH 
with rate of proliferation offers an explanation for the association 
with high WCC at presentation in children with ALL. 
A SURVEY OF CURRENT PRACTICE IN UK PAEDIATRIC 
ONCOLOGY CENTRES AND ASSISTED CONCEPTION UNIT 
FOR THE PRESERVATION OF FERTILITY FOR ADOLESCENT 
MALES WITH CANCER. Satinder Jagdev
1*, Linda Phelan
1, Marilyn 
Crawshaw, Juliet Hale, Adam Glaser
1. 
1Paediatric and Adolescent 
Oncology Unit, St James’ University Hospital, Leeds.  
HOW SHOULD GLOMERULAR FILTRATION RATES BE 
MEASURED IN TEENAGERS HAVING CHEMOTHERAPY?
Jeremy Whelan,* Caoimhe O'Sullivan, Susie Stanway and  Siew Ng
 Accurate assessment of renal function of patients receiving intensive 
chemotherapy is essential. Glomerular filtration rate (GFR) may be 
assessed by EDTA clearance or may also be derived from formulae 
using serum creatinine values. Isotopic EDTA clearance is the gold 
standard for measuring GFR but is invasive, slow and uses radio-
isotopes. The formulae most appropriate for use with teenagers has not 
yet been determined. The aim of this study was to compare three 
commonly used formulae (Schwartz, Modified Schwartz and 
Cockcroft-Gault) to EDTA in thirteen to twenty-one year olds having
chemotherapy.
Methods: EDTA clearance results from 114 patients were obtained
from the nuclear medicine department. The three calculations were
then performed and compared to the EDTA clearance.
Statistical analysis: Agreement between the three methods was 
assessed.  Sensitivities and specificities were computed for each
method, with GFR rates of less than 80 units considered as the cut-off 
point as this value is commonly used for a dose reduction or exclusion 
from a regimen. 
Results: We found low agreement and large variation in scores relative 
to their corresponding EDTA.  The sensitivities were 9% (95% CI: 3% 
to 22%),  37% (95% CI: 23% to 53%) and 2% (0% to 12%) for the 
Schwartz, Modified Schwartz, Cockcroft-Gault formulae respectively.
In contrast, the specificity of each formula was high. 
Conclusion: The poor agreement and the low specificity and high 
sensitivity of the Schwartz, Modified Schwartz, Cockcroft-Gault 
formulae compared to the EDTA measurements suggest that these 
methods may not be adequate for correctly identifying 13-21 year olds 
with reduced renal function. 
The treatment of cancers in childhood and adolescents may lead to 
impaired fertility. The offer of fertility preservation techniques for 
adolescent males has been a relatively new service. This postal 
survey(funded by NHS Executive) was conducted to establish current 
practice in the UK. Questionnaires were sent to 22 paediatric 
oncology(POCs) centres and 105 assisted conception units (ACUs) 
across the UK with 90% and 62% response rates respectively. Of the 
20 responding POCs, 100% offered access to storage facilities for 
sperm and/or testicular tissue. The techniques offered included 
ejaculation (100% of centres), electro-ejaculation (35%), epididymal 
aspiration (30%) and testicular biopsy (30%). Only 40% of POCs had 
access to written guidelines specifically for adolescent males. The 
commonest tumour types in which fertility preservation was offered in 
both settings were Hodgkin’s and Non-Hodgkin’s Lymphoma and 
sarcomas. Of 65 responding ACUs, 23 offered storage facilities to 
adolescent males. The techniques offered included ejaculation (95%), 
electro-ejaculation (26%), epididymal aspiration and testicular 
biopsy(69% respectively). 75% of POCs and 74% of ACUs required 
their adolescent male patients to be Gillick competent to undergo 
sperm banking. Fertility counselling and psychosocial support were 
provided by a variety of health professionals in both settings. These 
data highlight the inconsistencies in information and access to services 
for adolescent males with cancer. Specifically tailored national 
guidelines, are needed.  
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SELECTION FOR p53 MUTANT CELLS BY CHEMOTHERAPY
IN HIGH-RISK NEUROBLASTOMA 
Jane Carr*, Christine Challen, Julian Board, Katrina M. Wood,
Andrew D. J. Pearson, John Lunec and Deborah A. Tweddle 
Northern Institute for Cancer Research, Medical School, University of
Newcastle, NE2 4HH.  
  Background: Neuroblastoma is the most common cause of death from 
childhood cancer. Most high-risk neuroblastomas (stage 4 >1 yr, or MYCN 
amplified localised & infant disease) initially respond to cytotoxic therapy, 
but the majority relapse with chemoresistant disease. p53 mutations are 
rare in neuroblastoma at diagnosis, however they have been occasionally 
reported in relapse tumours and cell lines, and are associated with 
chemoresistance (Tweddle et al, Cancer Res, 2001:61:8-13). 
  Methods: Automated DNA sequencing was used to sequence exons 4-9 
of the p53 gene in 8 paired diagnostic and relapsed neuroblastomas. Four 
out of 8 cases were high-risk neuroblastoma and 6 patients died of 
progressive disease.  
  Results: A p53 mutation was detected in the relapse but not the 
diagnostic tumour in 1 of the 6 patients who subsequently died 
fromprogressive disease. This was a missense mutation at codon 270 
causing amino acid change from phenylalanine to leucine in a patient with 
high-risk (stage 4 >1yr) MYCN amplified neuroblastoma. The same 
mutation was identified in DNA from tumour after less than 3 months of 
induction (rapid COJEC) chemotherapy. Using mutation specific p53 
primers we were unable to amplify DNA from the tumour at diagnosis. 
The minimum concentration of mutant DNA required to generate a PCR 
product was 0.05%, suggesting that if the mutation was present at 
diagnosis then it was at a lower level than this.  
  Conclusions: These findings are consistent with selection of p53 mutant 
cells by chemotherapy in a subset of high-risk neuroblastomas and may 
have important therapeutic implications. 
EVIDENCE FOR A REDOX MECHANISM OF ACTION OF 
PREDNISOLONE IN CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKAEMIA THROUGH THE
IDENTIFICATION OF THE NOVEL GENE CGI-31. 
G. A. Amos Burke*, Pamela R. Kearns, Nicholas J. Goulden. 
Department of Pathology and Microbiology, School of Medical 
Sciences, University of Bristol, UK
   Glucocorticoids are the most important drugs used in the
treatment of acute lymphoblastic leukaemia and poor response to
these drugs during induction is a powerful adverse prognostic 
factor. However, the mechanisms by which glucocorticoids induce
cytotoxicity are poorly understood. Using the T-lymphoblastic cell 
line CCRF CEM C7, we have demonstrated the involvement of a 
novel gene with proposed thioredoxin function in the response to 
the glucocorticoid, prednisolone.  
   Global gene expression profiles were examined in sensitive and 
resistant populations of CCRF CEM C7 using the technique of 
differential display. Quantitative RT-PCR was used to confirm
altered gene expression. 
   Using differential display, down-regulation of the novel gene 
CGI-31 was seen in sensitive but not resistant leukaemia cells 
during 6 hours of prednisolone exposure and this was confirmed 
using quantitative RT-PCR.
   The involvement of CGI-31, a gene with proposed thioredoxin 
function, in the response to prednisolone of sensitive leukaemic 
cells supports the concept that prednisolone acts via a mechanism
involving changes in the redox status of the cell. We believe this 
novel mechanism offers the potential for the development of new 
therapies. Studies with RNA interference are ongoing to assess the
functional significance of CGI-31. 
HIERARCHICAL CLUSTERING ANALYSIS OF GENE
EXPRESSION PROFILES ACCURATELY IDENTIFIES
SUBTYPES OF ACUTE CHILDHOOD LEUKAEMIA
Frederik van Delft*, Tony Belloti, Mike Hubank, Tracy
Chaplin, Naina Patel, Maria Adamaki, Daniella Fletcher, Ian
Hann, Louise Jones, Alex Gammerman, Vaskar Saha. CRUK
Children’s Cancer Group, Charterhouse Sq, London EC1M.
Aims: Devising mathematical tools for diagnosing acute
leukaemia subtypes, based on data obtained from gene
expression profiling. 
Procedures: Bone marrow cells were obtained from all
patients newly diagnosed to have acute leukaemia at the Royal
London and Great Ormond Street Hospitals from February
2002. RNA was extracted immediately from the mononuclear
fraction and gene expression analysis performed using the
HGU133 A and B gene chip. Two supervised hierarchical
clustering techniques were used to identify the minimum
number of genes able to discriminate leukaemic subtypes. 
Findings: Data was refined on 30 ALL and 10 AML patients.
A 30 gene set, cross validated between the two methods, was
identified. Gene expression patterns were validated using Real-
Time PCR. This was able to accurately differentiate the
different leukaemic subtypes including immunophenotype and
cytogenetic changes. This gene set was then used to accurately
identify two cases of unclassified leukaemia. Preliminary
analysis also identifies similarities and diversities within
specific subgroups. 
Conclusion: Gene expression analyses provide a rapid and
single platform for the diagnosis of haematological
malignancies. Future correlation with response to treatment and
outcome has the potential to further refine risk-classification
and identify novel pathways for targeted therapy.
A CRYPTIC REARRANGEMENT INVOLVING MLL AND 
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We describe a child with a diagnosis of Acute Myeloid Leukaemia
(AML) FAB 5, who presented initially with a prodromal phase.
Routine cytogenetic G-banding identified a dic (1;19). Fluorescent in-
situ hybridisation, however, identified a cryptic insertion of MLL into
10p12. RT-PCR and sequence analysis confirmed the presence of a
MLL-MLLT10 fusion, resulting in an in-frame fusion of MLL exon 6
to MLLT10 979.  Using long range PCR, 21kb of intronic sequence
was analysed. The precise genomic breakpoint was localised to intron
6 of MLL (bp 1512) and MLLT10 bp 10884 (between coding
sequence 978/979). An identical genomic fusion was identified by
PCR and sequence analysis from DNA extracted from the neonatal
Guthrie blood spot. 
Sequence analysis shows both introns to contain 70% repetitive
elements. Junctional analysis of the genomic fusion shows that the
breakpoint is immediately flanked by an AluJb repeat on the MLL
side and L1MCa repeat on the MLLT10 side and contains short
sequence homologies, an indication of errors in end-joining of double
strand breaks.  
This is the first report of a MLL-MLLT10 fusion at birth and
provides further evidence of the prenatal origin of chromosomal
translocations seen in childhood AML.
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